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1 Introduction and Goals 
Since Fleming’s accidental discovery of a penicillin-producing mold in 1928,
1
 eighty years of steady 
progress has followed, and today the β-lactam class of antibiotics is one of the most succesful 
examples of natural product application and chemotherapy. The naturally or (semi)synthetic 
penicillins, cephalosporins, cephamycins, oxacephems, (carba)penems, monobactams, and 
nocardicins (Figure 1) all contain the β-lactam structural subunit and they all function by 
sequestering the catalytically active serine residue in bacterial penicillin binding proteins, 
transpeptidases responsible for the crucial cross-linking of peptidoglycan polymers as the final step 
of the bacterial cell wall synthesis, thus disturbing the integrity of the cell wall, finally leading to cell 
wall rupture and death.
2
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Figure 1 
In light of the rapidly emerging bacterial resistance to β-lactam antibiotics, caused by their 
widespread use during the past decades, the preparation and biological evaluation of new types of β-
lactams intended to overcome the defense mechanisms of the bacteria is a major topic in medicinal 
and pharmaceutical chemistry.
2
 
On the other hand, in addition to the key role that β-lactams have played in the fight against 
pathogenic bacteria, a renewed interest has been focused on the synthesis of azetidin-2-ones 
possessing diverse pharmacological activities including cholesterol absorption inhibitory activity, 
antidiabetic, antitumor, anti-inflammatory, antiparkinsonian, anti-HIV and antimalarial activity.
3
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Besides their biological activity, the importance of β-lactams as synthetic intermediates has been 
widely recognized in organic synthesis. Selective bond cleavage of the β-lactam nucleus coupled with 
further interesting synthetic transformations renders these fascinating molecules powerful synthetic 
building blocks. In this way, azetidin-2-ones act as important intermediates toward a wide variety of 
nitrogen-containing acyclic and heterocyclic target compounds.
4
 In that respect, in previous studies 
at the Department of Sustainable Organic Chemistry and Technology (UGent), the synthetic potential 
of 1-, 3- and 4-(ω-haloalkyl)azetidin-2-ones 1a, 1b and 1c has been elaborated in detail, leading to 
the preparation of different mono- and bicyclic heterocyclic compounds, including aziridines,
5,6,7
 
azetidines,
7,8,9
 piperidines,
9,10,11
 pyrrolidines,
9,12
 azepanes,
11
 pyrrolidin-2-ones,
13
 oxolanes,
7,14
 1,4- and 
3,4-fused bicyclic β-lactams,
11,14,15
 and bicyclic γ-lactams (Figure 2).
16
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Figure 2 
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In continuation of the above-illustrated synthetic potential of β-lactams containing a halogenated 
side chain (Figure 2) as building blocks in the stereoselective construction of heterocycles, which can 
serve as lead compounds for the development of new biologically relevant targets, in a first topic of 
this PhD thesis special attention will be devoted to the reactivity of the unexplored class of 
halogenated β-lactams bearing a halogenated side chain. More specifically, as an extension of the 
previously reported LiAlH4-induced ring contraction of 3-chloro-β-lactams and 1-(2-chloroethyl)-β-
lactams toward the corresponding 3-(hydroxymethyl)aziridines
5
 and 1-(3-hydroxypropyl)aziridines,
6
 
respectively, the aim of this part is to combine both structural features into one system. Thus, the 
reactivity of 3-chloro-1-(ω-chloroalkyl)azetidin-2-ones 2 toward LiAlH4 will be evaluated, leading to 
the formation of 1-(3-chloropropyl)-3-(hydroxymethyl)aziridines 3 (n = 2) and 1-(2-chloro-3-
hydroxypropyl)aziridines 5 (n = 1, Scheme 1). Subsequent treatment with a base would then furnish 
oxazepane-aziridine fused systems 4 and 1-(2-oxiranylmethyl)aziridines 6, respectively (Scheme 1). 
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Scheme 1 
Substituted six-membered azaheterocycles in general and piperidines in particular are found in a 
whole variety of natural products and pharmaceutical compounds, and they continue to attract 
considerable attention due to their diverse and important biological activities. The pivotal position of 
piperidines is illustrated by the fact that several thousands of piperidine derivatives have been 
mentioned in clinical or preclinical studies.
17
 The biological importance of this ring system makes 
short and versatile routes to substituted piperidines of high interest and value. Therefore, a 
continuous interest exists in the development of new methodologies for the synthesis of biologically 
active piperidines.
18
 In light of this biological relevance, the synthetic applicability of 2-(2-bromo-1,1-
dimethylethyl)azetidines 8 toward stereodefined 4-acetoxy- and 4-hydroxypiperidines 10 will be 
evaluated, as the latter compounds have become increasingly popular as building blocks toward 
bioactive compounds. Thus, the synthesis of cis-3,4-disubstituted 5,5-dimethylpiperidines 10 will be 
investigated starting from 4-(2-bromo-1,1-dimethylethyl)azetidin-2-ones 7. Monochloroalane-
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mediated reduction of β-lactams 7 would afford azetidines 8, which are susceptible to intramolecular 
ring closure toward intermediate bicyclic azetidinium salts 9. Subsequent ring opening by the 
additional nucleophile would then give rise to the formation of the premised piperidines 10 (Scheme 
2). The intermediacy of bicyclic azetidinium ions has previously been proposed in similar 
rearrangements,
9,19
 and particular attention will be devoted to the study of their viability in this 
work. 
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Scheme 2 
However, the synthesis of analogous piperidines 11, in which no 5,5-gem-dimethyl group is present, 
might open up interesting possibilities for the development of biologically and pharmaceutically 
relevant compounds as well. To achieve this goal, a different synthetic route will be developed. From 
a retrosynthetic point of view, the synthesis and subsequent ring enlargement of 2-(2-
mesyloxyethyl)azetidines 13 via bicyclic azetidinium ions 14 could offer a convenient alternative and 
an easy access to this new class of 5-nonsubstituted piperidines 11. Azetidines 13 will be prepared 
via 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 12, which will then undergo a AlH2Cl-
induced reduction and a TBAF-mediated deprotection toward the corresponding 2-(2-
hydroxyethyl)azetidines, which will be further converted via functional group transformation of the 
alcohol moiety to the mesyloxy group (Scheme 3). 
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Scheme 3 
Next to piperidines, the piperidin-4-one ring also comprises an important structural unit both from a 
medicinal and a chemical point of view, as piperidin-4-ones are known to possess inter alia CNS 
stimulant,
20
 antitumor,
21
 analgesic,
22
 and local anaesthetic
23
 activities, and selective modification of 
the carbonyl moiety can lead to a variety of functionalized piperidines. For these reasons, the one-
step ring enlargement of 2-(2-mesyloxyethyl)azetidines 13 toward novel piperidin-4-ones 15 via a 
ring expansion-oxidation protocol upon heating in DMSO will be examined as an efficient synthetic 
methodology toward this new class of functionalized piperidin-4-one scaffolds (Scheme 4). 
Furthermore, in order to demonstrate their synthetic usefulness, both a chemical and an enzymatic 
reduction of the carbonyl moiety will be investigated to provide a convenient entry into the 
biologically interesting 4-hydroxylated piperidines 16 (Scheme 4). Special attention will hereby be 
devoted to stereochemical implications. 
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In addition to the generation of monocyclic (aza)heterocyclic target compounds from azetidin-2-
ones, the β-lactam skeleton has been extensively used as a template to construct cyclic structures 
fused to the four-membered ring using the functionalization of the β-lactam nucleus as a 
stereocontrolling element.
4g,24
 In that respect, a new pathway toward 3,4-fused bicyclic β-lactams 
will be developed, involving initial synthesis of 3-benzyloxy-4-(2-mesyloxyethyl)azetidin-2-ones 17, 
which will undergo hydrogenolysis of the benzyl ether substituent followed by intramolecular 
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nucleophilic displacement to form 2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 18 (Scheme 5). Further 
hydrolysis of the amide bond in bicyclic β-lactams 18 would then give rise to the formation of 
constrained β-amino acid derivatives 19 (Scheme 5). β-Amino acids comprise a valuable class of 
compounds because of their broad biological and synthetic applicability.
25
 In particular, cyclic β-
amino acids are present in a variety of natural products and are metabolically more stable toward 
hydrolysis then their α-amino counterparts, which is of importance for the preparation of modified 
peptides.
26
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In previous studies at the Department of Sustainable Organic Chemistry and Technology (UGent), 2-
(bromomethyl)aziridines have proven to be valuable synthons for the preparation of a wide variety 
of nitrogen-containing heterocyclic compounds and acyclic amines such as 4-amino-3-
pyrrolidinylbutanenitriles,
27
 2-amino-1-aryloxy-3-methoxypropanes,
28
 cyclopropanecarbonitriles,
29
 β-
fluoro amines,
30
 2-(N-sulfonylimino)azetidines,
31
 pyrrolidin-2-ones,
32
 morpholines,
33
 2-(N-
ethylaminomethyl)aziridines,
34
 piperidines,
35
 thiazolines,
36
 δ-lactams and γ-lactones.
37
 The fact that 
both β-lactams and 2-(bromomethyl)aziridines have been shown amply to be valuable synthons in 
organic chemistry prompted us to design a strategy for the synthesis of new compounds in which 
these small ring systems are combined. In this way, initial selective manipulation of the β-lactam ring 
and/or the aziridine moiety followed by intramolecular rearrangements involving both structural 
units could provide a useful entry into a broad range of novel mono-, bi- and tricyclic target 
compounds. Thus, in a final section of this PhD thesis, β-lactam-aziridine hybrids 21 will be prepared 
through imination, bromination and reductive cyclization of β-lactam aldehydes 20, and will then 
undergo intramolecular nucleophilic displacement of bromide by the C-3 alkoxide (obtained upon 
hydrogenolysis of the benzyl ether substituent and subsequent treatment with a base) to yield 
tricyclic β-lactams 22 (Scheme 6). 
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Scheme 6 
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2 Literature Overview 
In this chapter, a literature overview of the main synthetic routes dealing with the transformation of 
functionalized β-lactams into azaheterocyclic six-membered ring systems by cleavage of the β-lactam 
ring through any of the three possibilities, i.e., N1-C2, C3-C4 or C4-N1 bond cleavage, is presented 
(Figure 3). As the synthesis and synthetic applicability of the azetidin-2-one moiety has been 
reviewed extensively,
4
 the emphasis in this chapter lies on new literature data published during the 
period 2005-2012. 
N
O
R2 R3
R1
C3-C4 cleavage
C4-N1 cleavage
N1-C2 cleavage  
Figure 3 
2.1 Ring transformation through N1-C2 bond cleavage  
Two concise, complementary stereocontrolled routes to optically pure orthogonally protected 
anti,anti-4-amino-3,5-piperidinediols 26 have been described. Key features of the first approach 
(method A) include a chemoselective reductive ring opening of the β-lactam nucleus with LiBH4 to 3-
amino-5-hydroxypentanenitriles 24, followed by reductive cyclization of conveniently functionalized 
δ-mesyloxynitriles 25 with NaBH4/NiCl2 (Scheme 7). The second approach (method B) involves a 
LiAlH4-induced reduction of protected anti,anti-4-amino-3,5-dihydroxypiperidin-2-ones, which were 
easily obtained by chemoselective reduction of the cyano group in γ-cyano-β-amino esters 27 and 
subsequent intramolecular ring closure of the resulting diamino esters (Scheme 7).
38
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N
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NHX
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CN
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MeO
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R R S
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1)
2)
Method A: 59-61% (X = Boc)
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26
A
B
3 equiv LiAlH4
Et2O, rt, 30 min
 
Scheme 7 
According to an analogous reaction sequence, β-lactams have been shown to play a key role in the 
synthesis of cisapride, a drug used for the treatment of various gastrointestinal disorders.
39
 The 
synthetic strategy consists of methanolysis of nitro-β-lactams 28 followed by a Pd-catalyzed 
reductive cyclization by means of ammonium formate and reduction of the carbonyl moiety upon 
treatment with borane (Scheme 8).
40
 The construction of the gastroprokinetic agent 32 was achieved 
in an additional three-step synthesis.
41
 
N
O R
H H
MeO
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NO2
R R
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HCl/MeOH (20%)
rt, 12 h
OMe
NHR
MeO
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R
R
O
NO2
5 equiv HCO2NH4
10 % Pd/C
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H
NHR
R
30 (55-67%)
O
OMe
R
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BH3/DMS
toluene, ∆, 4 h
N
H
NHR
R
31 (49-52%)
OMe
S
N
OMeH
N O
FO
OMeH2N
Cl SR
32
R = Bn
 
Scheme 8 
An alternative (diastereoselective) approach for the synthesis of piperidine derivatives from β-
lactams has been developed at the Department of Sustainable Organic Chemistry and Technology 
(Ghent University) and comprises the ring transformation of 3-(3-chloropropyl)-β-lactams 33, 
synthesized by treatment of N-(arylmethylidene)amines with 5-chloropentanoyl chloride in benzene 
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in the presence of 2,6-lutidine.
10
 The synthetic strategy involves a two-step synthesis of trans-2-
arylpiperidine-3-carboxylates 36, compounds of significant interest due to their potential use in the 
treatment of Alzheimer’s disease,
42
 upon subsequent treatment of 3-(3-chloropropyl)-β-lactams 33 
with hydrogen chloride in methanol and triethylamine in dichloromethane (Scheme 9). This reaction 
has been proposed to proceed through initial nucleophilic ring opening of the protonated β-lactam 
34 by methanol, followed by intramolecular displacement of chloride by the in situ formed free 
amine 35 upon addition of the base (Scheme 9).10 Interestingly, cis-piperidines would be expected, 
suggesting that epimerization has occurred during this transformation. Furthermore, these trans-2-
arylpiperidine-3-carboxylates 36 were easily converted into their corresponding cis-isomers 37 by 
means of hydrazine monohydrate in methanol (Scheme 9).
10
 
N
O R1
R2
Cl
33
N
O R1
R2
Cl
34
H
MeOH
Cl
MeOOC
NHR1
R2
HCl/MeOH, 0 °C, 1 h
then rt, 24 h
4 equiv Et3N
CH2Cl2, ∆, 4 h
1)
2)
N
R1 R2
36 (79-93%)
10 equiv NH2NH2.H2O N
R1 R2
37 (56-78%)
MeOH, ∆, 4 h
35
OMe
O
OMe
O
R1 = iPr, Bn
R2 = H, Me, OMe
 
Scheme 9 
Several examples are known in which aryl-substituted β-lactams are rearranged into functionalized 
quinolone derivatives, a family of compounds with inter alia broad-spectrum antibiotic,
43
 
antidiabetic,
44
 antidepressant, sedative and antiparkinson
45
 properties. For example, 1-arylazetidin-2-
ones 38, synthesized by a Goldberg-Buchwald-type copper-catalyzed coupling of N-unsubstituted 
azetidin-2-ones with the appropriate aryl halides or using Mitsunobu cyclization processes,
46
 have 
been treated with triflic acid under mild reaction conditions in CH2Cl2, which ensued a smooth Fries 
rearrangement delivering 2,3-dihydro-4(1H)-quinolinones 44 in good to high yields (71-98%) (Scheme 
10).
46
 This intramolecular Friedel-Crafts acylation is the result of an acid-mediated amide bond 
cleavage in β-lactams 38, generating a highly reactive free acylium ion in intermediates 43, which 
Chapter 2  Literature Overview 
12 
 
subsequently undergo an intramolecular electrophilic aromatic substitution (Scheme 10). Recently, 
this transformation has been used in the synthesis of TRPV1 antagonists as analgesic agents.
47
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R2 = H, 4-Me, 4-OMe, 4-F, 4-Cl, 4-I, 4-Br, 2-OMe
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38
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HO
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R1
N
H
R2
N
H
O
R2
R1
43
44 (71-98%)
R2 R2 R2 R2
 
Scheme 10 
Another method for the construction of dihydroquinolinones from β-lactams starts with the 
microwave-assisted transfer hydrogenation of the ortho-nitro group in azetidinones 45, synthesized 
via the Staudinger reaction, to afford intermediates 46 by using ammonium formate in ethylene 
glycol. Subsequent in situ intramolecular β-lactam ring opening provided 4-amino-3,4-
dihydroquinolin-2-ones 47 in 74-90% yield (Scheme 11).48 
R1 = Me, Ph, Bn, Ac
R2 = H, Me, OMe
N
O
45
R1O
R2
O2N 5 equiv HCO2NH4
10 % Pd/C
ethylene glycol, 3 min
microwave
H
NO
R1O
HN
R2
N
O
46
R1O
R2
H2N
47 (74-90%)
 
Scheme 11 
Isoquinoline-based scaffolds represent an important group of biologically active compounds and are 
attracting increasing attention in contemporary biomedical research and drug discovery programs. 
Several members of this group exhibit various pharmacological and biological activities, including 
potential anticancer properties.
49
 In that respect, recently, the single-step diastereoselective 
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synthesis of functionalized hexahydroisoquinolinones 52 and tetrahydroisoquinoline-1,3-diones 50 
has been realized by intermolecular NaOMe-induced amidolysis of 1-aryl-β-lactams 48 (Z = OMe) and 
subsequent intramolecular cyclization upon reflux in xylene, and by intramolecular base-induced 
amidolysis of 1-aryl-β-lactams 48 (Z = NH2) with concomitant two-carbon ring enlargement by stirring 
in MeOH at room temperature, respectively (Scheme 12).
50
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H
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N
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H H
49
R1
R2
H
O
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50 (82-90%)
R1 = H, Cl, Me, OMe
R2 = H, Cl, Me, OMe  
Scheme 12 
Furthermore, it has been observed that treatment of β-lactams 48 (Z = NH2) with NaOMe and I2 in 
methanol at room temperature gave rise to iodinated octahydropyrroloisoquinoline-1,3-diones 54 
and 4-[(4-iodophenylamino)arylmethyl]tetrahydroisoquinoline-1,3-diones 56 depending upon the N-
substituent of the β-lactam ring.
50
 In the case para-substituted 1-arylazetidin-2-ones 48 (Z = NH2, R
1
 = 
Me, Cl) were deployed as synthetic precursors, electrophilic addition of molecular iodine across the 
double bond in the initially formed tetrahydroisoquinoline-1,3-dione derivatives 50 yielded 
intermediate iodonium ions 53, which upon intramolecular cyclization afforded the corresponding 
functionalized tricyclic tetrahydropyrrole derivatives 54 in 49-55 % yield (Scheme 13).50 Interestingly, 
N-phenyl-β-lactams 48 (Z = NH2, R
1
 = H) underwent electrophilic aromatic substitution instead of 
iodocyclization upon addition of I2, which has been explained considering the initial formation of 
diketones 55 having a negative charge on the nitrogen atom. In this way, the electron density at the 
para-position of the phenyl substituent increases, thus favouring aromatic electrophilic substitution 
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with molecular iodine, resulting in the selective preparation of iodinated tetrahydroisoquinoline-1,3-
diones 56 in 68-74% yield after re-aromatization (Scheme 13).50 
N
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H H
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R2
H
O
H2N
1 equiv NaOMe
1 equiv I2
MeOH, rt, 3.5-3.8 h
1 equiv NaOMe
1 equiv I2
MeOH, rt, 42-46 h
R1 = Me, Cl R1 = H
N
H
O O
H H
H
HN
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I
53
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H H
H
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I H
R2 = H, Cl, Me
N
H
O O
NH H
H
R2
55
I I
N
H
O O
N
HH H
H
R2
56 (68-74%)
+ aromatization
I
 
Scheme 13 
The synthetic usefulness of β-lactam to piperidinone transformations has also been demonstrated 
through the synthesis of dihydroindolizinones. Enynyl β-lactams 57 have been rearranged into 5,6-
dihydro-8H-indolizin-7-ones 64 through a regiospecific Au-catalyzed β-lactam ring opening and 
recyclization sequence. The reaction mechanism of this ring expansion has been rationalized by 
considering an initial 5-exo-dig cyclization of the lactam nitrogen to the metal-activated alkyne 
moiety, followed by a heterocyclic fragmentation of the amide bond to generate acyl cations 61, 
which subsequently undergo cyclization to the enamine moiety to afford bicyclic zwitterions 62. 
Finally, recuperation of the Au-catalyst and subsequent 1,5-hydride migration gives bicyclic pyrroles 
64 (Scheme 14).51 This synthetic strategy was further extended by the development of naturally 
occurring indolizidine alkaloids, as demonstrated by the synthesis of racemic indolizidine 167B 65, an 
alkaloid isolated from neotropical poison dart frogs (Scheme 14).
51 
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Scheme 14 
A one-step approach has been reported for the conversion of 4-acyloxy-β-lactams 66 into 1,3-oxazin-
6-ones 70 by using acyl chlorides in the presence of DBU (Scheme 15).52 After initial acylation of the 
β-lactam nitrogen, the acidity of the H-3 proton of the β-lactam nucleus is enhanced by the electron-
withdrawing N-acyl group, thus making the β-lactam carbonyl group more “ketone-like”. As a result, 
the organic base DBU promotes the elimination of the carboxylic acid (R
1
CO2H) across the β-lactam 
C3-C4 bond generating highly strained azetinones 68, which rapidly experience a four-centered 
electrocyclic ring opening to N-acylimidoylketenes 69, which in turn provide 1,3-oxazin-6-ones 70 in 
40-76% yield through a six-centered electrocyclic ring closure (Scheme 15).
52
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Scheme 15 
Chapter 2  Literature Overview 
16 
 
Another example of a two-step ring transformation of β-lactams into nitrogen- and oxygen-
containing six-membered heterocycles, developed at the Department of Sustainable Organic 
Chemistry and Technology (Ghent University), comprises the synthesis of 1,3-oxazinanes 73 via 
LiAlH4-promoted reductive ring opening of cis-β-lactams 71 toward γ-aminoalcohols 72, followed by 
recyclization using formaldehyde in THF (Scheme 16).
53
 The biological importance of these classes of 
compounds has been demonstrated by evaluation of their in vitro antiplasmodial activity and 
cytotoxicity, pointing to their promising potential as a novel type of antimalarial agents.
53
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Scheme 16 
In a single example, racemic 3-allyl-4-formyl-β-lactam 74 was treated with N-methylhydroxylamine 
hydrochloride in the presence of triethylamine, which, upon intramolecular protonation of the olefin 
moiety toward the corresponding zwitterionic bicyclic hemiaminal 76 followed by imination of the 
latent aldehyde, gave rise to the selective formation of nitrone 78 in 50% yield (Scheme 17). This 
nitrone 78 proved to be unstable in chloroform and after one week 1,2-oxazinane-6-one 80 was 
obtained in quantitative yield through intramolecular ring opening of the β-lactam nucleus via the 
N1-C2 bond (Scheme 17).
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Scheme 17 
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Indane-fused dihydropyrimidinones 83 and 85 have been obtained by ring enlargement of 3,4-benzo-
6-azabicyclo[3.2.0]heptan-7-one 81, prepared from indene by chlorosulfonyl isocyanate addition, 
upon melting with imidates or lactim ethers at 150-160 °C for 8 hours (Scheme 18). The first step in 
the reaction is the formation of amidine intermediates 82 and 84, which, after intramolecular 
transamidation with simultaneous N1-C2 bond fission, rearrange into tri- and tetracycles 83 and 85, 
respectively (Scheme 18).
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Scheme 18 
In addition, 1,3-diamine 86, synthesized via N1-C2 bond cleavage of tricyclic β-lactam 81, has been 
treated with 2-formylbenzoic acid or levulinic acid in boiling toluene, which ensued, after initial 
imination, a smooth two ring-closure sequence delivering indane-fused hexahydropyrimidines 89 and 
92 with complete diastereoselectivity in 65% and 63% yield, respectively (Scheme 19).55 The 
stereochemical outcome of this overall ring rearrangement has been rationalized assuming the 
formation of a tautomeric equilibrium between the intermediates 87 and 90, respectively, in 
combination with a kinetic control governing the second cyclization step (Scheme 19).
55
 
Chapter 2  Literature Overview 
18 
 
H
N
O
81
NH2
HN Me
86 (44%)
CHO
COOH
1 equiv
toluene, ∆, 5 h
N
HN Me
HOOC
87a
N
HN
Me
HOOC
H
N
HN
Me
HOOC
H
87b 87c
N
N
Me
89 (65%)
O
H
N
N
Me
88
O
H
X
1 equiv
toluene, ∆, 5 h
Me
O
COOH
N
HN Me
90a
Me
HOOC
N
HN
Me
Me
N
HN
Me
Me
90b 90c
HOOC HOOC
N
N
Me
92 (63%)
O
Me
N
N
Me
91
O
Me
X
1) DMAP/Boc2O
2) MeNH2/MeOH
3) HCl/EtOH
4) NaOH/CHCl3
5) LiAlH4
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
 
Scheme 19 
2.2 Ring transformation through C3-C4 bond cleavage  
The tandem cycloetherification/β-lactam ring cleavage of racemic γ-olefinic α-allenols 93, prepared 
from the appropriate 4-oxoazetidine-2-carboxaldehydes via a regiocontrolled indium-mediated 
Barbier-type carbonyl-allenylation in aqueous medium,
56,57
 in the presence of catalytic iron(III) 
trichloride in dichloroethane at 80 °C in a sealed tube has been described to selectively afford allenic 
morpholinones 97 in good yields (78-85%) (Scheme 20).57 Probably, the hydroxyl-iron complex 94, 
formed initially through coordination of FeCl3 to the oxygen atom of olefinic allenols 93, considerably 
increases the acidity of the hydroxyl protons, thus inducing a chemo- and regioselective 
Chapter 2  Literature Overview 
19 
 
intramolecular protonation of the alkene moiety with concomitant 4-exo oxycyclization to yield 
bicycles 95, which, driven by relief of the strain associated with the four-membered ring, rapidly 
evolve to intermediates 96 through selective β-lactam ring cleavage. Finally, demetalation 
regenerates the iron catalyst and affords morpholinones 97 (Scheme 20).57 Alternatively, initial 
activation by coordination of FeCl3 to the olefinic double bond cannot be excluded. 
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Scheme 20 
As described above, β-lactams are excellent substrates for the synthesis of functionalized 
piperidinone derivatives through selective fragmentation of the N1-C2 amide bond of the β-lactam 
nucleus followed by ring expansion. Also, β-lactams have been proven to be suitable building blocks 
for the ring enlargement toward dihydropyridones, as demonstrated by the thermally induced [1,3]-
sigmatropic rearrangement with concomitant C3-C4 bond cleavage of 4,4-dienyl-β-lactams 99, which 
have been obtained through [2+2]-cyclocondensation of azatrienes 98 with the appropriate ketenes, 
upon heating in toluene or xylene (Scheme 21).
58
 When the starting β-lactams 99 have two different 
vinyl substituents (R
1
 = Ph; R
2
 = CO2Et; R
3
 = H or R
1
 = Ph, CO2Et; R
2
 = R
3
 = Me), the regioselectivity of 
the rearrangement reaction depends on steric factors and on the electronic demands of the 
substituents. Whereas in the former case (R
1
 = Ph; R
2
 = CO2Et; R
3
 = H) the predominant formation of 
dihydropyridones 100 can be attributed to the benzylic stabilization of the developing carbenium ion, 
in the latter case (R
1
 = Ph, CO2Et; R
2
 = R
3
 = Me) steric factors play a predominant role rather than 
electronic factors, inducing reaction at the monosubstituted diene C-terminus even if the substituent 
is an electron-withdrawing ethoxycarbonyl group (Scheme 21).
58
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Scheme 21 
A β-lactam to piperazinone rearrangement has been reported in the synthesis of 1,4-
diazabicyclo[4.3.0]nonanones 107 from 4-formyl-spiro-β-lactams 102 by means of a Pd-catalyzed 
hydrogenation. This ring transformation involves, after initial hydrogenolytic removal of the 
benzyloxycarbonyl protecting group, a retro-Mannich process, which induces β-lactam ring opening 
through selective C3-C4 bond fission, affording intermediate enols 104 (Scheme 22).59 Further 
hydrogenation, nucleophilic addition of the in situ liberated secondary amine to the aldehyde group 
and elimination finalizes the reaction pathway, generating pyrrolidine-fused pyrazinones 107 in good 
yields (70-90%) (Scheme 22).
59
 1,4-Diazabicyclo[4.3.0]nonanes comprise remarkable structural units 
encountered in several biologically active products, as demonstrated by their potential use in the 
treatment of inter alia schizophrenia, depression, memory dysfunction,
60
 filariasis
61
 and angina 
pectoris.
62
 In that respect, further derivatization of bicyclic piperazinone 107 [R = CH2CH2(3,4-
Cl2)C6H3], i. e., monochloroalane-mediated reduction of the carbonyl functionality, enabled the 
synthesis of 1,4-diazabicyclo[4.3.0]nonane 108 (Scheme 22),59 a compound claimed for the treatment 
of central nervous system disorders.
63
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Scheme 22 
2.3 Ring transformation through C4-N1 bond cleavage 
The first two-carbon ring expansion of a β-lactam through cleavage of the C4-N1 bond has been 
described in the synthesis of 1,3,4,5-tetrasubstituted glutarimides. The presence of a 4-
hydroxyphenyl substituent at the 4-position in the starting 3-alkylazetidin-2-ones 109 enabled a 
base-mediated C4-N1 bond fission upon treatment with potassium tert-butoxide in DMF, which 
induced the formation of the corresponding phenolate anions followed by rearrangement to 
intermediate quinone methides 110 with simultaneous C4-N1 bond cleavage (Scheme 23).64 The 
latter reactive quinone methides 110 are subsequently quenched by the tert-butyl methyl malonate 
anion in a Michael-type 1,6-conjugate addition at the benzylic carbon atom and are transformed into 
glutarimides 113 upon cyclization and removal of the tert-butyl group with trifluoroacetic acid 
(Scheme 23). The stereochemistry of the ring expansion proved to be dependent on the specific C3-
substituent of the starting β-lactams 109.64 
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Scheme 23 
Next to the base-catalyzed ring opening of 4-(4-hydroxyphenyl)-β-lactams, the latter azetidinones are 
also cleaved under acidic conditions. It has been observed that treatment of β-lactams 114 with neat 
trifluoroacetic acid gave rise to the formation of intermediates 115, which upon intramolecular 
Friedel-Crafts alkylation ensued to recyclize toward 3,4-dihydroquinolin-2-ones 116 in quantitative 
yields (Scheme 24).
65
 It has to be noted that the 4-(4-hydroxyphenyl) substituent in the starting β-
lactams 114 induces C4-N1 bond cleavage, whereas in the absence of a C4-substituent cleavage of 
the amide bond occurs upon treatment with trifluoroacetic acid (Scheme 10). 
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Scheme 24 
2.4 Conclusion 
Despite the β-lactam skeleton being just a four-membered cyclic amide, it is a useful and versatile 
building block exhibiting an extremely rich organic chemistry. The selective bond cleavage of the β-
lactam nucleus has proven to have many applications in stereocontrolled synthesis, including the 
synthesis of azaheterocyclic six-membered ring systems (Figure 4).  
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In this PhD thesis, the potential of substituted azetidin-2-ones as building blocks for the 
stereoselective preparation of various functionalized piperidines, piperidinones, oxazin-3-ones, 
morpholin-3-ones and pyrazinones will be explored with the intention to provide new entries toward 
biologically interesting scaffolds. 
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3 Results and Discussion 
This PhD-thesis is partly based on the following SCI-papers, referred to in the text by the Roman 
numerals I-VI: 
 
I. Transformation of trans-4-Aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones into 3-Aryl-2-
(ethylamino)propan-1-ols via Intermediate 1-(1-Aryl-2-chloro-3-hydroxypropyl)aziridines 
and trans-2-Aryl-3-(hydroxymethyl)aziridines. Mollet, K.; D’hooghe, M.; De Kimpe, N. J. 
Org. Chem. 2011, 76, 264. (SCI IF 4.45) 
II. Synthesis of stereodefined 3,4-disubstituted piperidines through rearrangement of 2-(2-
bromo-1,1-dimethylethyl)azetidines. Mollet, K.; Broeckx, L.; D’hooghe, M.; De Kimpe, N. 
Heterocycles 2012, 84, 431. (SCI IF 1.00) 
III. Stereoselective Synthesis of cis-3,4-Disubstituted Piperidines through Ring 
Transformation of 2-(2-Mesyloxyethyl)azetidines. Mollet, K.; Catak, S.; Waroquier, M.; 
Van Speybroeck, V.; D’hooghe, M.; De Kimpe, N. J. Org. Chem. 2011, 76, 8364. (SCI IF 
4.45) 
IV. Stereoselective synthesis of bicyclic tetrahydrofuran-fused β-lactams and their 
conversion into methyl cis-3-aminotetrahydrofuran-2-carboxylates. Mollet, K.; D’hooghe, 
M.; De Kimpe, N. Tetrahedron 2012, 68, 10787. (SCI IF 3.03) 
V. Synthesis of piperidin-4-ones starting from 2-(2-bromo-1,1-dimethylethyl)azetidines and 
2-(2-mesyloxyethyl)azetidines through a ring expansion-oxidation protocol. Mollet, K.; 
D’hooghe, M.; Broeckx, L.; Danneels, B.; Desmet, T.; De Kimpe, N. Tetrahedron 2013, 69, 
2603. (SCI IF 3.03) 
VI. Synthesis of 2-Hydroxy-1,4-oxazin-3-ones through Ring Transformation of 3-Hydroxy-4-
(1,2-dihydroxyethyl)-β-lactams and a Study of Their Reactivity. Mollet, K.; Goossens, H.; 
Piens, N.; Catak, S.; Waroquier, M.; Törnroos, K. W.; Van Speybroeck, V.; D’hooghe, M.; 
De Kimpe, N. Chem. Eur. J. 2013, 19, 3383. (SCI IF 5.93) 
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3.1 Reactivity of trans-4-aryl-3-chloro-1-(2-chloroethyl)azetidin-
2-ones toward LiAlH4 (Paper I) 
Both halogenated azetidin-2-ones and azetidin-2-ones bearing halogenated side chains are useful 
starting materials for rearrangements due to their high intrinsic reactivity, which is based on the 
combination of a strained four-membered ring system, a nucleophilic nitrogen (obtained after 
further elaboration) and an electrophilic carbon center. In that respect, in previous studies at the 
Department of Sustainable Organic Chemistry and Technology (Ghent University), intensive research 
on the synthetic applicability of the mainly unexplored class of 4-(haloalkyl)azetidin-2-ones 1c has 
resulted in the efficient and diastereoselective preparation of a wide variety of functionalized 
azaheterocyclic compounds, including aziridines,
7
 azetidines,
7,9
 piperidines,
9,11
 pyrrolidines,
9,12
 
azepanes,
11
 pyrrolidin-2-ones,
13
 oxolanes,
7,14
 1,4- and 3,4-fused bicyclic β-lactams,
11,14
 and bicyclic γ-
lactams (Figure 2).
16
 
One of the most straightforward transformations of β-lactams comprises their reductive ring opening 
toward γ-aminoalcohols.6,66 The presence of halogenated carbon atoms in these substrates is of 
synthetic relevance, as this can lead further to rearrangements toward azaheterocyclic compounds. 
In previous studies at the Department of Sustainable Organic Chemistry and Technology (Ghent 
University), the applicability of halogen-bearing β-lactams for the construction of stereodefined 
aziridines upon treatment with LiAlH4, e.g., the conversion of N-(2-chloroethyl)azetidin-2-ones 117 
into 1-(3-hydroxypropyl)aziridines 1196 and the reductive ring contraction of 3-chloro-β-lactams 120 
into 3-(hydroxymethyl)aziridines 1225, has been demonstrated (Scheme 25). However, up to now, 
the reactivity of halogenated β-lactams 2 bearing a halogenated side chain toward LiAlH4 has not 
been explored in the literature. 
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Scheme 25 
The chemistry of 3-chloro-β-lactams comprises a mainly unexplored field in the literature, although 
these compounds are very useful substrates for further elaboration due to their unique synthetic 
properties, e.g., dehalogenation toward 3-unsubstituted azetidinones
67
 and conversion into different 
3-substituted azetidines.
8
 In addition, also the use of N-(ω-haloalkyl)-β-lactams has been studied to a 
very limited extent, for example toward the synthesis of 1,4-diazepan-5-ones
68
 and bicyclic β-
lactams.
15
 In this chapter, both structural features were combined into a new type of substrates, i.e., 
3-chloro-1-(2-chloroethyl)-β-lactams, which were evaluated for their reactivity toward LiAlH4. 
Although other reducing agents such as LiBEt3H and LiBH4 could be used,
66
 the choice for LiAlH4 was 
based on previous experiments conducted at the Department of Sustainable Organic Chemistry and 
Technology (Ghent University). 
3.1.1 Synthesis of trans-4-aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones 
The synthesis of trans-4-aryl-3-chloro-1-(2-chloroethyl)-β-lactams 2a-d, in which the two halogen 
atoms reside in β-position with respect to the nitrogen atom, was accomplished by Staudinger’s 
ketene-imine cyclocondensation reaction. Thus, treatment of N-(arylmethylidene)-(2-
chloroethyl)amines 124a-d, prepared via imination of benzaldehydes 123a-d in dichloromethane in 
the presence of MgSO4 and Et3N utilizing one equiv of 2-chloroethylamine hydrochloride, with 1.5 
equiv of chloroacetyl chloride and three equiv of 2,6-lutidine in benzene gave the premised trans-4-
aryl-3-chloro-1-(2-chloroethyl)-β-lactams 2a-d in 60-75% yield (Scheme 26). 
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In accordance with previous results on β-lactam synthesis,5a,8 the latter β-lactams 2a-d were 
obtained stereoselectively (cis/trans 3-5/95-97) after a reflux period of 15 hours, and separation of 
both isomers was performed by means of column chromatography on silica gel. The trans-selectivity 
could be deduced based on the 
1
H NMR spectra of β-lactams 2a-d, as the observed coupling 
constants between the 3-H and 4-H protons varied between 1.1 and 2.0 Hz (
1
H NMR, CDCl3), which 
corresponds well with those reported in the literature for trans-β-lactams.69 It should be noted that 
dichlorinated β-lactams 2 represent a novel class of substrates suitable for further elaborations. 
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Cl  HCl
3 equiv Et3N
2 equiv MgSO4
CH2Cl2, rt, 2 h
H
N
Cl
Cl Cl
O
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3 equiv 2,6-lutidine
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Cl
O Cl
R
R R
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1 equiv
.
124a (R = 4-Me, 79%)
124b (R = H, 87%)
124c (R = 4-Cl, 79%)
124d (R = 3-OMe, 84%)
2a (R = 4-Me, 75%, cis/trans = 3/97)
2b (R = H, 60%, cis/trans = 3/97)
2c (R = 4-Cl, 69%, cis/trans = 5/95)
2d (R = 3-OMe, 66%, cis/trans = 5/95) 
Scheme 26 
The stereochemical outcome of this Staudinger reaction can be rationalized as follows. Next to 
different experimental factors, such as the choice of the solvent, base and reaction temperature,
70
 it 
is well known that the specific ketene substituent plays an important role in the diastereoselectivity 
of the Staudinger reaction.
71
 When the ketene, in situ generated from an acid chloride in the 
presence of a base, is substituted with a chloro atom (Moore ketene), E/Z-isomerisation across the 
iminium bond of the zwitterionic intermediate, formed by nucleophilic attack of the imine across the 
less hindered site of the ketene, followed by conrotatory ring closure will mostly afford the 
thermodynamically more stable trans-β-lactams (Figure 5), while electron-donating ketene 
substituents, e.g., in Bose-Evans ketenes (alkoxy ketenes), generally accelerate the direct conrotatory 
ring closure, leading to a preference of cis-β-lactam formation.71 
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Figure 5 
3.1.2 Synthesis of 3-aryl-2-(ethylamino)propan-1-ols 
The reductive ring opening of azetidin-2-ones by means of LiAlH4 has been described as an efficient 
approach toward β- en γ-aminoalcohols.5,6,53,66 In analogy, trans-4-aryl-3-chloro-1-(2-chloroethyl)-β-
lactams 2a-d were treated with three molar equiv of LiAlH4 in THF under reflux for 48 hours, resulting 
in full conversion of the starting material. Quite unexpectedly, spectroscopic analysis of the obtained 
reaction products revealed their molecular structure to be 3-aryl-2-(ethylamino)propan-1-ols 127a-d 
(Scheme 27). 
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127b (R = H, 70%)
127c (R = 4-Cl, 65%)
127d (R = 3-OMe, 68%)
2a-d
 
Scheme 27 
The synthesis of β-aminoalcohols merits considerable attention since these compounds play an 
important role in synthetic organic chemistry, for example as auxiliaries and ligands in asymmetric 
synthesis.
72
 The two heteroatoms allow great flexibility, as one or both can be bound to a Lewis acid, 
transition metal or achiral starting material.
72
 In addition, a variety of β-aminoalcohols exhibit various 
pharmacological properties, and the β-aminoalcohol moiety is present as a key structural unit in 
different biologically active compounds. For example, the β-blockers propranolol 128 and metoprolol 
129 are used for treating abnormal heart rhythm, high blood pressure, heart failure and angina 
(Figure 6).
73
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3.1.2.1 Elucidation of the reaction mechanism 
In order to elucidate the mechanistic background of this intriguing transformation, β-lactam 2a was 
subjected to different reaction conditions, involving variation of the reaction time, reaction 
temperature, solvent and number of molar equiv of LiAlH4. First, trans-3-chloro-1-(2-chloroethyl)-4-
(4-methylphenyl)-β-lactam 2a was treated with two molar equiv of lithium aluminium hydride in 
diethyl ether under reflux for two hours. 
This process resulted in 1,2-fission of the amide bond, followed by intramolecular displacement of 
the chloride at the primary carbon atom by the nucleophilic nitrogen, giving rise to the initially 
expected 1-[2-chloro-3-hydroxy-1-(4-methylphenyl)]aziridine 5a. Interestingly, next to the latter 
aziridine 5a, a substantial amount of trans-1-ethyl-3-hydroxymethyl-2-(4-methylphenyl)aziridine 
132a was observed in the crude reaction mixture as well (Scheme 28, ratio 5a/132a: 70/30).5 
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Scheme 28 
The unexpected formation of N-ethylaziridine 132a can be rationalized in two ways. In a first 
approach, the nucleophilic nitrogen in intermediate 131a, formed after cleavage of the amide bond 
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of β-lactam 2a, displaces the chloride at the secondary carbon atom to afford aziridine 132a in a 
direct way. Since a primary electrophilic carbon atom is more likely to be attacked than a secondary, 
this competition could not explain the observed ratio (70/30). Alternatively, the presence of the 
latter aziridine 132a can be explained by a possible ring transformation of aziridine 5a. Considering 
the in situ activation of the aziridine moiety by the Lewis acid character of aluminium in chair-like 
intermediate 134a, aziridine 132a can be formed by hydride-induced ring opening followed by 
intramolecular substitution of the chloro atom (Scheme 29, Route A). Alternatively, initial 
displacement of chloride by the nucleophilic aziridine nitrogen to form an N-spiro bis-aziridinium 
intermediate 136a, followed by hydride-induced ring opening toward aziridine 132a cannot be 
excluded (Scheme 29, Route B). 
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Scheme 29 
It should be mentioned that non-activated aziridines are generally known to be highly reluctant 
toward hydride-induced ring opening,
74
 and little information can be found in the literature 
concerning the corresponding intramolecular versions as in the case of intermediate 134a. 
Furthermore, although reaction mechanisms consistent with the formation of bicyclic aziridinium 
salts are known,
75
 the occurence of 1-azoniaspiro[2.2]pentanes 136 as such has not been described 
in the literature, apart from one paper in which the N-spiro bis-aziridinium ion is suggested to be a 
stable and isolable molecule based on ab initio studies.
76
  
In order to prevent hydride-induced ring transformation of aziridine 5a toward aziridine 132a, milder 
reaction conditions were applied for the reduction of β-lactam 2a. Thus, treatment of β-lactam 2a 
with one molar equiv of LiAlH4 in THF at room temperature for 6-91 hours afforded a mixture of γ-
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aminoalcohol 137a and aziridine 5a in varying amounts (Scheme 30, Table 1). From a mechanistic 
point of view, these results can be rationalized considering the conversion of β-lactam 2a into 
aziridine 5a via intermediate γ-aminoalcohol 137a, as mentioned before. In this way, 1-(1-aryl-2-
chloro-3-hydroxypropyl)aziridines 5a,b were isolated in pure form and in good yields after 
purification by column chromatography on silica gel (Table 2). Interestingly, all four hydrogen atoms 
of aziridines 5a,b were observed as separate doublets of doublets with characteristic aziridine 
chemical shifts (1.05-2.20 ppm, CDCl3). Also, spectroscopic analysis by 
13
C NMR revealed different δ-
values for the two aziridine carbon atoms (25.22-25.28 ppm and 31.62-31.64 ppm, CDCl3). These 
findings are in accordance with analogous results reported in the literature for C-unsubstituted 
aziridines.
6,77
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Scheme 30 
Table 1. Reduction of trans-3-chloro-1-(2-chloroethyl)-4-(4-methylphenyl)-β-lactam 2a in THF at room 
temperature 
Number of molar equiv LiAlH4 Solvent Temperature Time Result 
1 THF rt 6 h 137a/5a = 55/45 
1 THF rt 19 h 137a/5a = 25/75 
1 THF rt 91 h 137a/5a = 13/87 
 
Table 2. Transformation of trans-4-aryl-3-chloro-1-(2-chloroethyl)-β-lactams 2a,b into 1-(1-aryl-2-chloro-3-
hydroxypropyl)aziridines 5a,b 
Substrate R Reaction conditions Compound (yield)a 
2a 4-Me 1 molar equiv LiAlH4, THF, rt, 91 h 5a (40%) 
2b H 1 molar equiv LiAlH4, THF, rt, 91 h 5b (55%) 
a
 After purification by column chromatography (SiO2). 
 
In the next stage, different attempts were made to tune the reaction selectivity toward aziridine 
132a starting from β-lactam 2a upon treatment with LiAlH4 (Scheme 31, Table 3). From the 
presented results, it can be deduced that although complete conversion of aziridine 5a into aziridine 
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132a was achieved by establishing more forcing reaction conditions, the inherent reactivity of the 
intermediate 2-arylaziridine 132a toward LiAlH4 resulted in fast ring opening toward β-aminoalcohol 
127a at higher temperatures. In this transformation, LiAlH4 is responsible for both the activation of 
the aziridine ring, resulting in a considerable weakening of the C2-N bond due to benzylic 
stabilisation of the developing carbenium ion, and for the delivery of the nucleophilic hydride which 
subsequently induces ring opening in a regioselective manner.
5a
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Scheme 31 
Table 3. Reduction of trans-3-chloro-1-(2-chloroethyl)-4-(4-methylphenyl)-β-lactam 2a under different 
reaction conditions 
Entry Number of molar equiv LiAlH4 Solvent Temperature Time Result Yield 
1 1 THF reflux 2 h 137a/5a/132a = 
45/45/10 
80% 
2 2 THF reflux 2 h 5a/132a = 72/28 85% 
3 2 THF rt 18 h 5a/132a = 67/33 81% 
4 2 THF rt 20 h 5a/132a = 62/38 82% 
5 2 THF rt 100 h 5a/132a = 67/33 75% 
6 2 Et2O reflux 1 h 5a/132a = 73/27 68% 
7 2 Et2O reflux 2 h 5a/132a = 70/30 72% 
8 2 Et2O reflux 3 h 5a/132a = 62/38 87% 
9 2 Et2O reflux 4 h 5a/132a/127a = 
48/33/19 
83% 
10 2 THF reflux 7 h 132a/127a = 50/50 65% 
11 3 Et2O reflux 1 h 5a/132a = 71/29 69% 
12 3 Et2O reflux 5 h 5a/132a/127a = 
58/22/20 
79% 
13 3 Et2O reflux 20 h 132a/127a = 25/75 82% 
14 3 THF reflux 48 h 127a 82% 
15 4 THF reflux 1 h 132a/127a = 58/42 73% 
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These detailed experiments finally culminated in a straightforward and efficient synthesis of 3-aryl-2-
(ethylamino)propan-1-ols 127a-d from trans-4-aryl-3-chloro-1-(2-chloroethyl)-β-lactams 2a-d upon 
treatment with three molar equiv of LiAlH4 in THF under reflux for 48 hours (Table 3, Entry 14) 
through formation and subsequent conversion of intermediates 131a-d, 133a-d and 138a-d (Scheme 
32). 
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Scheme 32 
To provide additional evidence for this reaction mechanism, 3-aryl-2-(ethylamino)propan-1-ols 
127a,b were synthesized in excellent yields by reduction of 1-(1-aryl-2-chloro-3-
hydroxypropyl)aziridines 5a,b using three molar equiv of LiAlH4 in THF under reflux for 48 hours 
(Scheme 33). 
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127a (R = 4-Me, 91%)
127b (R = H, 93%)  
Scheme 33 
In conclusion, an efficient approach toward novel β-aminoalcohols is described by means of a LiAlH4-
mediated transformation of 3-chloro-1-(2-chloroethyl)-β-lactams. It is clear that the presence of two 
halogenated carbon atoms allows high synthetic flexibility, and selective manipulation of one 
electrophilic carbon center (followed by intramolecular rearrangements) opens new ways for the 
synthesis of biologically relevant target structures.  
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3.2 Diastereoselective synthesis of 3,4-disubstituted piperidines 
through rearrangement of azetidines 
As substituted six-membered azaheterocycles are among the most common building blocks in 
natural products and biologically active compounds, the preparation of piperidine-based organic 
scaffolds has been widely studied.
17,18
 To date, their synthesis still represents a major challenge in 
medicinal chemistry, as more and more (complex) piperidine-containing compounds are designed in 
order to improve the selectivity and reduce the side effects of potential new drugs.  
Ring enlargements of small-ring nitrogen heterocycles comprise very useful reactions because they 
can provide a straightforward and efficient access to different nitrogen-containing target 
molecules.
78
 These reactions frequently involve strained ring systems in which strain release acts as a 
driving force for the ring enlargement. In that respect, substituted azetidines have been proven to be 
suitable starting materials to perform rearrangements toward pyrroles, pyrrolidines, pyrrolidinones, 
imidazolidinones, isoxazolidines, piperidines, 1,2-oxazines, piperidin-2-ones, 2-iminopiperidines, 
azepanes and azepan-2-ones.
79
 Moreover, the introduction of a leaving group in one of the 
substituents of these small-ring heterocycles enables intramolecular transformations toward 
intermediate bicyclic azetidinium ions, which are subsequently prone to undergo ring opening 
(mostly implying ring expansion) by the expelled leaving group or by an additional 
nucleophile.
9,12,79a,80 
In the present chapter, the scope and synthetic applicability of the latter methodology is examined 
toward the preparation of novel piperidines by treatment of functionalized azetidines with different 
nucleophiles.  
3.2.1 Synthesis of 3,4-disubstituted 5,5-dimethylpiperidines through 
rearrangement of 2-(2-bromo-1,1-dimethylethyl)azetidines (Paper II) 
In previous studies at the Department of Sustainable Organic Chemistry and Technology (UGent), the 
diastereoselective ring expansion of 2-(2-bromo-1,1-dimethylethyl)azetidines 8, prepared via 
monochloroalane reduction of the corresponding β-lactams 7, toward cis-3,4-disubstituted 5,5-
dimethylpiperidines 10 upon treatment with NaOH, KCN, NaN3 and Me4NF has been described, and 
has been proposed to proceed via trapping of intermediate bicyclic azetidinium ions 9 (Scheme 
34).
9,19,81
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Scheme 34 
3.2.1.1 Synthesis of 4-acetoxy- and 4-hydroxy-5,5-dimethylpiperidines 
To broaden the scope of the above-described nucleophile-induced ring transformation of 2-(2-
bromoethyl)azetidines 8 toward novel stereodefined piperidines, the feasibility of introducing other 
nucleophiles than bromide, fluoride, hydroxide, cyanide and azide was evaluated by employing 
sodium acetate. Thus, treatment of azetidines 8a-d19 with ten equiv of NaOAc in DMSO at 100 °C for 
18 hours resulted in the selective formation of 4-acetoxy-5,5-dimethylpiperdines 139a-d in good 
yields (Scheme 35). The relative cis-stereochemistry was demonstrated by the vicinal coupling 
constants between the protons at C-3 and C-4 (3.0-3.3 Hz, 
1
H NMR, CDCl3), which are in accordance 
with literature data concerning 3,4-dioxygenated piperidines,
82
 and was rationalized considering the 
in situ formation and consecutive ring opening of bicyclic azetidinium intermediates 9a-d (Scheme 
35). This reaction mechanism is based on the intramolecular displacement of bromide by the 
nucleophilic nitrogen lone pair of azetidines 8a-d toward reactive bicyclic intermediates 9a-d, which 
are subsequently prone to undergo ring opening by the nucleophilic counterion, i.e., acetate, at the 
bridgehead carbon atom in a SN2 fashion to furnish the thermodynamically more favoured six-
membered piperidines 139a-d (Scheme 35).19 
The synthetic relevance of these novel 4-acetoxypiperidines 139a-d was demonstrated by means of 
their transformation into the biologically important class of 4-hydroxylated piperidines,
83
 producing 
the corresponding 4-hydroxypiperidines 140a-d upon hydrolysis of the ester moiety by means of 
three equiv of LiOH in methanol under reflux for 15 hours (Scheme 35). 
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Scheme 35 
Indeed, a vast array of molecules containing the 4-hydroxypiperidine skeleton has been reported in 
the treatment of arrhythmia,
83c
 hypotension,
83d
 tuberculosis,
83h
 and diarrhea,
83i
 and others are known 
as anti-inflammatory agents,
83e
 CCR1 chemokine receptor antagonists
83f
 and TNF-α converting 
enzyme (TACE) inhibitors
83g
 useful for the treatment of rheumatoid arthritis, multiple sclerosis and 
Crohn’s disease (Figure 7). 
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Figure 7 
Following a protocol previously developed at the Department of Sustainable Organic Chemistry and 
Technology (UGent) concerning a one-step ring enlargement of cis-1-allyl-3-benzyloxy-2-(2-bromo-
1,1-dimethylethyl)azetidine 8a into the corresponding 4-hydroxypiperidine 140a by means of sodium 
hydroxide in DMSO (Scheme 36),
9
 different attempts were made to prepare the latter 4-
hydroxypiperidines 140b-d selectively through NaOH- and/or H2O-mediated ring transformation of 2-
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(2-bromoethyl)azetidines 8b-d (Scheme 37, Table 4). However, in all cases the competition between 
hydroxide and bromide to induce ring enlargement resulted in a mixture of 4-hydroxypiperidines 
140b-d and 4-bromopiperidines 144b-d in varying ratios (Table 4).  
N
O Br
8a
10 equiv NaOH
DMSO, 100 °C, 18 h
Ref. 9
N
OH
O
140a (86%)  
Scheme 36 
N
R1
R2O Br
8b-d
N
R1
OH
R2O
N
R1
Br
R2O
+
Table 4
140b-d 144b-d
(17/83 - 71/29)  
Scheme 37 
Table 4. Attempts toward the synthesis of 4-hydroxy-5,5-dimethylpiperidines 140b-d via a one-step ring 
expansion of 2-(2-bromo-1,1-dimethylethyl)azetidines 8b-d 
Substrate R1 R2 Reaction conditions Resulta 
8b tBu Bn 10 equiv NaOH, DMSO, 100 °C, 18 h 140b/144b = 29/71 
8c iPr Ph 10 equiv NaOH, DMSO, 100 °C, 18 h 140c/144c = 43/57 
8d cHex Ph 10 equiv NaOH, DMSO, 100 °C, 18 h complex mixture 
8b tBu Bn H2O/DMSO (5/1), 80 °C, 15 h 140b/144b = 71/29 
8b tBu Bn 1 equiv NaOH, H2O/DMSO (3/1), 80 °C, 5 h 140b/144b = 63/37 
8b tBu Bn H2O/DMSO (1/1), 80 °C, 6 h 140b/144b = 55/45 
8c iPr Ph H2O/DMSO (1/1), 80 °C, 6 h 140c/144c = 20/80 
8d cHex Ph 11 equiv NaOH, DMSO, 80 °C, 3 h complex mixture 
8d cHex Ph H2O/DMSO (3/1), 80 °C, 15 h complex mixture 
8d cHex Ph 1 equiv NaOH, H2O/DMSO (3/1), 80 °C, 19 h 140b/144b = 17/83 
8d cHex Ph 10.3 equiv NaOH, DMSO, 80 °C, 3 h complex mixture 
8d cHex Ph 15 equiv NaOH (1M), DMSO, 80 °C, 3 h complex mixture 
a
 Based on 
1
H NMR analysis of the crude reaction mixture.  
 
As a result, it can be concluded that the two-step synthesis of 4-hydroxypiperidines 140a-d via 4-
acetoxypiperidines 139a-d comprises an improved alternative in terms of selectivity and efficiency. 
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In conclusion, 2-(2-bromo-1,1-dimethylethyl)azetidines were proven to be useful starting materials 
to perform rearrangements toward substituted six-membered azaheterocycles. These reactions 
presumably involve the intermediacy of 1-azoniabicyclo[2.2.0]hexanes, which are subsequently 
prone to undergo a nucleophile-induced ring enlargement toward a wide variety of highly 
functionalized piperidines. In particular, this methodology allowed the development of novel 
stereodefined 4-hydroxypiperidines, which are of high importance in pharmaceutical chemistry. 
3.2.2 Synthesis of 3,4-disubstituted 5,5-dinor-dimethylpiperidines through 
rearrangement of 2-(2-mesyloxyethyl)azetidines (Paper III, IV and V) 
In the next part of this work, the synthesis of analogous dinor-dimethylpiperidines 11 was envisaged 
(Figure 8), as the absence of a 5,5-gem-dimethyl group might have a pronounced influence on the 
biological profile of this class of compounds. From a retrosynthetic point of view, the synthesis and 
subsequent ring expansion of 2-(2-mesyloxyethyl)azetidines 13, prepared via mesylation of the 
corresponding alcohols, could offer a convenient alternative and an easy access to this new class of 
5-unsubstituted piperidines 11. The present paragraph will focus on the reactivity of 2-(2-
mesyloxyethyl)azetidines 13 with regard to different nucleophiles to develop new pathways toward 
biologically relevant piperidines 11 (Figure 8). 
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Figure 8 
3.2.2.1 Synthesis of 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 
In order to achieve a selective oxidation and to circumvent difficulties associated with the presence 
of a free hydroxyl group during β-lactam formation, 1,3-propanediol 145 was first monoprotected as 
its tert-butyldimethylsilyl ether 146 using a literature protocol, involving silylation of the 
monosodium salt (obtained upon treatment of diol 145 with one equiv of NaH in THF) with one equiv 
of tert-butyldimethylsilyl chloride (TBDMSCl) in THF,
84
 and was then oxidized to the corresponding 
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aldehyde 147 by means of a Swern oxidation using oxalyl chloride, DMSO and Et3N in CH2Cl2 (Scheme 
38).
85
 Subsequent imination of 3-(tert-butyldimethylsilyloxy)propanal 147 with one equiv of the 
corresponding primary amines in dichloromethane in the presence of MgSO4 as a drying agent led to 
the formation of (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]alkylamines 148a-h in good yields 
(Scheme 38). 
1 equiv NaH
 THF, rt, 1 h
    
1 equiv TBDMSCl
 THF, rt, 1 h 146 (97%)
1.1 equiv (COCl)2
2.2 equiv DMSO
5 equiv Et3N
CH2Cl2, -78 °C      rt, 1 h
147 (98%)
O
H OTBDMS
1 equiv R1NH2
2 equiv MgSO4
CH2Cl2, rt, 2 h
145
148a (R1 = iPr, 70%)
148b (R1 = cHex, 75%)
148c (R1 = iBu, 68%)
148d (R1 = allyl, 76%)
148e (R1 = nPr, 63%)
148f (R1 = nBu, 80%)
148g (R1 = Bn, 71%)
148h (R1 = Ph, 69%)
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2)
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H
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HO OTBDMSHO OH
 
Scheme 38 
Subsequently, in order to evaluate the Staudinger synthesis of 4-[2-(tert-
butyldimethylsilyloxy)ethyl]azetidin-2-ones 12, N-isopropylimine 148a was selected as a model 
substrate and was subjected to different reaction conditions, involving variation of the solvent, base, 
temperature and reaction time (Scheme 39, Table 5). In almost all cases, mixtures of cis-4-[2-(tert-
butyldimethylsilyloxy)ethyl]-1-isopropyl-3-phenoxyazetidin-2-one 12a and N-[3-(tert-
butyldimethylsilyloxy)prop-1-en-1-yl]-N-isopropyl-2-phenoxyacetamide 149a were obtained 
(12a/149a 25-85/15-75), next to negligible amounts of unidentified side products. Furthermore, 
different attempts to tune the reaction selectivity toward β-lactam 12a by applying more harsh 
reaction conditions were not successful, as the ratio of compounds 12a and 149a remained 
unaffected independent of the reaction temperature and the temperature of acid chloride addition 
(Table 5, Entry 6-8). 
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Scheme 39 
Table 5. Staudinger reaction of (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]isopropylamine 148a under 
different reaction conditions 
Entry Solvent Base Acid chloride added 
at 
Reaction temperature and 
time 
Resulta 
1 C6H6 Et3N reflux reflux, 1 h; rt, 15 h 12a/149a = 25/75 
2 C6H6 2,6-lutidine reflux reflux, 15 h complex mixture 
3 C6H6 Et3N reflux reflux, 15 h 12a/149a = 30/70 
4 CH2Cl2 PPh3 0 °C rt, 15 h complex mixture 
5 CH2Cl2 Et3N 0 °C rt, 15 h 12a/149a = 83/17 
6 CH2Cl2 Et3N 0 °C reflux, 15 h 12a/149a = 80/20 
7 CH2Cl2 Et3N reflux reflux, 15 h 12a/149a = 81/19 
8 CH2Cl2 Et3N reflux reflux, 1 h; rt, 15 h 12a/149a = 85/15 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
In the next phase, the synthesis of a number of 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 
12 was evaluated according to the optimal reaction conditions as described in Table 5, Entry 5. Thus, 
treatment of (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]alkylamines 148 with 1.3 equiv of 
phenoxy- or benzyloxyacetyl chloride in dichloromethane in the presence of three equiv of Et3N 
resulted in the corresponding mixtures of β-lactams 12 and N-acyl enamines 149 (22/78 – 83/17) 
after 15 hours at room temperature (Scheme 40, Table 6). It should be noted that the specific N-
substituent in imines 148 has a pronounced influence on the ratio of β-lactams 12 and N-acyl 
enamines 149, as the presence of an isobutyl, allyl or benzyl group favors the formation of the 
corresponding N-acyl enamines 149, while an isopropyl group leads to the corresponding β-lactams 
12. The Staudinger synthesis of β-lactams 12 proceeded in a highly diastereoselective way, which can 
be attributed to the electron-donating benzyloxy or phenoxy group present in the Boose-Evans 
ketenes (see paragraph 3.1.1).
71
 As the coupling constant between the protons at C-3 and C-4 in 
1
H 
NMR (CDCl3) was between 4.1 and 5.2 Hz, the relative stereochemistry of β-lactams 12 was assigned 
as cis.
69
 It should be noted that the reported yields are yields obtained after purification by column 
chromatography on silica gel. 
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Scheme 40 
Table 6. Synthesis of 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 12 and N-[3-(tert-
butyldimethylsilyloxy)prop-1-en-1-yl]acetamides 149 
Substrate R1 R2 Resulta 
148a iPr Ph 12a/149a = 83/17 
148a iPr Bn 12b/149b = 75/25 
148b cHex Bn 12c/149c = 67/33 
148c iBu Bn 12d/149d = 40/60 
148d allyl Bn 12e/149e = 22/78 
148b cHex Ph 12f/149f = 33/67 
148e nPr Ph complex mixture 
148f nBu Bn complex mixture 
148g Bn Ph 12g/149g = 33/67 
148h Ph Bn complex mixture 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
The presence of N-acyl enamines 149 can be explained as follows. Nucleophilic addition of imines 
148 across the acid chloride and subsequent α-deprotonation with respect to the in situ formed 
iminium moiety 150 can account for the formation of the observed enamides 149 (Scheme 41). It is 
known that N-(alkylmethylidene)amines are less reactive toward [2+2]-cyclocondensation reactions 
as compared to N-(arylmethylidene)amines, sometimes resulting in the full and selective formation 
of enamides instead of azetidin-2-ones.
10,86
 The E-stereochemistry assigned to the olefinic moiety in 
enamides 149 is supported by the observed vicinal coupling constants between both olefinic protons 
(J = 13.8 Hz, 
1
H NMR, CDCl3). 
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Scheme 41 
Although the chemistry of β-lactams has been thoroughly investigated in the past,4 very little is 
known about the synthetic applicability of the latter class of 2-azetidinones 12, pointing at the 
unexplored nature of this subject. Indeed, β-lactams 12 hold interesting potential for further 
elaboration due to the presence of a strained four-membered ring and an oxygenated carbon center 
in the side chain. Therefore, a thorough investigation was executed to reveal the synthetic 
applicability of these new β-lactam scaffolds, which will be presented in the following sections. 
3.2.2.2 Synthesis of 2-(2-mesyloxyethyl)azetidines 
In accordance with the synthesis of 3,4-disubstituted 5,5-dimethylpiperidines from 2-(2-bromo-1,1-
dimethylethyl)azetidines (see paragraph 3.2.1), a similar strategy was contemplated for the 
preparation of piperidines from 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 12a-c. This 
methodology involves an initial reduction toward the corresponding azetidines in order to enhance 
the nucleophilicity of the nitrogen atom, followed by the introduction of a leaving group in γ-position 
with respect to the azetidine nitrogen. In this way an intramolecular substitution reaction toward 
bicyclic azetidinium intermediates can take place, which are prone to undergo ring opening by the 
liberated leaving group or by an additional nucleophile, furnishing the premised piperidine 
derivatives. 
In order to perform a selective reduction of the carbonyl moiety without affecting the four-
membered ring system, β-lactams 12a-c were treated with monochloroalane (AlH2Cl), as this method 
had already been proven to be a suitable method for the synthesis of functionalized azetidines.
66a,87
 
Also in the present case, reductions of highly functionalized β-lactams 12a-c were performed 
successfully in that respect. Thus, 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 12a-c, 
obtained in analytically pure form after column chromatography on silica gel, were treated with one 
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molar equiv of AlH2Cl, prepared in situ from three molar equiv of LiAlH4 and one equiv of AlCl3, in 
diethyl ether at 0 °C for two hours, affording novel 2-(2-hydroxyethyl)azetidines 151a-c in good yields 
(48-50%) after deprotection of the silyl ether using 1.1 equiv of tetra-n-butylammonium fluoride 
(TBAF) in THF (Scheme 42). It has to be noted that in all cases significant amounts of 2-(2-
hydroxyethyl)azetidines 151a-c (40-85%) were present in the crude reaction mixtures after 
monochloroalane reduction of the corresponding β-lactams 12a-c without subsequent introduction 
of TBAF. Furthermore, it was necessary to perform an inverse addition by adding β-lactams 12a-c to 
one molar equiv of AlH2Cl in diethyl ether. 
N
R2O
O R1
OTBDMS 1 equiv AlH2Cl
Et2O, rt, 1 h; 0 °C, 2 h
1.1 equiv TBAF
THF, 0 °C     rt, 5 h
N
R2O
R1
OH
N
R2O
R1
OMs
1.05 equiv MsCl
1.1 equiv Et3N
0.1 equiv DMAP
1)
2) CH2Cl2, 0 °C, 3 h
12a-c 151a (R1 = iPr, R2 = Ph, 48%)
151b (R1 = iPr, R2 = Bn, 49%)
151c (R1 = cHex, R2 = Bn, 50%)
13a (R1 = iPr, R2 = Ph, 90%)
13b (R1 = iPr, R2 = Bn, 88%)
13c (R1 = cHex, R2 = Bn, 85%) 
Scheme 42 
The reductive removal of the carbonyl group in β-lactams 12a-c proceeded with the expected 
retention of the stereochemistry as defined during the Staudinger synthesis of these β-lactams. The 
relative stereochemistry of azetidines 151a-c with regard to the protons at C-2 and C-3 was assigned 
as cis based on the coupling constants between these protons (6.6-7.7 Hz, 
1
H NMR, CDCl3), in 
accordance with literature data.
9,75b,87
  
In general, azetidines are an important class of azaheterocyclic systems, as the strained four-
membered ring is found in many naturally occurring and synthetic organic compounds with 
interesting biological and pharmacological properties.
88
 In addition, azetidines have been shown to 
be excellent building blocks in organic synthesis.
79,80,19
 Also, 2-(2-hydroxyethyl)azetidines 151a-c were 
expected to furnish a broad scala of reactivities, although little has been reported on the synthesis 
and reactivity of this type of functionalized azetidines. In this way, the hydroxyl moiety in azetidines 
151a-c was activated upon treatment with 1.05 equiv of mesyl chloride (MsCl) in the presence of a 
base and a catalytic amount of 4-(dimethylamino)pyridine (DMAP) in dichloromethane at 0 °C for 
three hours (Scheme 42), in order to provide the dinor-dimethyl analogues of 2-(2-bromo-1,1-
dimethylethyl)azetidines 8 (see paragraph 3.2.1) as eligible substrates for ring expansion toward 
novel piperidine derivatives (Figure 9). 
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It should be stressed that during workup of the obtained mesylated azetidines 13a-c, careful 
monitoring of the temperature proved to be very important, as evaporation of the solvent in vacuo 
at temperatures higher than 25 °C led to the spontaneous formation of reasonable amounts (4-35%) 
of ring-expanded 4-mesyloxypiperidines 152a-c, which can be explained considering the formation 
and subsequent mesylate-induced ring opening of intermediate 1-azoniabicyclo[2.2.0]hexanes 14a-c. 
In addition, small amounts of 2-vinylazetidines 153a-c (3-12%) were observed as well in the crude 
reaction mixtures (Scheme 43). It should be mentioned that the transformation of the hydroxyl group 
in 2-(2-hydroxyethyl)azetidines 151 into other leaving groups, such as a tosylate or a chloride, is 
expected to result in the formation of analogous ring-expanded piperidines and vinylazetidines due 
to the high inherent instability of the azetidine-containing substrates. 
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Scheme 43 
3.2.2.3 Synthesis of 3,4-disubstituted 5,5-dinor-dimethylpiperidines 
In this section, the above-described synthetic methodology concerning the nucleophile-induced ring 
expansion of 2-(2-bromo-1,1-dimethylethyl)azetidines 8 toward functionalized piperidine derivatives 
via intermediate 1-azoniabicyclo[2.2.0]hexanes 9 is extended toward the synthesis of their dinor-
dimethyl variants, as, given the broad medicinal relevance of piperidines in general, the absence of a 
5,5-gem-dimethyl moiety can modify the related bioactivity due to changes in conformational 
properties (Figure 10). 
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Figure 10 
3.2.2.3.1 Synthesis of 4-bromopiperidines 
In a first part, treatment of 2-(2-mesyloxyethyl)azetidines 13a-c with two equiv of LiBr in acetonitrile 
for 15 hours under reflux resulted in the selective formation of 4-bromopiperidines 154a-c in good 
yields (47-65%) after column chromatography on silica gel or recrystallization from absolute ethanol 
(Scheme 44). The cis-stereochemistry of 3-oxygenated 4-bromopiperidines 154a-c was assessed 
based on the coupling constants between the protons at positions 3 and 4 (3.6-3.9 Hz, 
1
H NMR, 
CDCl3), which are in accordance with those reported in the literature for cis-vicinal substituted 
piperidines.
82
 Furthermore, also the fact that dehydrobromination occurred upon treatment of 
piperidines 154a,b with dimsylsodium (four equiv) in DMSO at 150 °C for 15 h was indicative of a cis-
relationship between the C-3 and C-4 substituents, which is required to obtain an anti-elimination 
(Scheme 44). The obtained cyclic enol ethers 155a,b could be easily hydrolysed to give 1-
isopropylpiperidin-3-one 156 by reaction with aq 2 M HCl at 40 °C for 40 h (Scheme 44). Piperidin-3-
ones constitute a class of compounds of high biological interest as they are considered as 
pharmacophores in medicinal sciences and their synthesis is often associated with the preparation of 
biologically relevant compounds.
89
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From a mechanistic point of view, the observed cis-stereochemistry of piperidines 154a-c can be 
rationalized considering the in situ formation and consecutive ring opening of bicyclic azetidinium 
intermediates 14a-c (Scheme 44). This reaction mechanism is based on the intramolecular 
displacement of the mesyloxy substituent by the nucleophilic nitrogen lone pair of azetidines 13a-c 
toward reactive bicyclic intermediates 14a-c, which are subsequently prone to undergo ring opening 
by a nucleophile, i.e., bromide, at the bridgehead carbon atom in an SN2 fashion to furnish the 
thermodynamically more favored six-membered 4-bromopiperidines 154a-c (Scheme 44). An 
alternative reaction pathway, involving direct nucleophilic substitution of the mesyloxy group by 
bromide followed by ring expansion via bicyclic azetidinium ions 14a-c should not be excluded. The 
selective formation of 4-bromopiperidines 154a-c over 4-mesyloxypiperidines 152a-c can be 
attributed to the considerably stronger nucleophilicity of bromide in acetonitrile as compared to the 
mesyloxy anion. 
Upon detailed spectroscopic analysis, small amounts of 2-vinylazetidines 153a-c (5-9%) were 
observed as well in the crude reaction mixtures, as characteristic azetidine chemical shifts and typical 
signals for vinylic protons were detected in the 
1
H NMR spectra of these mixtures (CDCl3, Table 7). 
Table 7. Conversion of 2-(2-mesyloxyethyl)azetidines 13a-c toward 4-bromopiperidines 154a-c 
Substrate R1 R2 Resulta 
13a iPr Ph 153a/154a = 6/94 
13b iPr Bn 153b/154b = 5/95 
13c cHex Bn 153c/154c = 9/91 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
3.2.2.3.2 Synthesis of 4-acetoxy- and 4-hydroxypiperidines 
The scope of this synthetic methodology was further extended toward other 4-substituted piperidine 
derivatives. The possibility of introducing other nucleophiles than bromide was first tested through 
the addition of sodium acetate. Thus, treatment of azetidines 13a-c with two equiv of NaOAc in 
acetonitrile under reflux for 15 hours resulted in the selective formation of 4-acetoxypiperidines 
157a-c in good yields after purification (Scheme 45). The relative cis-stereochemistry controlled by 
the Staudinger synthesis of β-lactams 12a-c was transferred through the reaction sequence, 
affording cis-piperidines 157a-c in a stereoselective way as demonstrated by the vicinal coupling 
constants between the protons at C-3 and C-4 (2.9-4.0 Hz, 
1
H NMR, CDCl3), which are in accordance 
with literature data concerning cis-3,4-dioxygenated piperidines.
82
 Again, small amounts of 2-
vinylazetidines 153a-c (2-6%) were present in the crude reaction mixtures as well (Table 8).  
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Next, the reactivity of 4-acetoxypiperidines 157a-c was evaluated with the intention to provide a 
convenient entry into the biologically relevant class of 4-hydroxylated piperidines,
83
 yielding the 
corresponding 4-hydroxypiperidines 158a-c in 56-70% yield via methanolysis of the ester moiety 
upon treatment with two equiv of K2CO3 in methanol under reflux for one hour (Scheme 45).  
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Scheme 45 
Table 8. Conversion of 2-(2-mesyloxyethyl)azetidines 13a-c toward 4-acetoxypiperidines 157a-c 
Substrate R1 R2 Resulta 
13a iPr Ph 153a/157a = 2/98 
13b iPr Bn 153b/157b = 6/94 
13c cHex Bn 153c/157c = 3/97 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
3.2.2.3.3 Attempts toward the synthesis of 4-fluoropiperidines 
In the pharmaceutical industry, about 20% of the prescribed pharmaceuticals and 30% of the leading 
30 blockbuster drugs by sales contain a C-F bond, as illustrated by inter alia Lipitor (inhibits 
cholesterol synthesis), Advair Discus (anti-asthmatic), and Prevacid (antacid/stomach ulcer).
90
 In 
addition, organofluorine compounds have also achieved significant advances in the area of 
agrochemistry.
91
 This is mainly due to the fact that the replacement of a hydrogen atom with fluorine 
often gives rise to drastic changes in biological activity because of the altered electronic distribution 
and changes in conformational properties.
92
 Consequently, during the last decades, much effort has 
been devoted to synthesize site-specific fluorinated compounds, and the development of new 
synthetic approaches and new commercial applications are the subject of intense research in organic 
chemistry and related disciplines.
93
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In particular, fluorinated azaheterocyclic compounds attract widespread attention, and fluorine-
containing piperidines are important building blocks from a medicinal point of view.
93a-e,94
 The 
numerous patents concerning fluorinated piperidines emphasize the possibility of these compounds 
as substituents to modulate the activity of different active compounds, such as antidiabetic,
95
 
anticancer,
96
 antidepressant,
97
 antibacterial,
98
 anti-inflammatory and immunomodulatory agents
99
 
and compounds for the treatment of neurological and psychiatric diseases (Figure 11).
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Figure 11 
In light of this biological importance, efforts were made in order to perform a ring enlargement of 2-
(2-mesyloxyethyl)azetidines 13a-c as a convenient synthetic approach toward new 4-fluorinated 
piperidines lacking a 5,5-dimethyl moiety. 
In analogy with the previously described ring expansion of 2-(2-bromo-1,1-dimethylethyl)azetidines 8 
toward 4-fluoropiperidines,
19
 2-(2-mesyloxyethyl)azetidine 13a was treated with 
tetramethylammonium fluoride (TMAF or Me4NF) under different reaction conditions, involving 
variation of the number of equiv of Me4NF (2, 10), solvent (DMSO, DMF, CH3CN), temperature (35 °C, 
60 °C, 100 °C, reflux), reaction time (15-48 h), and time of TMAF-addition (0–3 h), inevitable leading 
to the formation of mixtures of 2-(2-fluoroethyl)azetidine 162a, 4-fluoropiperidine 163a and 
tetrahydropyridine 155a in varying ratios (40-82/18-60/15-63, Scheme 46, Table 9), next to negligible 
amounts of 2-vinylazetidine 153a (< 8%). 
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Scheme 46 
Table 9. Attempts toward the selective synthesis of cis-4-fluoro-1-isopropyl-3-phenoxypiperidine 163a 
through TMAF-mediated ring expansion of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a 
Entry Number of 
equiv of Me4NF 
Solvent Temperature Me4NF added 
at 
Time after 
addition 
Resulta 
1 2 DMSO 100 °C 0 h 18 h 162a/163a = 80/20 
2 2 DMF 60 °C 0 h 18 h 162a/163a = 82/18 
3 2 DMSO 100 °C 0 h 48 h 162a/163a = 78/22 
4 10 DMSO 60 °C 0 h 18 h 162a/163a = 81/19 
5 2 CH3CN 35 °C - reflux 5 min (35 °C) 15 h (reflux) 162a/163a/155a = 
60/25/15 
6 2 CH3CN 35 °C - reflux 30 min (35 °C) 15 h (reflux) 162a/163a/155a = 
40/30/30 
7 2 CH3CN 35 °C - reflux 1 h (35 °C) 15 h (reflux) 163a/155a = 60/40 
8 2 CH3CN 35 °C - reflux 2 h (35 °C) 15 h (reflux) 163a/155a = 45/55 
9 2 CH3CN 35 °C - reflux 3 h (35 °C) 15 h (reflux) 163a/155a = 37/63 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
From a mechanistic viewpoint, mesylated azetidine 13a probably undergoes competition between 
intermolecular SN2-substitution at the electrophilic oxygenated carbon center leading to the 
formation of 2-(2-fluoroethyl)azetidine 162a on the one hand, and intramolecular nucleophilic 
substitution toward bicyclic azetidinium intermediate 14a, followed by regiospecific ring opening by 
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the nucleophilic fluoride at the bridgehead carbon atom in an SN2 fashion to yield the premised 4-
fluoropiperidine 163a on the other (Scheme 46, Table 9, Entry 1-4).  
In order to circumvent the formation of 2-(2-fluoroethyl)azetidine 162a, 2-(2-mesyloxyethyl)azetidine 
13a was first allowed to rearrange toward bicyclic azetidinium salt 14a by heating in CH3CN at 35 °C 
without the addition of the fluorine source (Table 9, Entry 5-9). Indeed, as the heating time before 
Me4NF-addition was prolonged, the ratio gradually changed in favor of the premised fluorinated 
piperidine 163a, but 1H NMR analysis revealed that substantial amounts (15-63%) of cyclic enol ether 
155a were present in the crude reaction mixtures as well. The latter observation can be rationalized 
considering the initial formation of the ring expanded 4-mesyloxypiperidine 152a, followed by the 
fluoride-induced mesylate elimination toward cyclic enol ether 155a, as the ability of the fluoride 
anion to act as a base is well known in the literature.
101
 Consequently, this strategy for the selective 
synthesis of fluorinated piperidines was abandoned. 
In a second approach toward the synthesis of fluorinated piperidines, a totally different synthetic 
route starting from 4-bromopiperidine 154a was contemplated, involving either an initial bromine 
dislocation induced by the nitrogen lone pair leading to the formation of azetidinium salt 14a 
followed by a regiospecifically fluoride-mediated ring opening toward 4-fluoropiperidine 163a due to 
a double Walden inversion (Scheme 47, Route A), or a direct SN2-substitution at the brominated 
carbon atom toward the corresponding trans-derivative 164a (Scheme 47, Route B). Following this 
rationale, cis-4-bromo-1-isopropyl-3-phenoxypiperidine 154a was initially heated in acetonitrile, DMF 
or DMSO in the presence of two equiv of tetrabutylammonium fluoride (TBAF or Bu4NF), 
unfortunately resulting in complete recovery of the starting material (Table 10, Entries 1, 5, 9). 
Subsequently, extensive efforts using different silver salts (AgBF4, Ag2CO3) in order to enhance halide 
dissociation driven by the precipitation of the resulting silver bromide failed, as the starting 
compound was recovered completely or the formation of rather complex reaction mixtures was 
observed in which no typical signals for the expected substitution product could be detected, as 
shown by GC and 
1
H NMR analysis (Table 10).  
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Scheme 47 
Table 10. Attempts toward the synthesis of 4-fluoro-1-isopropyl-3-phenoxypiperidine 163a/164a from cis-4-
bromo-1-isopropyl-3-phenoxypiperidine 154a 
Entry Additive Solvent Temperature Time Resulta 
1 - CH3CN reflux 22 h no reaction 
2 Ag2CO3 (5 equiv) CH3CN rt 15 h no reaction 
3 Ag2CO3 (5 equiv) CH3CN reflux 3 h complex mixture 
4 AgBF4 (5 equiv) CH3CN reflux 2 h complex mixture 
5 - DMF 60 °C 18 h no reaction 
6 Ag2CO3 (5 equiv) DMF rt 15 h no reaction 
7 Ag2CO3 (5 equiv) DMF 80 °C 2 h complex mixture 
8 AgBF4 (5 equiv) DMF 80 °C 1.5 h complex mixture 
9 - DMSO 100 °C 22 h no reaction 
10 AgBF4 (5 equiv) DMSO rt 18 h no reaction 
11 Ag2CO3 (5 equiv) DMSO 60 °C 2 h complex mixture 
12 AgBF4 (5 equiv) DMSO 100 °C 2 h complex mixture 
a
 Based on 
1
H NMR and/or GC analysis of the crude reaction mixture. 
 
Among the broad variety of fluorinating agents used to fulfill the increasing demand for site-selective 
fluorination of organic compounds, N,N-diethylaminosulfur trifluoride (DAST) has emerged as a 
powerful reagent to convert alcohols into the corresponding monofluorinated target molecules.
102
 
This reagent is described to initiate rearrangements through anchimeric assistance of an electron-
rich group (e.g., in compounds with methoxy,
103
 amino,
104
 oxiranyl,
105
 azido
106
 groups, or with a 
double bond
103c
) due to the formation of a very good leaving group. In that respect, the selective and 
efficient ring expansion of cyclic α-(hydroxymethyl)amines 165 and 168 toward cyclic β-fluoro amines 
167 and 170 upon treatment with DAST has been reported very recently (Scheme 48).104b  
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Scheme 48 
Accordingly, a similar strategy was envisaged for the rearrangement of cyclic 2-
(hydroxyethyl)azetidines 151 into cyclic γ-fluoro amines 163. This methodology involves a DAST-
mediated activation of the hydroxyl functionality in γ-position with respect to the azetidine nitrogen. 
Subsequent intramolecular nucleophilic substitution by the nitrogen lone pair in intermediate 
azetidines 171 toward azetidinium salts 14 can take place, which can finally furnish 4-
fluoropiperidines 163 through ring opening by fluoride (Scheme 49). 
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Scheme 49 
In order to achieve this goal, cis-2-(2-hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 151a was 
selected as a model substrate and treated with 1.5 equiv of DAST in different solvents and at 
different temperatures (Scheme 50, Table 11). Unfortunately, no formation of the desired 4-
fluoropiperidine 163a was observed and only complex reaction mixtures were obtained. 
Consequently, this methodology was abandoned as well. 
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Scheme 50 
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Table 11. Attempts toward the selective synthesis of cis-4-fluoro-1-isopropyl-3-phenoxypiperidine 163a 
through DAST-mediated ring expansion of cis-2-(2-hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 151a 
Solvent Conditions Resulta 
CH2Cl2 0 °C, 1 h then rt, 1 h complex mixture 
CH2Cl2 -78 °C, 1 h then rt, 1 h complex mixture 
THF 0 °C, 1 h then rt, 1 h complex mixture 
acetone 0 °C, 1 h then rt, 1 h complex mixture 
acetone -78 °C, 1 h then rt, 1 h complex mixture 
THF + 3 equiv Et3N 0 °C, 1 h then rt, 1 h complex mixture 
a
 Based on 
1
H NMR and/or GC analysis of the crude reaction mixture. 
 
It is clear that the transformation of 2-(2-mesyloxyethyl)azetidines and 2-(2-hydroxyethyl)azetidines 
into the corresponding 4-fluoropiperidines remains troublesome applying the proposed 
methodologies. Nevertheless, the TMAF-mediated ring expansion of 2-(2-mesyloxyethyl)azetidines 
clearly needs further elaboration, as cis-4-fluoro-1-isopropyl-3-phenoxypiperidine 163a was formed 
in 18-60% through ring enlargement of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a. 
3.2.2.3.4 Synthesis of 4-(formyloxy)piperidines 
In order to further assess their intrinsic reactivity, azetidines 13a-c were heated in DMF at 80 °C for 
three hours. Surprisingly, next to small amounts of 2-vinylazetidines 153a-c (3-7%, Table 12), 
azetidines 13a-c were almost exclusively converted into 4-(formyloxy)piperidines 173a-c (Scheme 
51). A plausible explanation for this transformation involves the formation of intermediate 
azetidinium salts 14a-c, followed by nucleophilic ring opening by dimethylformamide at the 
bridgehead carbon atom. Subsequent hydrolysis of intermediates 172a-c during aqueous workup 
afforded the corresponding piperidines 173a-c in high yields (53-70%) after purification by column 
chromatography on silica gel. Again, the relative cis-stereochemistry obtained during the Staudinger 
synthesis of β-lactams 12a-c was retained, thus affording cis-piperidines 173a-c as can be derived 
from the coupling constants between the protons at C-3 and C-4 (3.9-4.1 Hz, 
1
H NMR, CDCl3).
82
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Scheme 51 
Table 12. Conversion of 2-(2-mesyloxyethyl)azetidines 13 toward 4-(formyloxy)piperidines 173 
Substrate R1 R2 Resulta 
13a iPr Ph 153a/173a = 5/95 
13b iPr Bn 153b/173b = 3/97 
13c cHex Bn 153c/173c = 7/93 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
In addition to the elegant nature of this transformation (no additional reagents required), 4-
(formyloxy)piperidines thus obtained exhibit interesting structural characteristics, making them 
suitable substrates for further elaboration. The presence of a formyloxy substituent at the 4-position 
of the piperidine backbone provides an entry into functionalized piperidines through further 
modification of the ester functionality. 
3.2.2.3.5 Synthesis of piperidin-4-ones through a ring expansion-oxidation protocol 
Piperidin-4-ones represent an important class of bioactive azaheterocycles attracting a progressive 
interest due to their observed biological and pharmaceutical properties, such as antiviral, 
antitumor,
21
 analgesic,
22
 local anaesthetic,
23
 antimicrobial, bactericidal, fungicidal, herbicidal, 
insecticidal, antihistaminic, anti-inflammatory, anticancer, CNS stimulant and depressant activities.
20
 
Furthermore, piperidin-4-ones have been used as eligible intermediates in the synthesis of a variety 
of biologically active compounds, including functionalized piperidines, through further modification 
of the carbonyl moiety.
107
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At the Department of Sustainable Organic Chemistry and Technology (UGent), 2-(2-bromo-1,1-
dimethylethyl)azetidines 8 have been rearranged into 5,5-dimethylpiperidin-4-ones 174 in high 
purity upon treatment with five equiv of silver carbonate or silver tetrafluoroborate in DMSO for 18 
hours at 100 °C.
19
 During these transformations, the presence of a silver salt proved to be 
indispensable. This smooth rearrangement probably proceeded through nucleophilic attack of the 
nitrogen lone pair onto the electrophilic halogenated carbon atom, affording an intermediate 
azetidinium salt. Hereby, the exempted bromide was unable to induce ring enlargement toward 4-
bromopiperidines due to complexation with the silver ion. The necessity of the silver counterion was 
thus based on trapping of the bromide so that ring transformation toward brominated piperidines 
was excluded. The intermediate bicyclic azetidinium salts were subsequently converted into 
piperidin-4-ones 174 upon DMSO-mediated ring enlargement, followed by abstraction of the acidic 
proton at the oxygenated carbon atom and liberation of dimethylsulfide.
19
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Scheme 52 
In order to broaden the scope of this synthetic transformation, the ring enlargement of 2-(2-
mesyloxyethyl)azetidines 13a-c via a similar ring expansion-oxidation mechanism was envisaged. In 
that respect, azetidines 13a-c were stirred in DMSO at 100 °C for 18 hours in the presence of five 
equiv of K2CO3,
89g
 resulting in full conversion of the starting material toward the desired piperidin-4-
ones 15a-c in 43-48% yield (Scheme 53), together with minor amounts of unidentified side products 
(8-27%). However, when wet DMSO was used, in some cases a substantial amount (up to 70%) of 4-
hydroxypiperidines 158a-c was obtained along with piperidin-4-ones 15a-c after heating of azetidines 
13a-c in DMSO, which might be the result of an incomplete oxidation reaction or direct hydrolysis of 
the strained intermediates 14a-c, probably due to the presence of water in DMSO. Moreover, the 
addition of K2CO3 appeared to be essential, as piperidin-4-ones 15a-c were formed in very low yields 
(5-8%) if the reaction was performed in the absence of K2CO3. In analogy with the above-described 
reaction mechanism, the initially formed bicyclic azetidinium ions 14a-c undergo a Kornblum-type 
reaction and are ring opened by DMSO at the bridgehead carbon atom in an SN2-type fashion to yield 
intermediate piperidines 175a-c, which are subsequently transformed into the corresponding 
piperidin-4-ones 15a-c upon proton abstraction. The preferential formation of piperidin-4-ones 15a-c 
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over 4-mesyloxypiperidines can be attributed to the relative higher nucleophilicity of DMSO as 
compared to the mesylate anion, making inactivation of the latter by complexation unnecessary. This 
stands in contrast with the necessity of a silver salt for the selective ring expansion-oxidation of 2-(2-
bromoethyl)azetidines 8 toward piperidin-4-ones 174. It should be stressed that this type of 
transformations is peculiar, as DMSO is known to directly oxidize organic halides and tosylates to the 
corresponding carbonyl compounds, as demonstrated amply by the Kornblum reaction and its 
variants.
108
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Scheme 53 
3.2.2.3.5.1 Reduction toward 4-hydroxypiperidines 
As mentioned before, the 4-hydroxypiperidine moiety comprises a privileged scaffold that is 
encountered in many bioactive compounds.
83
 In that respect, the reduction of piperidin-4-ones 15a-c 
was contemplated in the next phase. At first, treatment with two molar equiv of NaBH4 in MeOH was 
performed, affording the corresponding 4-hydroxypiperidines 158a-c in 73-88% yield after reflux for 
two hours (Scheme 54). It should be noted that this NaBH4-mediated reduction of racemic piperidin-
4-ones 15a-c toward 4-hydroxypiperidines 158a-c proceeded with complete cis-diastereoselectivity. 
The relative cis-stereochemistry at positions 3 and 4 is a direct result of the steric approach control, 
resulting in a preferential equatorial attack of the reducing agent with respect to the sterically 
hindered six-membered ring.
109
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Scheme 54 
In a second approach, an enzyme-mediated enantioselective reduction of piperidin-4-ones was 
investigated using alcohol dehydrogenases. The reduction of carbonyl compounds by alcohol 
dehydrogenases and their cofactors has numerous advantages compared to classical chemical 
reactions, such as the high level of enantioselectivity and the environmentally benign reaction 
conditions, and this field of research has gained an increased relevance over the past few years, 
especially concerning the synthesis of important intermediates for pharmaceuticals and bioactive 
compounds.
110
 As a selected example, racemic 3-benzyloxy-1-isopropylpiperidin-4-one 15b was 
treated with a commercially available S-specific
111
 or R-specific
112
 alcohol dehydrogenase in aqueous 
MES-buffer [2-(N-morpholino)ethanesulfonic acid] at 30 °C in the presence of NADH. This biocatalytic 
reduction reaction was performed by colleagues at the Department of Biochemical and Microbial 
Technology (UGent). In contrast to the chemical reduction process, the merit of this enzymatic 
approach comprises the S- and R-enantioselective reduction of the carbonyl functionality, in each 
case resulting in the formation of two diastereoisomers (ratio 1/1, based on 
1
H NMR, Scheme 55). 
The four enantiomers 176, 177, 178 and 179 were obtained in analytically pure form in 43-49% yield 
by separation of the latter diastereoisomeric mixtures through column chromatography on silica gel. 
In order to establish their enantiomeric ratio, esterification of hydroxypiperidines 176, 177, 178 and 
179 was performed utilizing one equivalent of (1S)-(-)-camphanic chloride in CH2Cl2 at room 
temperature for 15 hours in the presence of 0.1 equiv of DMAP [4-(dimethylamino)pyridine] and two 
equiv of Et3N, pointing to a diastereoisomeric ratio of 99.4/0.6, 99.4/0.6, 98.1/1.9 and 97.9/2.1 for 
piperidines 176, 177, 178 and 179, respectively (based on GC/MS-analysis). Consequently, an 
enantiomeric ratio of 99.4/0.6, 99.4/0.6, 98.1/1.9 and 97.9/2.1 could be assigned to 4-
hydroxypiperidines 176, 177, 178 and 179 (Scheme 55). The absolute configurations were assigned 
by comparison of the observed rotation of piperidines 176 (αD = +27.7°, CH2Cl2), 177 (αD = +7.6°, 
CHCl3), 178 (αD = -7.6°, CHCl3) and 179 (αD = -27.7°, CH2Cl2) with optical rotations described in the 
literature for similar 3,4-dioxygenated piperidines.
113
 Based on these findings, both chemical and 
enzymatic reductions can be used in a complementary way to effect a diastereoselective or 
enantioselective synthesis of 4-hydroxypiperidines from piperidin-4-ones, respectively. 
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Scheme 55 
3.2.2.3.6 Theoretical rationalization 
As described in the previous paragraphs, the reactivity of 2-(2-mesyloxyethyl)azetidines with regard 
to different nucleophiles was evaluated for the first time, resulting in the stereoselective preparation 
of a variety of new 4-acetoxy-, 4-hydroxy-, 4-bromo-, and 4-(formyloxy)piperidines. These 
diastereoselective ring expansions are expected to proceed via transient 1-
azoniabicyclo[2.2.0]hexanes, which are subsequently prone to undergo an SN2-type ring opening at 
the bridgehead carbon atom to afford the final heterocycles. To assess the feasibility of this process 
and the relative stability of the intermediates, Density Functional Theory (DFT) calculations were 
conducted by colleagues at the Center for Molecular Modeling, Ghent University, on both the 
formation of bicyclic azetidinium ion 14a and its ring opening by acetate, leading to the formation of 
the corresponding 4-acetoxypiperidine 157a (Scheme 45).  
The formation of bicyclic azetidinium intermediate 14a occurs via intramolecular nucleophilic attack 
of the nitrogen lone pair in azetidine 13a and simultaneous displacement of the mesylate anion as 
depicted TS1 (Figure 12). Three explicit acetonitrile molecules were used to stabilize the 
nucleophuge, each interacting with one of the mesylate oxygen atoms through charge-dipole 
interactions. Subsequently, ring opening of bicyclic intermediate 14a occurs via acetate-mediated 
nucleophilic attack at the bridgehead carbon atom, as shown in TS2 (Figure 13). Analogously, the 
incoming acetate anion is stabilized by explicit interactions with two acetonitrile molecules.  
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Figure 12. Formation of bicyclic azetidinium ion 14a, solvated by explicit acetonitrile molecules (M06-2X/6-
311++G(d,p)//B3LYP/6-31+G(d,p)); critical distances in Å 
 
Figure 13. Transition state structure (TS2) for the acetate-induced ring opening of bicyclic azetidinium ion 
14a, solvated by explicit acetonitrile molecules (B3LYP/6-31+G(d,p) geometries); critical distances in Å 
The relative free energies along the reaction path for the formation and consecutive ring opening of 
bicyclic intermediate 14a were calculated using two different solvation schemes, namely 
microsolvation (explicit solvation) and mixed solvation (explicit/implicit solvation). Explicit solvation 
involves placing discrete solvent molecules around the chemically active species to form a so-called 
“supermolecule” structure. However, in order to account for possible long-range interactions with 
the solvent environment, the supermolecule was immersed in a dielectric continuum using two 
different models (C-PCM and SMD). For all three solvation models, energies were refined using five 
different DFT methods (Table 13).  
Compared to non-solvated gas-phase results [relative free energy of TS1 in gas-phase = 136.6 kJ/mol, 
BMK/6-311++G(d,p)//B3LYP/6-31+G(d,p)], explicit solvation lowers barriers by an average of 15 
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kJ/mol by means of stabilizing the forming charge through intermolecular interactions. Results for 
both mixed solvation models, i.e., C-PCM and SMD, indicate that implicit solvation lowers the 
barriers by an additional 20 kJ/mol, bringing the barrier for the formation of bicyclic intermediate 
14a down to ~100 kJ/mol (Table 13). These results indicate that the formation of intermediate 14a is 
a feasible process and, furthermore, its stability is comparable to that of the starting azetidine 13a. 
Nucleophilic ring opening (TS2) of bicyclic azetidinium ion 14a occurs readily, as illustrated in the 
small barriers and highly exergonic nature of this reaction step (Table 13). 
Table 13. Relative Gibbs free energies (kJ/mol, 298K and 1atm) for the formation and consecutive 
nucleophilic ring opening of bicyclic azetidinium intermediate 14aa-c 
  Formation of intermediate 14a Ring opening of intermediate 14a 
  13a TS1 14a + 
mesylate 
14a + 
acetate 
TS2 157a 
Explicit 
solvation 
B3LYP 0.0 123.2 26.1 0.0 37.6 -141.1 
BMK 0.0 124.8 1.4 0.0 60.4 -120.3 
M06-2X 0.0 121.1 6.8 0.0 52.8 -142.6 
CAM-B3LYP 0.0 127.2 17.3 0.0 47.6 -141.4 
ωB97X-D 0.0 111.2 -1.8 0.0 57.6 -118.6 
Explicit/implicit 
solvation with 
C-PCM 
B3LYP 0.0 104.3 3.4 0.0 43.8 -134.9 
BMK 0.0 105.9 -21.4 0.0 65.4 -114.7 
M06-2X 0.0 102.3 -16.9 0.0 58.5 -135.3 
CAM-B3LYP 0.0 108.1 -5.7 0.0 53.1 -135.3 
ωB97X-D 0.0 92.2 -25.0 0.0 63.3 -111.9 
Explicit/implicit 
solvation with 
SMD 
B3LYP 0.0 103.3 -2.7 0.0 45.1 -135.3 
BMK 0.0 105.5 -26.8 0.0 66.2 -116.1 
M06-2X 0.0 102.2 -22.1 0.0 59.2 -136.8 
CAM-B3LYP 0.0 107.3 -11.6 0.0 54.2 -136.2 
ωB97X-D 0.0 91.8 -30.4 0.0 64.2 -113.1 
a
 B3LYP/6-31+G(d,p) optimized structures. 
b
 Single point energy calculations at all levels of theory with 6-
311++G(d,p) basis set. 
c
 Implicit solvation in acetonitrile, ε = 36.6. 
 
3.2.3 Conclusions 
In summary, next to their established reactivity toward the synthesis of 4-bromo-, 4-cyano-, 4-azido-, 
4-fluoro-, and 4-oxo-5,5-dimethylpiperidines, 2-(2-bromo-1,1-dimethylethyl)azetidines were proven 
to be useful starting materials to perform rearrangements toward 4-acetoxy- and 4-
hydroxypiperidines as well. Furthermore, the reactivity of 2-(2-mesyloxyethyl)azetidines, lacking a 
gem-dimethyl group, toward different nucleophiles was evaluated for the first time, pointing to a 
useful transformation of the former into the class of cis-3,4-disubstituted 5,5-dinor-
dimethylpiperidines, resulting in the stereoselective preparation of a variety of new 4-acetoxy-, 4-
hydroxy-, 4-bromo-, 4-formyloxy-, and 4-oxopiperidines in moderate to high yields. This approach 
constitutes a convenient alternative for the preparation of the former class of 5,5-
dimethylpiperidines and 5,5-dimethylpiperidin-4-ones, as the corresponding 5,5-dinor-dimethyl 
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variants provide interesting opportunities within the field of drug development, which can be of high 
importance in pharmaceutical and medicinal chemistry. In addition, the synthetic applicability of the 
latter 5,5-dinor-dimethylpiperidin-4-ones was demonstrated by means of both a chemical and an 
enzymatic reduction. Whereas the NaBH4-induced reduction is characterized by a cis-
diastereoselectivity, the alcohol dehydrogenase-mediated reductions proceeded with S- or R-
enantioselectivity at the carbonyl functionality. 
During these reactions, transient 1-azoniabicyclo[2.2.0]hexanes were prone to undergo an SN2-type 
ring opening at the bridgehead carbon atom to afford the final azaheterocycles in a stereoselective 
way. The cis-diastereoselectivity is thus controlled by the Staudinger synthesis of the starting β-
lactams and the SN2-ring opening of the intermediate bicyclic azetidinium ions. 
In addition to the experimental results, the intermediacy of transient 1-azoniabicyclo[2.2.0]hexanes 
in these transformations was further validated by means of high-level computational analysis. These 
results show that the bicyclic intermediate could be localized on the potential energy surface as a 
stable species. 
3.3 Synthesis of bicyclic tetrahydrofuran-fused β-lactams and 
their conversion into methyl cis-3-aminotetrahydrofuran-2-
carboxylates (Paper IV) 
In addition to the generation of different biologically interesting nitrogen-containing (heterocyclic) 
systems from azetidin-2-one derivatives by selective bond cleavage and rearrangements,
4
 as 
demonstrated in the previous paragraphs, the azetidin-2-one skeleton has also been extensively used 
as a template to construct cyclic structures fused to the four-membered ring using the 
functionalization of the β-lactam nucleus as a stereocontrolling element.
4g,24
 Among them, 3,4-fused 
(C-fused) bicyclic β-lactams have received much less attention as compared to their celebrated N-
fused analogues.
4g,14,24,114
 However, in many cases the resistance to β-lactam antibiotics can be 
attributed to a high level of expression of class C β-lactamases, which are reported to be selectively 
inhibited by 3,4-bridged monobactam derivatives, as some β-lactams C-fused with a cyclopentene,
115
 
pyrrolidine
116
 or thiazolidine
117
 ring have been found to possess promising β-lactamase inhibitory 
activities. In addition, recently, bicyclic β-lactams C-fused with carbocycles and a carbohydrate unit 
have been reported to exhibit promising activities against malaria,
118a
 leishmaniasis
118b
 and several 
types of cancer.
118c
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Although the tetrahydrofuran motif is ubiquitous as a structural feature in bioactive natural and 
synthetic molecules,
119
 relatively few methods are available for the construction of tetrahydrofuran-
based β-lactams.114a-i For example, the transition metal-catalyzed heterocyclization of azetidin-2-one-
tethered γ-allenols114a,114c and γ-alkynols114d and the Ag-mediated intramolecular 1,3-dipolar 
cycloaddition of oxo-N-propargylamides
114b
 comprise regiocontrolled routes to β-lactams bearing an 
oxygen-containing 3,4-fused five-membered ring system. Very recently, chlorinated 
tetrahydrofuro[3,2-c]azetidin-2-ones have been prepared by a copper(I)-catalyzed atom transfer 
radical cyclization.
114e
 The radical-mediated ring closure of 3-benzyloxy-4-ethynylazetidin-2-ones has 
been described toward the corresponding C-fused bicyclic cis-β-lactams,114g and a cis-4-(2-
fluorophenyl)-3-hydroxy-β-lactam was transformed into a tricyclic β-lactam via an (η
6
-
arene)tricarbonylchromium(0) complex through a number of reaction steps.
114f 
In view of the continuous quest for new lead compounds in the pharmaceutical industry, the 
synthesis of new (cyclic) β-amino acid derivatives comprises an important research field in modern 
organic chemistry. The selective synthesis of β-amino acids120 has been the subject of tremendous 
effort principally due to their important biological activities
121
 as for example enzyme inhibitors or α-
amino acid surrogates in the construction of peptides possessing unique conformational properties 
(β-peptides).122 Furthermore, cyclic β-amino acids in which the amino group and the acid 
functionality are vicinally attached to an aliphatic ring system represent an important challenge due 
to their biological utility.
123
 Cispentacin 180,124 an antifungal agent against various Candida strains 
and a subunit of the natural antibiotic amipurimycin,
125
 comprises a relevant example and has 
attracted considerable attention to these five-membered β-amino acids (Figure 14).
126
 Their 
oxaheterocyclic analogues, i.e., tetrahydrofurancarbocyclic acid derivatives, vicinally substituted with 
an amino group, are known to possess antimycotic activities.
127
 Consequently, the synthesis of 
oxolane β-amino acid derivatives such as 181 constitutes a relevant challenge in organic chemistry 
(Figure 14). 
H2N
O
HO
R
S
180
cispentacin
O
3R2RN
O
R1O
181
 
Figure 14 
At the Department of Sustainable Organic Chemistry and Technology (UGent), cis-3-benzyloxy-4-(2-
bromo-1,1-dimethylethyl)-β-lactams 7 have been transformed into cis-4,4-dimethyl-2-oxa-6-
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azabicyclo[3.2.0]heptan-7-ones 182, which served as eligible intermediates for the preparation of cis-
3-amino-4,4-dimethyletrahydrofuran-2-carboxylates 183 via acidic methanolysis (Figure 15).14 In line 
with paragraph 3.2 and in continuation of the interest in the use of 4-[2-(tert-
butyldimethylsilyloxy)ethyl]azetidin-2-ones 12 as versatile synthons, the present chapter focuses on 
the synthesis of cis-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 18 and cis-3-aminotetrahydrofuran-2-
carboxylates 19, thus providing an easy access to the 4,4-dinor-dimethyl variants as valuable 
templates in medicinal chemistry (Figure 15). 
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Figure 15 
Thus, the potential of 3-benzyloxy-β-lactams 12b,c as selected synthons in the synthesis of bicyclic 
azetidin-2-ones was investigated. Deprotection of the silyl ether in β-lactams 12b,c using 1.1 equiv of 
tetra-n-butylammonium fluoride (TBAF) in THF, followed by treatment with 1.05 equiv of mesyl 
chloride (MsCl) in the presence of a base (1.1 equiv of Et3N) and a catalytic amount of 4-
(dimethylamino)pyridine (DMAP) in dichloromethane at 0 °C for three hours furnished the 
corresponding cis-3-benzyloxy-4-(2-mesyloxyethyl)azetidin-2-ones 17a,b in 86-89% yield (Scheme 
56). The latter β-lactams hold interesting potential for further elaboration due to the presence of a 
strained four-membered ring and a leaving group in one of the side chains. 
Subsequently, hydrogenolysis of the benzyl ether substituent of the latter cis-3-benzyloxy-4-(2-
mesyloxyethyl)azetidin-2-ones 17a,b using 20% (w/w) palladium on activated carbon in methanol at 
room temperature for 60 hours afforded the corresponding cis-3-hydroxy-β-lactams in high purity (> 
90%, 
1
H NMR), which were used as such for further elaboration. Indeed, the latter 3-hydroxy-β-
lactams were subjected to ring closure via intramolecular substitution of the mesyloxy functionality 
upon treatment with one equiv of NaH in THF under reflux for 15 hours, yielding the premised new 
cis-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 18a,b in high yields (52-62%) after purification by column 
chromatography on silica gel. The cis-stereochemistry of bicyclic β-lactams 18a,b, which is a direct 
consequence of the relative stereochemistry defined during the Staudinger synthesis of the starting 
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β-lactams 12b,c, was unambiguously assigned based on the coupling constants between the protons 
at C-1 and C-5 (3.3 Hz, 
1
H NMR, CDCl3), pointing to a cis-configuration of the bicyclic framework.
14,114g
 
It has to be mentioned that this comprises the first synthesis of β-lactams C-fused with an 
unsubstituted tetrahydrofuran unit, in which the oxygen atom is connected to the C-3 β-lactam 
carbon atom. 
As mentioned before, (cyclic) β-amino acids are important constituents of biologically active natural 
products and pharmaceutical agents.
121,122,123
 In addition, oligomers of β-amino acids, for example β-
peptides, have attracted considerable attention as useful peptidomimetics because of their 
proteolytic stability relative to natural α-peptides and their propensity to adopt stable secondary 
structures.
122
 Since the use of β-lactams as synthons for the synthesis of β-amino acids with a pre-
determined stereochemistry is well known in the literature,
4h,128
 hydrolysis of the amide functionality 
in bicyclic-β-lactams can lead to the selective formation of (hetero)cyclic β-amino acids. In that 
respect, the reactivity of bicyclic β-lactams 18a,b toward methanolic hydrogen chloride was 
evaluated with the intention to develop an efficient and straightforward route toward the class of 3-
aminotetrahydrofuran-2-carboxylates 19a,b. Treatment of β-lactams 18a,b with five equiv of HCl in 
MeOH (3 M) under reflux for 24 hours resulted in the selective formation of novel methyl cis-3-
aminotetrahydrofuran-2-carboxylates 19a,b in good yields and purity (Scheme 56). The observed 
coupling constants between the protons at C-2 and C-3 in β-amino esters 19a,b (5.5-6.6 Hz, 1H NMR, 
CDCl3) were in good accordance with those reported for their 4,4-dimethyl variants.
14
 In this way, the 
transfer of the stereochemical information, introduced by the stereoselective Staudinger synthesis of 
β-lactams 12b,c, through the reaction pathway enables the selective preparation of cis-3-
aminotetrahydrofuran-2-carboxylates 19a,b. 
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3.4 Synthesis of 2-hydroxy-1,4-oxazin-3-ones through ring 
transformation of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-
lactams (Paper VI) 
Within the general objective of this thesis to synthesize new nitrogen-containing (a)cyclic target 
compounds based on novel fragmentations and rearrangements of the β-lactam ring, the fusion of 
the β-lactam ring and a second strained small-ring heterocycle in one chemical entity might give rise 
to the development of novel classes of highly reactive compounds. The interest in these fused 
bicyclic compounds stems from the combination of different reactive ring systems, which can (after 
initial selective manipulation) interact intramolecularly with each other, thus leading to the 
preparation of novel mono-, bi- and tricyclic target compounds. 
Next to β-lactams, aziridines display an uncommon combination of reactivity and synthetic utility as 
well.
129
 In particular, 2-(bromomethyl)aziridines are frequently deployed as versatile synthetic 
intermediates for the regio- and stereoselective preparation of a variety of (a)cyclic amines, including 
β-fluoro amines, piperidines, thiazolines, δ-lactams and γ-lactones.
27-37
  
In view of the expertise at the Department of Sustainable Organic Chemistry and Technology (UGent) 
regarding the synthetic potential of both functionalized β-lactams and 2-(bromomethyl)aziridines, 
the introduction of the reactive [2-(bromomethyl)aziridin-1-ylmethyl] substituent at the 4-position in 
β-lactams 187 via imination and subsequent reductive ring formation of 4-formyl-β-lactams 185, 
synthesized starting from (R)-glyceraldehyde acetonide, was investigated (Scheme 57). β-Lactam 
hybrids 187 comprise an unexplored class of compounds with high synthetic potential due to the 
presence of a reactive β-lactam ring, a strained aziridine moiety and a halogenated electrophilic 
carbon atom. In this way, initially, a synthetic concept was devised based on intramolecular 
nucleophilic displacement of bromide in β-lactams 187 by the C-3 alkoxide (obtained upon treatment 
with a base) to provide a convenient entry into the interesting class of tricyclic β-lactams 22 (Scheme 
57). Indeed, due to increased bacterial resistance, the discovery of tricyclic β-lactam antibiotics 
(‘trinems’) and β-lactamase inhibitors
130
 has triggered a renewed interest in the preparation and 
biological evaluation of new polycyclic β-lactam systems in an attempt to move away from the 
classical structures. For example, Sanfetrinem 188 shows a broad-spectrum antibacterial activity 
against inter alia Streptococcus pneumoniae, Acinetobacter calcoaceticus, Staphylococcus aureus, 
Haemophilus influenzae and Moraxella catarrhalis,
130h,i
 and LK-157 189 exhibits inhibitory activity 
against a variety of class A and class C β-lactamases (Figure 16).
130g
 In that respect, as in the case of 
their bicyclic analogues, the construction of 3,4-fused tricyclic β-lactams comprises an interesting 
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challenge as an alternative for their 1,4-fused counterparts, both from a synthetic and biological 
viewpoint, as very little information regarding this type of potential antibacterials and/or β-
lactamase inhibitors can be found in the literature.  
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In order to evaluate the synthesis of 4-[2-(bromomethyl)aziridin-1-ylmethyl]-3-hydroxy-β-lactams 
187 and their reactivity toward oxazepane-tethered tricyclic β-lactams 22, the synthesis of 4-formyl-
3-hydroxyazetidin-2-ones 185 was envisaged. 
3.4.1 Synthesis of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 
The synthesis of the starting β-lactams 193a-f was performed by means of a two-step literature 
procedure.
15,131
 Thus, (R)-glyceraldehyde acetonide 190 was condensed with different primary 
amines in dichloromethane in the presence of MgSO4 as drying agent, and the resulting chiral imines 
191a-f were used as substrates in the Staudinger synthesis of β-lactams 192a-f. Therefore, imines 
191a-f were treated with benzyloxyacetyl chloride in dichloromethane in the presence of 
triethylamine to afford the corresponding optically active β-lactams 192a-f in 43-81% yield and with 
high diastereomeric excess (Scheme 58, Table 14). The cis-diastereoselectivity could be deduced 
from the 
1
H NMR spectra of β-lactams 192a-f, as the coupling constants between the 3-H and 4-H 
protons on the β-lactam ring varied between 4.8 and 5.0 Hz (
1
H NMR, CDCl3), which correspond well 
with those reported in the literature for cis-β-lactams.
69
 Subsequently, the latter azetidin-2-ones 
192a-f could be easily converted into the premised chiral 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 
193a-f by consecutive hydrolysis in THF/H2O (1/1) using one equiv of p-toluenesulfonic acid under 
reflux for four hours and hydrogenolysis of the benzyl ether moiety by using 20% (w/w) palladium on 
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activated carbon in methanol at room temperature for 18 hours, yielding β-lactams 193a-f in 63-93% 
yield after column chromatography (SiO2) or recrystallization from EtOAc/hexane (30/1). 
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Scheme 58 
Table 14. Synthesis of imines 191a-f, 3-benzyloxy-β-lactams 192a-f and 3-hydroxy-β-lactams 193a-f 
R Compound 191 (yield) Compound 192 (yield)a dr (192)b Compound 193 (yield)a 
iPr 191a (93%) 192a (81%) 91/9 193a (83%) 
iBu 191b (94%) 192b (50%) 92.5/7.5 193b (74%) 
nBu 191c (95%) 192c (43%) 92.5/7.5 193c (63%) 
cHex 191d (90%) 192d (65%) 93.5/6.5 193d (88%) 
nPr 191e (92%) 192e (70%) 95/5 193e (68%) 
iPent 191f (85%) 192f (50%) 94/6 193f (93%) 
a
 After purification by column chromatography (SiO2) or recrystallization. 
b
 Determined by 
1
H NMR and GC. 
 
3.4.2 Synthesis of 2-hydroxy-1,4-oxazin-3-ones 
In the next stage, the reactivity of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 193a-f with regard to 
the oxidant sodium periodate (NaIO4) was investigated as a potential entry into the synthetically 
useful class of 4-formyl-β-lactams,
15,131
 which are known to be attractive synthons for further 
elaboration. Indeed, a significant interest has been focused on the synthesis and reactivity of 4-
formyl-β-lactams as viable intermediates in (medicinal) organic synthesis, as illustrated by their use in 
the asymmetric synthesis of bi- and polycyclic β-lactams, different kinds of heterocycles, alkaloids, 
non proteinogenic α- and β-amino acids, amino sugars, taxoids, and complex natural products like 
biotin and sphingosines.
54,130e,132
 In analogy, 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 193a-f were 
treated with two equiv of NaIO4 in a two-phase system of saturated aqueous sodium bicarbonate 
and dichloromethane (1/15) at room temperature for two hours, but the expected 4-formyl-3-
hydroxy-β-lactams 185 were not detected. Nonetheless, full and selective substrate conversion 
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occurred, and detailed spectroscopic analysis finally revealed the molecular structure of the obtained 
reaction products to be exclusively 2-hydroxy-1,4-oxazin-3-ones 194a-e, which were isolated in good 
yields (69-94%, Scheme 59). Only in the case of an n-propyl unit as the N-substituent, a complex 
reaction mixture was obtained. This remarkable reactivity stands in sharp contrast with the known 
NaIO4-mediated oxidation of 3-alkoxy- and 3-phenoxy-4-(1,2-dihydroxyethyl)-β-lactams, which 
exclusively leads to the corresponding 4-formyl-β-lactam derivatives under the same reaction 
conditions.
15,131
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Scheme 59 
From a mechanistic point of view, the formation of the latter 2-hydroxy-1,4-oxazin-3-ones 194 can be 
rationalized considering the initial oxidation of the starting 3-hydroxy-4-(1,2-dihydroxyethyl)-β-
lactams 193 toward the corresponding 4-formyl-β-lactams 185, which proved to be unstable under 
the given reaction conditions. Considering the presence of an electron-donating hydroxyl 
functionality at C-3, a subsequent C3-C4 bond cleavage in β-lactams 185 toward intermediates 
195/196 is facilitated, whether or not periodate-promoted through activation of the aldehyde. 
Finally, ring closure of the latter intermediates 196 results in the selective formation of 2-hydroxy-
1,4-oxazin-3-ones 194 (Scheme 60).  
In an attempt to further assess the intrinsic reactivity of 4-formyl-β-lactams 185, 3-benzyloxy-4-
formyl-1-isopropyl-β-lactam15 was subjected to hydrogenolysis (one bar H2) as a possible entry into 
the corresponding 4-formyl-3-hydroxy-β-lactam 185a. However, as could be anticipated, the 
substrate was overreduced to provide the 3-hydroxy-4-(hydroxymethyl)azetidin-2-one system 
instead. Subsequent Swern oxidation of the primary alcohol using oxalyl chloride, DMSO, and Et3N 
gave rise to the exclusive formation of 2-hydroxy-1,4-oxazin-3-one 194a and no traces of the desired 
4-formyl-3-hydroxy-β-lactam 185a could be found in the reaction mixture, pointing to the high 
intrinsic reactivity of 4-formyl-3-hydroxy-β-lactams 185 as probably the main driving force governing 
this new ring-expansion reaction. The presence of periodate is apparently not essential to effect this 
rearrangement, although it might have a propitious influence by coordinating to the carbonyl moiety 
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in intermediates 185. As mentioned before, it should be stressed that this ring-expansion reaction is 
not compatible with β-lactam substrates bearing an alkoxy or phenoxy group at the C-3 position. 
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Scheme 60 
According to this reaction mechanism, the observed ring expansion of 3-hydroxy-4-(1,2-
dihydroxyethyl)-β-lactams 193 toward 2-hydroxy-1,4-oxazin-3-ones 194 should proceed with loss of 
chirality, which was supported experimentally by measurement of the optical rotation of 4-
cyclohexyl-2-hydroxy-1,4-oxazin-3-one 194d (αD = 0.0°, c = 1.22, CH2Cl2). By the way, the stereocenter 
of the hemiacetal is also subject to lability in terms of stereochemical integrity. In addition, 
esterification of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a with one equiv of (1S)-(-)-camphanic 
chloride in CH2Cl2 at 0 °C for two hours in the presence of three equiv of triethylamine afforded the 
corresponding 2-camphanoyloxy-4-isopropyl-1,4-oxazin-3-one 198 as a mixture of two 
diastereoisomers in a ratio of 54/46 (based on 
1
H NMR and GC analysis), pointing to the racemic 
character of 2-hydroxy-1,4-oxazin-3-ones 194 (Scheme 61). 
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Scheme 61 
Albeit starting from different substrates and triggered by different reaction conditions, two other 
approaches involving ring enlargement of appropriate β-lactam derivatives toward morpholinone 
scaffolds have been reported in the literature. The first method involves a SnCl2·2H2O-promoted 
Chapter 3  Results and Discussion 
71 
 
carbenium ion rearrangement of 4-acyl-β-lactams 199 bearing an acetal functionality at the C-3 
carbon, yielding the corresponding 1,4-oxazin-2,3-diones 204 in good yields (75-95%).133 Two 
possible reaction pathways, involving initial coordination of tin to the carbonyl moiety in β-lactams 
200 followed by a C3-C4 bond cleavage due to the enhanced reactivity of the double bond and the 
ability of the acetal functionality to stabilize the emerging carbenium ion in intermediates 201 
(Method A) and dicoordination of tin at the acetal functionality in β-lactams 199 to yield 
intermediates 203, which subsequently evolve through a concerted or stepwise six-electron 
rearrangement (Method B), may account for the observed reactivity (Scheme 62).
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Scheme 62 
The second approach comprises a single-step molecular iodine-catalyzed rearrangement of 3-alkoxy-
4-formyl-β-lactams 20 into monocyclic γ-lactams 205 upon treatment with allylic and propargylic 
trimethylsilanes, inevitable leading to 2-alkoxy-1,4-oxazin-3-ones 207 as minor constituents (4-9%), 
except for the reaction of 4-formyl-3-methoxy-1-(4-methoxybenzyl)azetidin-2-one 20 (R1 = PMB, R2 = 
Me) with allyltrimethylsilane (R = H) which gave rise to the corresponding morpholinone 207 in 66% 
yield (Scheme 63).
134
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Scheme 63 
Although a similar reaction mechanism was proposed (Scheme 64), the achiral outcome observed in 
the above-described ring expansion of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 193 toward the 
corresponding 2-hydroxy-1,4-oxazin-3-ones 194 contradicts with the reported formation of optically 
pure 2-alkoxy-1,4-oxazin-3-ones 207 as minor constituents in the molecular iodine-catalyzed 
rearrangement of chiral 3-alkoxy-4-formyl-β-lactams 20 (Scheme 63).134 In the latter case, although 
not discussed in the original paper, the chiral outcome could be explained by the partial carbenium 
ion character of the Zwitterionic intermediates 209 controlling the subsequent intramolecular 
nucleophilic attack to occur from the same side from which the initial β-lactam C3-C4 bond was 
cleaved (Scheme 64). A similar stereochemical control (“memory effect”) has been described in the 
literature for reactions of carbenium ions in which the latter “remember” how they were formed 
before taking part in the second step.
135
 In our case, however, the hydroxyl group in intermediates 
195, formed after C3-C4 bond cleavage of the intermediate 4-formyl-β-lactams 185, can induce 
prototropy toward intermediates 196. Since these intermediates 196 possess a planar configuration 
due the presence of a polycentric molecular orbital (PCMO) spread over the entire molecule, there is 
no stereocontrol during the subsequent intramolecular nucleophilic attack, resulting in the formation 
of racemic 2-hydroxy-1,4-oxazin-3-ones 194 (Scheme 60). 
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Scheme 64 
Although a less expensive, achiral approach toward 2-hydroxy-1,4-oxazin-3-ones 194 starting from 
the oxidation of the commercially available racemic solketal
136
 can be developed applying the same 
reaction sequence as mentioned above, the use of optically pure (R)-glyceraldehyde acetonide 190 
provided some additional mechanistic insights into this unexpected transformation. 
Whereas in these two reported routes 4-acyl- and 4-formyl-β-lactams 199 and 20 have been 
prepared as the substrates to perform the ring enlargement, in the above-described ring 
enlargement a different type of starting compounds, i.e., 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams 
193, served as substrates for the ring rearrangement. 
Subsequently, with the intention to support the proposed mechanistic rationale, the synthesis of the 
aza-analogues of the former 2-hydroxy-1,4-oxazin-3-ones 194 was envisaged. Thus, treatment of the 
latter compounds 194a-c with 12 equiv of NH4OAc and ten equiv of HOAc in ethyl acetate furnished 
the corresponding 1H-pyrazin-2-ones 211a-c in 30-51% yield after a reflux period of 24 hours 
(Scheme 65, the synthesis of 1H-pyrazin-2-ones 211b,c was performed by a colleague137).138 This 
transformation suggests a reaction mechanism in which acetic acid-mediated hydrolysis of the hemi-
acetal in 2-hydroxy-1,4-oxazin-3-ones 194 gives rise to the selective formation of dialdehydes 197, 
which are subsequently transformed into the corresponding diimines 213 and enamino imines 214 
through the action of ammonium acetate. Finally, ring closure followed by the elimination of 
ammonia results in the selective formation of 1H-pyrazin-2-ones 211 (Scheme 65, Route A). 
However, alternative reaction pathways should not be excluded. For example, initial elimination of 
water followed by the addition of ammonia can account for the formation of 2-amino-1,4-oxazin-3-
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ones 217, which subsequently undergo an acetic acid-mediated ring opening toward the 
corresponding intermediates 218/219. Finally, ring closure and elimination of water give rise to the 
formation of 1H-pyrazin-2-ones 211 (Scheme 65, Route B).  
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Scheme 65 
In order to confirm the formation of 1H-pyrazin-2-ones 211, an independent synthesis was 
performed. Alkylation of 1H-pyrazin-2-one 221 by means of 1.1 equiv of isobutyl bromide and two 
equiv of potassium carbonate in acetonitrile under reflux afforded the expected 1-isobutyl-1H-
pyrazin-2-one 211b in 28% yield (Scheme 66),139 which was identical to the compound obtained from 
1-isobutyl-2-hydroxy-1,4-oxazin-3-one 194b (Scheme 65). 
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N
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Scheme 66 
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3.4.2.1 Theoretical rationalization 
As mentioned before, the above-described four- to six-membered ring-expansion reaction is only 
compatible for substrates bearing a hydroxyl group at the C-3 position, and not for substrates 
bearing a alkoxy or phenoxy group, as 3-alkoxy- and 3-phenoxy-4-(1,2-dihydroxyethyl)-β-lactams 222 
(R = Me, Bn, Ph) are known to be oxidized to the corresponding 4-formyl-β-lactam derivatives 20 
under the same reaction conditions without subsequent rearrangement into six-membered 
heterocycles (Scheme 67).
15,131
 In order to shed light on this remarkable difference in reactivity and 
to provide additional insights into the mechanism (Scheme 60) and the factors governing this new 
ring-expansion reaction, Density Functional Theory calculations were conducted by colleagues at the 
Center for Molecular Modeling, Ghent University. 
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Scheme 67 
The first step in the proposed transformation of β-lactams 185 toward oxazin-3-ones 194 comprises 
the ring opening of the β-lactam nucleus (Scheme 60, R = Me). This ring opening could give rise to an 
unstable zwitterionic species 195, which is easily converted to intermediate 196 by proton transfer. 
However, a concerted reaction mechanism in which β-lactam 185 is directly converted to 
intermediate 196 was found more plausible. Indeed, the Gibbs free energy of activation (∆G‡) for the 
β-lactam ring opening involving a simultaneous proton transfer is 35.6 kJ/mol lower in energy than 
that for the formation of the zwitterionic intermediate 195 (Figure 17, TS(185-196) and TS(185-195), 
respectively). The subsequent ring closure of intermediate 196 toward oxazin-3-one 194, which also 
involves a simultaneous proton transfer, has a relatively high Gibbs free energy of activation (∆G
‡
 = 
145.6 kJ/mol), indicating that this model might be inappropriate to represent the system. Finally, a 
concerted reaction mechanism in which β-lactam 185 is directly converted to oxazin-3-one 194 by 
simultaneous ring opening and ring closure was considered. The Gibbs free energy of activation for 
this conversion was found to be higher than that for the conversion of β-lactam 185 to intermediate 
196 or zwitterionic intermediate 195 and therefore seems very unlikely. 
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Figure 17. Gibbs free energy profile for the ring transformation of 4-formyl-3-hydroxy-β-lactams 185 to 2-
hydroxy-1,4-oxazin-3-ones 194, without assistance of a second β-lactam (M06-2X/6-31+G(d,p)//B3LYP/6-
31+G(d,p), ε=8.93; free energies in kJ/mol at 298K and 1 atm) 
This ring transformation is not observed for β-lactam substrates bearing an alkoxy or phenoxy group 
instead of a hydroxyl group at the C-3 position. For comparative purposes, the hypothetical ring 
transformation of 4-formyl-3-methoxy-β-lactam 20 to 2-methoxy-1,4-oxazin-3-one 224 was 
investigated as well (Figure 18). The reaction mechanism with the ring opening of the starting β-
lactam 20 to an unstable zwitterionic species 223 has a free energy of activation of 138.4 kJ/mol, 
which is higher than that for compound 185 (Figure 17). Moreover, if this relatively high Gibbs free 
energy of activation would be overcome, the formed very unstable species 223 will readily go back to 
β-lactam 20 instead reacting further to the oxazin-3-one 224 (∆G‡ = 0.9 kJ/mol and 105.4 kJ/mol, 
respectively). Furthermore, the concerted reaction mechanism in which β-lactam 20 is directly 
converted to oxazin-3-one 224 has a high Gibbs free energy of activation (∆G‡ = 167.0 kJ/mol). 
185 
195 
TS(185-195) 
TS(185-196) 
196 
TS(185-194) 
194 
TS(196-194) 
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Figure 18. Gibbs free energy profile for the ring transformation of 4-formyl-3-methoxy-β-lactams 20 to 2-
methoxy-1,4-oxazin-3-ones 224 (M06-2X/6-31+G(d,p)//B3LYP/6-31+G(d,p), ε=8.93; free energies in kJ/mol at 
298K and 1 atm) 
To make the model more realistic, a second β-lactam was added to the system. All barriers were 
brought down by β-lactam assistance (Figure 19). In case of proton transfer, the hydroxyl group of 
the second β-lactam acts as a proton conduit, accepting the proton from the first β-lactam and 
donating its own. If no proton transfer takes place, the second β-lactam stabilizes transition states 
and reactants due to intermolecular H-bonds. The reaction mechanism proposed for compound 185, 
ring opening to intermediate 196 and subsequent ring closure toward oxazin-3-one 194 with 
simultaneous proton transfer in both steps, was found to be most plausible. Indeed, the Gibbs free 
energy of activation for the β-lactam ring opening with a simultaneous proton transfer is lower in 
energy than that for the ring opening with formation of the zwitterionic intermediate 195 and for the 
simultaneous ring opening and ring closure (∆G
‡
 = 91.1, 120.1 and 140.3 kJ/mol for TS(185-196)+B, 
TS(185-195)+B and TS(185-194)+B, respectively). Moreover, the Gibbs free energy of activation for 
the subsequent ring closure of intermediate 196 with simultaneous proton transfer was brought 
down significantly (∆G
‡
 = 145.6 kJ/mol for TS(196-194) and 84.1 kJ/mol for TS(196-194)+B, Figure 17 
and Figure 19, respectively), demonstrating the need for the assistance of a second β-lactam for the 
reaction to proceed. 
TS(20-223) 
20 
224
TS(20-224) 
223
TS(223-224) 
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Figure 19. Gibbs free energy profile for the ring transformation of 4-formyl-3-hydroxy-β-lactams 185 to 2-
hydroxy-1,4-oxazin-3-ones 194, with assistance of a second β-lactam (M06-2X/6-31+G(d,p)//B3LYP/6-
31+G(d,p), ε=8.93; free energies in kJ/mol at 298K and 1 atm) 
Thus, the transformation of 4-formyl-3-hydroxy-β-lactams 185 into 2-hydroxy-1,4-oxazin-3-ones 194 
is facilitated by the proton transfer of the hydroxyl group and the assistance of the hydroxyl group of 
a second β-lactam. Both mechanisms are not feasible for β-lactam substrates bearing an alkoxy or 
phenoxy group. 
2-Hydroxy-1,4-oxazin-3-ones 194 exhibit a number of interesting structural characteristics, making 
them suitable substrates for further elaboration. For example, the presence of a double bond in the 
oxazin-3-one backbone provides an entry into highly substituted monocyclic morpholinone 
derivatives upon treatment with electrophilic species. Additionally, the double bond can be deployed 
in intermolecular cycloaddition reactions leading to bicyclic morpholinones, and the free hydroxyl 
group can be used in coupling reactions with biologically relevant pharmacophores. 
In order to show the capacity of the above-described method to prepare a broad array of oxazin-3-
ones and morpholin-3-ones bearing chemical diversity, several functionalities in 2-hydroxy-1,4-
oxazin-3-ones 194 were selectively manipulated, which will be discussed in the next section. 
185+B 
195+B 
196+B 
194+B 
 
 
 
TS(185-195)+B 
TS(185-196)+B 
TS(185-194)+B 
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3.4.3 Reactivity study of 2-hydroxy-1,4-oxazin-3-ones 
In a first approach, the hydroxyl group in the latter heterocycles 194a-d was protected upon 
treatment with three equiv of benzoylchloride in dichloromethane in the presence of three equiv of 
triethylamine, furnishing the corresponding 2-benzoyloxy-1,4-oxazin-3-ones 225a-d after two hours 
at 0 °C (Scheme 68, Table 15, the synthesis of 2-benzoyloxy-1,4-oxazin-3-ones 225b,c was performed 
by a colleague
137
). As morpholine chemistry is of significant importance because of the occurence of 
these scaffolds in a large number of biologically active compounds useful in different therapeutical 
areas,
140
 the search for new, functionalized morpholine derivatives remains a relevant issue in 
medicinal chemistry. In particular, morpholin-3-one derivatives
141
 have attracted considerable 
interest owing to their biological and pharmacological activity, as they comprise key features in HIV-
protease inhibitors,
142
 non-peptide ligands with high affinity and selectivity for tachykinin 
receptors,
143
 cornea permeable calpain inhibitors exhibiting anticataract properties,
144
 A549 lung 
cancer cell inhibitors,
145
 and potassium channel openers useful in the treatment of urinary 
incontinence (Figure 20).
146
 In that respect, the attention was turned to the catalytic hydrogenation 
of the double bond in 2-benzoyloxy-1,4-oxazin-3-ones 225a-d to provide an entry to the morpholin-
3-one framework. Thus, the latter compounds 225a-d were converted into the corresponding 2-
benzoyloxymorpholin-3-ones 226a-d in high yields (69-89%) and purity upon treatment with 20% 
(w/w) palladium on activated carbon in methanol at room temperature for 18 hours while applying 
five bar of hydrogen gas (Scheme 68, Table 15, the synthesis of 2-benzoyloxymorpholin-3-ones 
226b,c was performed by a colleague137). 
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Table 15. Synthesis of 2-benzoyloxy-1,4-oxazin-3-ones 225a-d and 2-benzoyloxymorpholin-3-ones 226a-d 
R Compound 225 (yield)a Compound 226 (yield)a 
iPr 225a (45%) 226a (69%) 
iBu 225b (64%) 226b (79%) 
nBu 225c (93%) 226c (82%) 
cHex 225d (34%) 226d (89%) 
a
 After purification by column chromatography (SiO2) or recrystallization from EtOAc/hexane (30/1). 
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Figure 20 
As mentioned before, the incorporation of fluorine in organic compounds can tune their 
physicochemical characteristics due to the unique physical, chemical and biological properties of 
fluorine as a substituent.
92
 In that respect, it became of interest to verify whether the use of 
appropriate fluorinating agents could introduce fluorine in a site-selective manner in the above 
synthesized heterocyclic compounds. In a first attempt, selective deoxyfluorination of 2-hydroxy-1,4-
oxazin-3-ones 194a-d was effected in the presence of two equiv of Morph-DAST in dichloromethane, 
resulting in a complete conversion toward 2-fluoro-1,4-oxazin-3-ones 232a-d in 78-94% yield 
(Scheme 69, the synthesis of 2-fluoro-1,4-oxazin-3-ones 232b,c was performed by a colleague137). 
The presence of a monofluorinated carbon center was unambiguously assigned based on the 
coupling constants between the proton and the fluoro atom at C-2, as the observed J-values of 52.7-
53.7 Hz (
1
H NMR, 
19
F NMR, CDCl3) correspond well with those reported in the literature (50-57 Hz, 
1
H 
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NMR, CDCl3).
147
 Also, the 
13
C NMR spectra revealed a coupling between the carbon and the fluorine 
at the C2-position, characterized by J-values between 233.1 and 234.2 Hz (
13
C NMR, CDCl3). These 
results are in good accordance with 
13
C NMR data (CDCl3) reported in the literature for compounds 
bearing similar structural subunits.
147b,148
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Scheme 69 
In another strategy to introduce fluorine, 2-benzoyloxy-1,4-oxazin-3-ones 225a-d were smoothly 
bromofluorinated with 2.5 equiv of triethylamine trihydrofluoride (Et3N·3HF) and 1.5 equiv of N-
bromosuccinimide (NBS) in dichloromethane at room temperature for 24 hours, resulting in the 
regiospecific formation of a diastereomeric mixture of 2-benzoyloxy-6-bromo-5-fluoromorpholin-3-
ones 234a-d and 235a-d through anti addition across the C-C double bond (234/235 = 67-80/20-33, 
Scheme 70, Table 16, the synthesis of 2-benzoyloxy-6-bromo-5-fluoromorpholin-3-ones 234b,c and 
235b,c was performed by a colleague137). 
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Table 16. Synthesis of 2-benzoyloxy-6-bromo-5-fluoromorpholin-3-ones 234a-d and 235a-d 
R Ratio 234/235a Compound 234 (yield)b 
iPr 75/25 234a (63%) 
iBu 80/20 234b (33%) 
nBu 80/20 234c (42%) 
cHex 67/33 234d (67%) 
a
 Based on 
1
H NMR and/or GC of the crude reaction mixture. 
b
 After purification by column chromatography 
(SiO2) or recrystallization from EtOAc/hexane (30/1). 
 
Detailed spectroscopic analysis of the obtained reaction mixtures revealed that the Br
+
-initiated 
electrophilic addition across the double bond of 2-benzoyloxy-1,4-oxazin-3-ones 225 proceeded with 
complete regioselectivity, which was determined based on the experimental coupling pattern in the 
13
C NMR spectra (Scheme 71), as one carbonyl carbon appeared as a singlet while the other clearly 
coupled with fluorine and appeared as a doublet with a coupling constant between 3.4 Hz and 3.5 Hz 
(
13
C NMR, CDCl3). Since these values are in good agreement with 
3
JF-C=O-coupling constants of 0-3.4 Hz 
(
13
C NMR, CDCl3) reported in the literature for C(=O)NCHF-systems,
149
 and no 
4
JF-C=O-, 
5
JF-C=O- and 
6
JF-
C=O-coupling pattern is described for compounds bearing analogous structural subunits,
149a-c,150
 the 
regiospecificity was unambiguously assigned (Scheme 71), pointing to the N-acyliminium ion 
character of the intermediates 233 during the bromofluorination. 
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Scheme 71 
With the intention to provide additional experimental evidence for the above-mentioned 
regiospecificity and to exclude the formation of regioisomers 236, nucleophilic halide substitution via 
N-acyliminium intermediates through treatment of the diastereomeric reaction mixtures with 
external nucleophiles was envisaged. This reaction would involve the dislocation of the nitrogen lone 
pair, followed by halide dissociation leading to the formation of N-acyliminium ions, which are 
subsequently susceptible to intermolecular trapping by the additional nucleophile resulting in the 
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formation of new 2,5,6-trisubstituted 1,4-oxazin-3-one derivatives. As (cyclic) brominated amides are 
known to readily undergo substitution reactions via N-acyliminium intermediates
151
 and fluoride is 
generally recognized as a poor leaving group, nucleophilic substitution via N-acyliminium ions is 
expected to occur only for 2-benzoyloxy-5-bromo-6-fluoromorpholin-3-ones 236. Following this 
rationale, the diastereomeric reaction mixture obtained after bromofluorination of 2-benzoyloxy-1,4-
oxazin-3-one 225a was treated with potassium cyanide under different reaction conditions (Table 17, 
Entry 1-7). However, even in the presence of a silver salt, all attempts resulted in recovery of the 
starting material or formation of complex reaction mixtures in which no typical signals for the 
expected substitution products could be detected. 
Alternatively, in order to accomplish the afore-mentioned goal, a bromine-lithium exchange 
reaction
152
 was contemplated upon treatment with nBuLi and subsequent quenching with saturated 
aqueous NH4Cl, again resulting in the formation of a complex reaction mixture (Table 17, Entry 8). 
Finally, according to a literature procedure concerning the Zn-mediated radical dehalogenation of 
organic compounds,
153
 the diastereomeric reaction mixture obtained after bromofluorination of 2-
benzoyloxy-1,4-oxazin-3-one 225a was treated with two equiv of Zn in acetic acid at room 
temperature for 22 hours, unfortunately resulting in both debromination and defluorination toward 
2-benzoyloxy-1,4-oxazin-3-one 225a in 80% yield (Table 17, Entry 9). 
Table 17. Attempted conversion of the diastereomeric reaction mixture obtained after bromofluorination of 
2-benzoyloxy-1,4-oxazin-3-one 225a 
Entry Substrate Reaction conditions Resulta 
1 234a/235a or 236a 2 equiv KCN, CH3CN, rt, 18 h no reaction 
2 234a/235a or 236a 2 equiv KCN, CH3CN, ∆, 6 h no reaction 
3 234a/235a or 236a 2 equiv KCN, DMSO, 80 °C, 2 h complex mixture 
4 234a/235a or 236a 1) 5 equiv Ag2CO3, DMSO, rt, 1 h 
2) 2 equiv KCN, DMSO, rt, 18 h 
no reaction 
5 234a/235a or 236a 1) 5 equiv Ag2CO3, DMSO, 60 °C, 1 h 
2) 2 equiv KCN, DMSO, 60 °C, 3 h 
complex mixture 
6 234a/235a or 236a           1 equiv AgBF4, 3 equiv KCN, DMSO, rt, 18 h no reaction 
7 234a/235a or 236a         1 equiv AgBF4, 3 equiv KCN, DMSO, 60 °C, 2 h complex mixture 
8 234a/235a or 236a 1) 1 equiv nBuLi, Et2O, -78 °C, 1 h 
2) sat. aq. NH4Cl, Et2O, rt, 20 h 
complex mixture 
9 234a/235a or 236a 2 equiv Zn, HOAc, rt, 22 h     1,4-oxazin-3-one 225a 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
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Intensive efforts were thus devoted to experimentally confirm the assigned regiospecificity, but no 
conclusive support could be achieved without further investigation. Furthermore, no irrefutable 
proof could be obtained concerning the diastereoselectivity of the bromofluorination reaction based 
on spectral analysis of the obtained reaction products (Scheme 70). Finally, the full configuration of 
2-benzoyloxy-6-bromo-5-fluoromorpholin-3-ones 234 was established by single crystal X-ray analysis 
of 2-benzoyloxy-6-bromo-5-fluoro-4-isopropylmorpholin-3-one 234a (Figure 21), providing 
irrefutable proof for the formation of cis-2-benzoyloxy-6-bromomorpholin-3-ones 234 as the major 
diastereoisomers. 
 
Figure 21. X-Ray crystallographic analysis of compound 234a 
On the other hand, a direct epoxidation of the double bond in 2-benzoyloxy-1,4-oxazin-3-one 225d 
with 3-chloroperbenzoic acid (mCPBA) was examined as a possible entry into morpholinone-fused 
bicyclic systems. For this purpose, upon treatment with 1.05 equiv of mCPBA in CH2Cl2 at room 
temperature or under reflux, either the starting 1,4-oxazin-3-one 225d or complex reaction mixtures 
were obtained (Scheme 72, Table 18), probably because multiple side reactions, such as incomplete 
epoxidation and oxidation of the acetal moiety
154 
can occur. 
N
OO
O
O
225d
mCPBA
Reaction conditions
see Table 18 N
OO
O
O
237d
OX
 
Scheme 72 
 
 
N
OO
O
O
F
Br
Chapter 3  Results and Discussion 
85 
 
Table 18. Reaction of 2-benzoyloxy-4-cyclohexyl-1,4-oxazin-3-one 225d with mCPBA 
Reaction conditions Resulta 
1.05 equiv mCPBA, CH2Cl2, rt, 18 h no reaction 
1.05 equiv mCPBA, CH2Cl2, rt, 48 h no reaction 
1.05 equiv mCPBA, CH2Cl2, ∆, 2 h no reaction 
1.05 equiv mCPBA, CH2Cl2, ∆, 7 h complex mixture 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
After this unsuccessfull attempt, an indirect expoxidation of the double bond by preparation of the 
corresponding halohydrins as valuable precursors was contemplated. However, all attempts to 
selectively prepare bromohydrin 238d by treatment of 1,4-oxazin-3-one 225d with 1 equiv of N-
bromosuccinimide (NBS) in water/THF (1/1) gave complex reaction mixtures (Scheme 73).  
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Scheme 73 
A final objective of the present study comprised the transformation of 2-benzoyloxy-1,4-oxazin-3-
ones 225 toward the corresponding 6-hydroxymorpholin-3-ones by a BH3·THF-mediated 
hydroboration-oxidation protocol. Unfortunately, all attempts to perform a net addition of water at 
the double bond of 2-benzoyloxy-4-cyclohexyl-1,4-oxazin-3-one 225d applying this methodology 
resulted in complete recovery of the starting oxazin-3-one 225d or the formation of rather complex 
reaction mixtures (Scheme 74, Table 19), which can probably be attributed to the propensity of 
borane in THF to induce the reductive cleavage of acetals.
155
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Scheme 74 
Table 19. Hydroboration of 2-benzoyloxy-4-cyclohexyl-1,4-oxazin-3-one 225d 
Reaction conditions Resulta 
1) 1.1 equiv BH3·THF (1M), THF, rt, 18 h 
2) 1 equiv NaOH (3M), 3 equiv H2O2 (30%), THF, rt, 4 h 
no reaction 
1) 1.1 equiv BH3·THF (1M), THF, rt, 1 h to ∆, 5 h 
2) 2 equiv NaOH (3M), 3 equiv H2O2 (30%), THF, rt, 1 h to ∆, 3 h 
complex mixture 
a
 Based on 
1
H NMR analysis of the crude reaction mixture. 
 
3.4.4 Conclusions 
In conclusion, 2-hydroxy-1,4-oxazin-3-ones were prepared through ring transformation of the 
corresponding 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams involving an unexpected C3-C4 bond 
cleavage of the β-lactam nucleus in the intermediate 4-formyl-3-hydroxy-β-lactams, followed by a 
ring expansion. This peculiar transformation stands in sharp contrast with the known NaIO4-mediated 
oxidation of 3-alkoxy- and 3-phenoxy-4-(1,2-dihydroxyethyl)-β-lactams, which exclusively leads to the 
corresponding 4-formyl-β-lactams without a subsequent ring enlargement. Furthermore, the 
synthetic applicability of these novel oxazin-3-one derivatives was demonstrated by means of their 
transformation into the classes of substituted oxazin-3-ones, morpholin-3-ones, and pyrazinones. 
This comprises the first full and selective conversion of β-lactam scaffolds into 1,4-oxazin-3-ones in 
high yields and purity. 
3.4.5 Perspectives 
From the above-described unexpected ring-expanion reaction, it is clear that, in order to achieve the 
selective synthesis of 4-[2-(bromomethyl)aziridin-1-ylmethyl]-3-hydroxy-β-lactams 187 (Scheme 57), 
the elaboration of alternative hydroxyl protecting groups is highly recommended. 
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In the literature, the synthesis of azetidin-2,3-diones by Swern oxidation of the corresponding 3-
hydroxy-β-lactams is known.
156
 In this way, 3-hydroxy-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-
2-ones 240, obtained by hydrogenation of 3-benzyloxy-β-lactams 192, could be transformed into the 
corresponding azetidin-2,3-diones 241,156 which might be eligible substrates for further elaboration 
toward 4-iminoazetidin-2,3-diones 243 upon consecutive treatment with p-toluenesulfonic acid, 
sodium periodate and 2,3-dibromopropylamine hydrobromide (Scheme 75). The latter β-lactams 243 
can be further functionalized via NaBH4-induced reduction, allowing the synthesis of a wide variety of 
the premised 4-[2-(bromomethyl)aziridin-1-ylmethyl]-3-hydroxy-β-lactams 187, as NaBH4 is reported 
to selectively reduce the carbonyl group at C-3 in azetidin-2,3-diones (R = alkyl, Scheme 75).
157
 
Alternatively, the coupling of 3-hydroxy-β-lactams 240 with p-methoxybenzylchloride (PMBCl) can be 
investigated as a possible entry into the corresponding 4-[2-(bromomethyl)aziridin-1-ylmethyl]-3-(4-
methoxybenzyloxy)-β-lactams 245. Finally, deprotection with 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) or ceric ammonium nitrate (CAN) can lead to the formation of the synthetically 
interesting β-lactam hybrids 187 (Scheme 75). 
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4 Perspectives 
As mentioned before, the selective synthesis of β-lactam-tethered 2-(bromomethyl)aziridines 
comprises a challenging topic as these synthons are expected to possess a broad synthetic potential, 
which can be attributed to the presence of two small-ring azaheterocycles and a brominated carbon 
atom. In that regard, a reactivity study toward functionalized azaheterocycles could provide a 
valuable and fruitfull research area. 
Imination and NaBH4-mediated reductive cyclization of 4-formyl-β-lactams 20 can lead to the 
formation of 4-[2-(bromomethyl)aziridin-1-ylmethyl]-β-lactams 21, which might be eligible substrates 
for further elaboration toward nitrogen-containing heterocycles (Scheme 76). 
N
O R1
R2O
R S
N
∗ Br
Reactivity study 
toward azaheterocycles
21
N
O R1
H H
R2O
R R
O
H
20
N
H O
O
S
R1
H
191
1) R2OCH2COCl
2) pTsOH.H2O
3) NaIO4
R1 = alkyl, (hetero)aryl
R2 = Bn, Ph, Me  
Scheme 76 
In this PhD thesis, the synthetic usefulness of 2-(2-bromo-1,1-dimethylethyl)azetidines and 2-(2-
mesyloxyethyl)azetidines was demonstrated by the preparation of a wide variety of functionalized 
piperidines via intermediate bicyclic azetidinium salts. Based on the same methodology, the 
construction of piperazines 248 from azetidines 246 can be envisaged, involving an intramolecular 
nucleophilic substitution reaction toward tricyclic azetidinium intermediates 247, which are 
subsequently prone to undergo regioselective ring opening by the liberated leaving group or the 
additional nucleophile (Scheme 77). Furthermore, direct access to analogous monocyclic piperazines 
251 via LiAlH4-induced rearrangement of β-lactam-tethered aziridines 249, which might be obtained 
by nucleophilic substitution of the starting compounds 21, can be investigated (Scheme 77). During 
this transformation, LiAlH4 is responsible for both β-lactam amide bond cleavage and the in situ 
activation of the aziridine moiety. It should be mentioned that a vast array of molecules containing 
the piperazine skeleton has been reported as antipsychotics,
158
 antidepressants,
159
 antihistamines,
160
 
and antianginals,
161
 and others are known for the treatment of inter alia HIV,
162
 and neuropathic 
pain.
163
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Scheme 77 
Alternatively, this reactivity study can be extended to the chiral synthesis of the unexplored class of 
3-chloro-4-formyl-β-lactams 252 as potential synthons for 4-[2-(bromomethyl)aziridin-1-ylmethyl]-3-
chloro-β-lactams 253 (Scheme 78). 
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Scheme 78 
In light of the continuous quest for new β-lactam antibiotics and β-lactamase inhibitors, efforts can 
be directed toward the deployment of β-lactam hybrids 253 in the synthesis of bi- and tricyclic 
systems containing medium-sized rings fused to the β-lactam nucleus. In that respect, introduction of 
a hydroxymethyl or aminomethyl moiety in β-lactams 254 or 257 can be studied as a suitable method 
for the formation of new oxazepane- or diazepane-fused tricyclic β-lactams 255 or 258 upon 
intramolecular cyclization. The latter can be further functionalized via nucleophile-induced aziridine 
ring opening, allowing the synthesis of a wide range of new C-fused bicyclic β-lactams 256 and 259 
(Scheme 79). Oxazepanes and diazepanes are key structural features in many biologically active 
compounds, as illustrated by their use in the treatment of neurological and psychiatric diseases,
164
 
including epilepsy, Parkinson disease, and depression,
165
 and by their reported anticancer,
166
 anti-
HIV,
167
 inotropic,
168
 and antihypertensive
169
 activity. 
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5 Experimental Part 
5.1 General methods 
Diethyl ether, tetrahydrofuran and toluene were distilled from sodium benzophenone ketyl or 
sodium, while dichloromethane was distilled from calcium hydride prior to use. Commercially 
available solvents and reagents were purchased from Sigma-Aldrich or Acros and used as such 
without further purification unless stated otherwise. 
The purification of reaction mixtures was performed by column chromatography using a glass column 
filled with silica gel (Acros, particle size 0.035-0.070 mm, pore diameter ca. 6 nm). Solvent systems 
were determined via initial TLC analysis on glass plates, coated with silica gel (Merck, Kieselgel 60F254, 
precoated 0.25 mm) using UV light or coloring with a potassium permanganate solution as detection 
methods.  
High resolution 
1
H NMR (300 MHz) and 
13
C NMR spectra (75 MHz) were recorded on a Jeol Eclipse FT 
300 NMR spectrometer at room temperature. Peak assignments were obtained with the aid of DEPT, 
HSQC and/or 2D-COSY experiments. The compounds were diluted in a deuterated solvent, while 
tetramethylsilane (TMS) was used as an internal standard.  
IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer. All compounds were 
analyzed in neat form with an ATR (Attenuated Total Reflectance) accessory. 
Low resolution mass spectra were recorded via direct injection on an Agilent 1100 Series LC/MSD 
type SL mass spectrometer with Electron Spray Ionisation Geometry (ESI 70 eV) and using a Mass 
Selective Detector (quadrupole). 
Gas chromatography analysis was performed on an Agilent 6890 Series. The column was of the type 
Alltech EC-5 with a film thickness of 0.25 µm (length 30.0 m, i.d. 250 µm) with He as carrier gas. The 
GC was connected to a FID detector (H2 gas). 
Melting points of crystalline compounds were measured using a Büchi B-540 apparatus. 
Elemental analyses were obtained by means of a Perkin-Elmer 2400 Series II apparatus.  
High resolution electro spray (ES) mass spectra were obtained with an Agilent Technologies 6210 
Series Time-of-Flight. 
Optical rotations were taken with an JASCO P-2000 series polarimeter. 
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5.2 Synthesis of (E)-N-(alkylidene)amines 
All imines were obtained in high purity (> 95% based on 
1
H NMR) and were used as such in the next 
reaction step due to their hydrolytic instability (no HRMS data could be obtained). 
5.2.1 Synthesis of (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]amines 
As a representative example, the synthesis of (E)-N-[3-(tert-
butyldimethylsilyloxy)propylidene]isopropylamine 148a is described. To a solution of 3-(tert-
butyldimethylsilyloxy)propanal 147 (1.88 g, 10 mmol, 1 equiv) in anhydrous CH2Cl2 (40 mL) were 
added MgSO4 (2.40 g, 20 mmol, 2 equiv) and isopropylamine (0.59 g, 10 mmol, 1 equiv). After stirring 
for 2 hours at room temperature, MgSO4 was removed by filtration. After evaporation of the solvent 
in vacuo, (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]isopropylamine 148a was obtained in 70% 
yield. 
 
(E)-N-[3-(tert-Butyldimethylsilyloxy)propylidene]isopropylamine 148a 
Yellow oil. Yield 70%. 
1
H NMR (300 MHz, CDCl3): δ -0.05 (6H, s, Si(CH3)2); 0.79 (9H, s, SiC(CH3)3); 1.05 
(6H, d, J = 6.3 Hz, (CH3)2CHN); 2.34 (2H, q, J = 5.8 Hz, CH2C=N); 3.19 (1H, septet, 
J = 6.3 Hz, (CH3)2CHN); 3.73 (2H, t, J = 5.8 Hz, CH2O); 7.63 (1H, t, J = 5.8 Hz, 
HC=N). 
13
C NMR (75 MHz, CDCl3): δ -5.4 (Si(CH3)2); 18.2 (SiCquat); 24.1 
((CH3)2CHN); 25.9 (SiC(CH3)3); 38.9 (CH2C=N); 60.5 (CH2O); 61.5 ((CH3)2CHN); 
160.1 (C=N). IR (ATR, cm
-1
): νC=N = 1666; νmax = 2956, 2856, 1253, 1097, 834, 774, 733. MS (70 eV): m/z 
(%) 229 (M
+
, 1), 214 (10), 172 (100), 142 (14), 130 (35), 100 (32), 73 (18), 59 (9), 43(10). 
 
(E)-N-[3-(tert-Butyldimethylsilyloxy)propylidene]cyclohexylamine 148b 
Yellow oil. Yield 75%. 
1
H NMR (300 MHz, CDCl3): δ 0.05 (6H, s, Si(CH3)2); 0.89 (9H, s, SiC(CH3)3); 1.09-
1.37, 1.40-1.53, 1.61-1.66 and 1.71-1.82 (10H, 4 × m, (CH2)5CHN); 2.44 (2H, q, 
J = 5.7 Hz, CH2C=N); 2.88-2.98 (1H, m, CHN); 3.83 (2H, t, J = 5.7 Hz, CH2O); 
7.74 (1H, t, J = 5.7 Hz, HC=N). 
13
C NMR (75 MHz, CDCl3): δ -5.3 (Si(CH3)2); 18.3 
(SiCquat); 24.9, 25.2 and 25.7 (3 × CH2); 25.9 (SiC(CH3)3); 34.4 and 36.3 (2 × 
CH2); 39.2 (CH2C=N); 60.7 (CH2O); 69.9 (CHN); 160.5 (C=N). IR (ATR, cm
-1
): νC=N = 1667; νmax = 2927, 
2854, 1450, 1253, 1097, 834, 774. MS (70 eV): m/z (%) 270 (M
+
+1, 100). 
 
 
 
 
H
N
OTBDMS
H
N
OTBDMS
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(E)-N-[3-(tert-Butyldimethylsilyloxy)propylidene]isobutylamine 148c 
Yellow oil. Yield 68%. 
1
H NMR (300 MHz, CDCl3): δ 0.05 (6H, s, Si(CH3)2); 0.88 (9H, s, SiC(CH3)3); 0.89 
and 0.90 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CH); 1.90 (1H, nonet, J = 6.8 Hz, 
(CH3)2CH); 2.47 (2H, q, J = 5.7 Hz, CH2C=N); 3.19 (2H, d, J = 6.8 Hz, CH2N); 3.85 
(2H, t, J = 5.7 Hz, CH2O); 7.61 (1H, t, J = 5.7 Hz, HC=N). 
13
C NMR (75 MHz, 
CDCl3): δ -5.4 (Si(CH3)2); 18.3 (SiCquat); 20.6 ((CH3)2CH); 25.9 (SiC(CH3)3); 29.0 ((CH3)2CH); 38.9 
(CH2C=N); 60.6 (CH2O); 69.6 (CH2N); 163.6 (C=N). IR (ATR, cm
-1
): νC=N = 1671; νmax = 2954, 1471, 1254, 
1097, 834, 774. MS (70 eV): m/z (%) 244 (M
+
+1, 100). 
 
5.2.2 Synthesis of (E)-N-[((4S)-2,2-dimethyl-1,3-dioxolan-4-
yl)methylidene]amines 
The synthesis of (E)-N-[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methylidene]amines 191 was analogous 
to the synthesis of (E)-N-[3-(tert-butyldimethylsilyloxy)propylidene]amines 148 (Section 5.2.1), using 
(R)-glyceraldehyde acetonide 190 as the starting material. 
 
(E)-N-Isobutyl-[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methylidene]amine 191b 
Yellow oil. Yield 94%. [α]D = +60.9° (c = 1.51, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.90 and 0.91 (2 × 
3H, 2 × d, J = 6.8 Hz, (CH3)2CH); 1.41 and 1.46 (2 × 3H, 2 × s, (CH3)2C); 1.91 (1H, nonet, J 
= 6.8 Hz, (CH3)2CH); 3.19-3.30 (2H, m, CH2N); 3.92 and 4.21 (2 × 1H, 2 × (d × d), J = 8.4, 
6.3, 6.1 Hz, (HCH)O); 4.58 (1H, d × d × d, J = 6.3, 6.1, 5.4 Hz, CHO); 7.61 (1H, d, J = 5.4 
Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 20.3 ((CH3)2CH); 25.3 and 26.4 ((CH3)2C); 
29.0 ((CH3)2CH); 67.2 (CH2O); 68.9 (CH2N); 76.8 (CHO); 109.8 ((CH3)2C); 162.9 (HC=N). IR 
(ATR, cm
-1
): νC=N = 1674; νmax = 2956, 1468, 1370, 1213, 1062, 846. MS (70 eV): m/z (%) 
186 (M
+
+1, 100). 
 
(E)-N-Butyl-[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methylidene]amine 191c 
Yellow oil. Yield 95%. [α]D = +61.3° (c = 2.00, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.92 (3H, t, J = 7.2 
Hz, CH2CH3); 1.32 (2H, sextet, J = 7.2 Hz, CH2CH3); 1.40 and 1.46 (2 × 3H, 2 × s, (CH3)2C); 
1.59 (2H, pentet, J = 7.2 Hz, CH2CH2N); 3.42 (2H, t, J = 7.2 Hz, CH2CH2N); 3.91 and 4.20 
(2 × 1H, 2 × (d × d), J = 8.5, 6.5, 6.2 Hz, (HCH)O); 4.57 (1H, d × d × d, J = 6.5, 6.2, 5.5 Hz, 
CHO); 7.63 (1H, d × t, J = 5.5, 1.4 Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 13.6 
(CH2CH3); 20.1 (CH2CH3); 25.2 and 26.3 ((CH3)2C); 32.4 (CH2CH2N); 60.5 (CH2N); 67.1 
(CH2O); 76.8 (CHO); 109.7 ((CH3)2C); 162.5 (HC=N). IR (ATR, cm
-1
): νC=N = 1673; νmax = 
2932, 1457, 1213, 1061, 844. MS (70 eV): m/z (%) 186 (M
+
+1, 100). 
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(E)-N-Cyclohexyl-[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methylidene]amine 191d 
Colourless oil. Yield 90%. [α]D = +55.4° (c = 1.60, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 1.13-1.51 (5H, 
m, (CH2)5CHN); 1.40 and 1.46 (2 × 3H, 2 × s, (CH3)2C); 1.59-1.80 (5H, m, (CH2)5CHN); 
2.97-3.07 (1H, m, (CH2)5CHN); 3.88 and 4.20 (2 × 1H, 2 × (d × d), J = 8.3, 6.3, 6.3 Hz, 
(HCH)O); 4.55 (1H, d × d × d, J = 6.3, 6.3, 5.7 Hz, CHO); 7.65 (1H, d, J = 5.7 Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 24.3 ((CH3)2C); 25.2, 25.3, 26.2, 33.7 and 33.9 
((CH2)5CHN); 67.1 (CH2O); 68.8 ((CH2)5CHN); 76.8 (CHO); 109.6 ((CH3)2C); 160.4 
(HC=N). IR (ATR, cm
-1
): νC=N = 1672; νmax = 2928, 1450, 1371, 1212, 1060, 843. MS (70 
eV): m/z (%) 212 (M
+
+1, 100). 
 
(E)-N-[((4S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methylidene]propylamine 191e 
Colourless oil. Yield 92%. [α]D = +70.7° (c = 1.62, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.90 (3H, t, J = 
7.2 Hz, CH2CH3); 1.41 and 1.46 (2 × 3H, 2 × s, (CH3)2C); 1.63 (2H, sextet, J = 7.2 Hz, 
CH2CH3); 3.39 (2H, t, J = 7.2 Hz, CH2N); 3.92 and 4.20 (2 × 1H, 2 × (d × d), J = 8.2, 6.5, 
6.4 Hz, (HCH)O); 4.57 (1H, d × d × d, J = 6.5, 6.4, 5.5 Hz, CHO); 7.63 (1H, d × t, J = 5.5, 
1.3 Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 11.5 (CH2CH3); 23.4 (CH2CH3); 25.3 and 
26.3 ((CH3)2C); 62.6 (CH2N); 67.2 (CH2O); 76.8 (CHO); 109.8 ((CH3)2C); 162.7 (HC=N). IR 
(ATR, cm
-1
): νC=N = 1673; νmax = 2934, 1456, 1371, 1213, 1061, 844. MS (70 eV): m/z (%) 
172 (M
+
+1, 100). 
 
(E)-N-Isopentyl-[((4S)-2,2-dimethyl-1,3-dioxolan-4-yl)methylidene]amine 191f 
Colourless oil. Yield 85%. [α]D = +69.7° (c = 1.61, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.91 (6H, d, J = 
7.7 Hz, (CH3)2CH); 1.40 and 1.46 (2 × 3H, 2 × s, (CH3)2C); 1.48 (2H, q, J = 7.7 Hz, 
CH2CH2N); 1.61 (1H, nonet, J = 7.7 Hz, (CH3)2CH); 3.43 (2H, t, J = 7.7 Hz, CH2N); 3.91 
and 4.20 (2 × 1H, 2 × (d × d), J = 8.0, 6.9, 6.4 Hz, (HCH)O); 4.56 (1H, d × d × d, J = 6.9, 
6.4, 5.2 Hz, CHO); 7.64 (1H, d, J = 5.2 Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 
22.3 ((CH3)2CH); 25.3 (CH3CCH3); 25.6 ((CH3)2CH); 26.3 (CH3CCH3); 39.4 (CH2CH2N); 
59.0 (CH2N); 67.2 (CH2O); 76.8 (CHO); 109.8 (CH3CCH3); 162.5 (HC=N). IR (ATR, cm
-1
): 
νC=N = 1673; νmax = 2955, 1468, 1370, 1213, 1062, 848. MS (70 eV): m/z (%) 200 
(M
+
+1, 100). 
 
5.3 Synthesis of azetidin-2-ones 
5.3.1 Synthesis of trans-4-aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones 
As a representative example, the synthesis of trans-3-chloro-1-(2-chloroethyl)-4-(4-
methylphenyl)azetidin-2-one 2a is described. To a solution of N-(4-methylphenylmethylidene)-(2-
chloroethyl)amine 124a (1.82 g, 10 mmol, 1 equiv) in dry benzene (50 mL) was added 2,6-lutidine 
(3.21 g, 30 mmol, 3 equiv), and the resulting mixture was heated under reflux. Immediately 
thereafter, chloroacetyl chloride (1.69 g, 15 mmol, 1.5 equiv) was added dropwise to the boiling 
N
H O
O
S
H
N
H O
O
S
H
N
H O
OH
S
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mixture, followed by a reflux period of 15 hours. Afterwards, the resulting suspension was filtered in 
order to remove 2,6-lutidine hydrochloride, after which the filtrate was washed with an aqueous 
solution of 1 M HCl (2 × 15 mL). The organic phase was dried over MgSO4, followed by removal of the 
drying agent and evaporation of the solvent in vacuo. Purification by means of column 
chromatography on silica gel (hexane/EtOAc 6/1) afforded pure trans-3-chloro-1-(2-chloroethyl)-4-
(4-methylphenyl)azetidin-2-one 2a in 75% yield. 
 
Trans-3-chloro-1-(2-chloroethyl)-4-(4-methylphenyl)azetidin-2-one 2a 
Yellow oil. Rf = 0.10 (hexane/EtOAc 6/1). Yield 75%. 
1
H NMR (300 MHz, CDCl3): δ 2.39 (3H, s, CH3); 
3.20 (1H, d × d × d, J = 14.6, 7.4, 5.2 Hz, (HCH)N); 3.51-3.68 (2H, m, CH2Cl); 3.84 (1H, d 
× d × d, J = 14.6, 6.1, 5.2 Hz, (HCH)N); 4.54 and 4.70 (2 × 1H, 2 × d, J = 1.6 Hz, CHCl 
and CHN); 7.20–7.28 (4H, m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 21.2 (CH3); 41.3 
(CH2Cl); 42.7 (CH2N); 63.3 and 66.9 (CHCl and CHN); 126.7 and 130.0 (4 x HCarom); 
131.6 and 139.8 (2 x Carom,quat); 164.1 (C=O). IR (ATR, cm
-1
): νC=O = 1767; νmax = 1675, 
1395, 821, 756. MS (70 eV): m/z (%) 258/60/2 (M
+
+1, 100). Anal. Calcd. for C12H13Cl2NO: C 55.83, H 
5.08, N 5.43. Found: C 55.70, H 5.46, N 5.47. 
 
Trans-3-chloro-1-(2-chloroethyl)-4-phenylazetidin-2-one 2b 
Yellow crystals. Mp 50.8 °C. Rf = 0.15 (hexane/EtOAc 6/1). Yield 60%. 
1
H NMR (300 MHz, CDCl3): δ 
3.21 (1H, d × d × d, J = 14.7, 7.6, 5.1 Hz, (HCH)N); 3.52–3.69 (2H, m, CH2Cl); 3.86 (1H, 
d × d × d, J = 14.7, 6.1, 5.2 Hz, (HCH)N); 4.56 and 4.74 (2 × 1H, 2 × d, J = 1.7 Hz, CHCl 
and CHN); 7.32–7.35 and 7.41–7.48 (2H and 3H, 2 × m, CHarom). 
13
C NMR (75 MHz, ref 
= CDCl3): δ 41.5 (CH2Cl); 42.9 (CH2N); 63.3 and 66.9 (CHCl and CHN); 126.9, 129.5 and 
129.8 (5 x HCarom); 134.7 (Carom,quat); 164.1 (C=O). IR (ATR, cm
-1
): νC=O = 1765; νmax = 
1676, 1395, 738, 698. MS (70 eV): m/z (%) 244/6/8 (M
+
+1, 100). Anal. Calcd. for C11H11Cl2NO: C 54.12, 
H 4.54, N 5.74. Found: C 53.91, H 4.64, N 5.48.  
 
Trans-3-chloro-1-(2-chloroethyl)-4-(4-chlorophenyl)azetidin-2-one 2c 
Yellow crystals. Mp 55.3 °C. Rf = 0.12 (hexane/EtOAc 6/1). Yield 69%. 
1
H NMR (300 MHz, CDCl3): δ 
3.19 (1H, d × d × d, J = 14.7, 7.7, 4.7 Hz, (HCH)N); 3.54–3.70 (2H, m, CH2Cl); 3.87 (1H, 
d × d × d, J = 14.7, 5.8, 4.7 Hz, (HCH)N); 4.53 and 4.74 (2 × 1H, 2 × d, J = 2.0 Hz, CHCl 
and CHN); 7.28–7.36 and 7.41–7.46 (2 × 2H, 2 × m, CHarom). 
13
C NMR (75 MHz, 
CDCl3): δ 41.4 (CH2Cl); 42.8 (CH2N); 63.3 and 66.5 (CHCl and CHN); 128.1 and 129.6 
(4 x HCarom); 133.2 and 135.7 (2 x Carom,quat); 163.8 (C=O). IR (ATR, cm
-1
): νC=O = 1768; 
νmax = 1676, 1394, 1090, 828, 770. MS (70 eV): m/z (%) no M
+
; 172 (M
+
-3×Cl, 100), 
137, 102, 101, 75. Anal. Calcd. for C11H10Cl3NO: C 47.43, H 3.62, N 5.03. Found: C 47.21, H 3.77, N 
5.13.  
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Trans-3-chloro-1-(2-chloroethyl)-4-(3-methoxyphenyl)azetidin-2-one 2d 
Yellow oil. Rf = 0.15 (hexane/EtOAc 6/1). Yield 66%. 
1
H NMR (300 MHz, CDCl3): δ 3.24 (1H, d × d × d, J 
= 14.4, 7.6, 5.4 Hz, (HCH)N); 3.54–3.69 (2H, m, CH2Cl); 3.81–3.90 (1H, m, 
(HCH)N); 3.83 (3H, s, CH3O); 4.56 and 4.70 (2 × 1H, 2 × d, J = 1.1 Hz, CHCl and 
CHN); 6.85–6.96 and 7.33–7.38 (3H and 1H, 2 × m, CHarom). 
13
C NMR (75 MHz, ref 
= CDCl3): δ 41.5 (CH2Cl); 43.0 (CH2N); 55.5 (CH3O); 63.3 and 66.7 (CHCl and CHN); 
112.3, 115.1, 118.9, 130.5 (4 x HCarom); 136.4 (CHNCquat); 160.4 (OCarom,quat); 163.9 
(C=O). IR (ATR, cm
-1
): νC=O = 1768; νmax = 1676, 1394, 1261, 1039, 779, 735, 695. MS (70 eV): m/z (%) 
274/6/8 (M
+
+1, 100). Anal. Calcd. for C12H13Cl2NO2: C 52.57, H 4.78, N 5.11. Found: C 52.36, H 4.97, N 
5.03.  
 
5.3.2 Synthesis of 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones and 
N-[3-(tert-butyldimethylsilyloxy)prop-1-en-1-yl]acetamides 
As a representative example, the synthesis of cis-3-benzyloxy-4-[2-(tert-butyldimethylsilyloxy)ethyl]-
1-isobutylazetidin-2-one 12d and 2-benzyloxy-N-[3-(tert-butyldimethylsilyloxy)prop-1-en-1-yl]-N-
isobutylacetamide 149d is described. To an ice-cooled solution of (E)-N-[3-(tert-
butyldimethylsilyloxy)propylidene]isobutylamine 148c (2.43 g, 10 mmol, 1 equiv) and triethylamine 
(3.04 g, 30 mmol, 3 equiv) in anhydrous CH2Cl2 (25 mL) was added dropwise a solution of 
benzyloxyacetyl chloride (2.40 g, 13 mmol, 1.3 equiv) in CH2Cl2 (10 mL). After stirring for 15 hours at 
room temperature, the reaction mixture was poured into water (30 mL) and extracted with CH2Cl2 (2 
× 25 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent afforded cis-3-
benzyloxy-4-[2-(tert-butyldimethylsilyloxy)ethyl]-1-isobutylazetidin-2-one 12d and 2-benzyloxy-N-[3-
(tert-butyldimethylsilyloxy)prop-1-en-1-yl]-N-isobutylacetamide 149d, which were further purified in 
5% and 66% yield, respectively, by column chromatography on silica gel (hexane/EtOAc 12/1). 
 
Cis-4-[2-(tert-butyldimethylsilyloxy)ethyl]-1-isopropyl-3-phenoxyazetidin-2-one 12a 
Yellow crystals. Mp 57.2 °C. Rf = 0.14 (hexane/EtOAc 6/1). Yield 47%. 
1
H NMR (300 MHz, CDCl3): δ 
0.02 and 0.04 (2 × 3H, 2 × s, Si(CH3)2); 0.89 (9H, s, SiC(CH3)3); 1.29 and 
1.34 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CHN); 1.95-2.12 (2H, m, CH2CHN); 
3.60-3.68 and 3.71-3.78 (2 × 1H, 2 × m, (HCH)O); 3.85 (1H, septet, J = 6.8 
Hz, (CH3)2CHN); 4.13 (1H, d × d × d, J = 8.8, 4.1, 4.1 Hz, CH2CHN); 5.16 
(1H, d, J = 4.1 Hz, CHO); 6.96-7.11 and 7.26-7.32 (5H, 2 × m, CHarom). 
13
C 
NMR (75 MHz, CDCl3): δ -5.42 and -5.37 (2 × SiCH3); 18.2 (SiCquat); 20.1 and 21.8 ((CH3)2CHN); 25.9 
(SiC(CH3)3); 32.7 (CH2CHN); 44.6 ((CH3)2CHN); 54.3 (CH2CHN); 59.7 (CH2O); 79.7 (CHO); 115.6, 122.0 
and 129.5 (5 x HCarom); 157.8 (OCarom,quat); 165.5 (C=O). IR (ATR, cm
-1
): νC=O = 1754; νmax = 2954, 2929, 
2857, 1238, 1085, 836, 774, 752. MS (70 eV): m/z (%) 364 (M
+
+1, 100). Anal. Calcd. for C20H33NO3Si: C 
66.07, H 9.15, N 3.85. Found: C 65.87, H 9.37, N 4.18. 
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Cis-3-benzyloxy-4-[2-(tert-butyldimethylsilyloxy)ethyl]-1-isopropylazetidin-2-one 12b 
Yellow oil. Rf = 0.10 (hexane/EtOAc 6/1). Yield 35%. 
1
H NMR (300 MHz, CDCl3): δ -0.07 and -0.06 (2 × 
3H, 2 × s, Si(CH3)2); 0.87 (9H, s, SiC(CH3)3); 1.20 and 1.24 (2 × 3H, 2 × d, J 
= 6.6 Hz, (CH3)2CHN); 1.91-1.97 (2H, m, CH2CHN); 3.58-3.81 (3H, m, 
CH2CH2O and (CH3)2CHN); 3.88 (1H, d × d × d, J = 8.8, 4.7, 4.4 Hz, 
CH2CHN); 4.52 (1H, d, J = 4.7 Hz, CHO); 4.65 and 4.87 (2 × 1H, 2 × d, J = 
11.9 Hz, O(HCH)Ph); 7.23-7.35 (5H, m, CHarom). 
13
C NMR (75 MHz, 
CDCl3): δ -5.4 and -5.3 (2 × SiCH3); 18.3 (SiCquat); 20.1 and 21.8 
((CH3)2CHN); 25.9 (SiC(CH3)3); 32.6 (CH2CHN); 44.2 ((CH3)2CHN); 53.9 (CH2CHN); 59.9 (CH2CH2O); 72.6 
(OCH2Ph); 80.6 (CHO); 127.8, 128.1 and 128.4 (5 x HCarom); 137.5 (Carom,quat); 167.3 (C=O). IR (ATR, cm
-
1
): νC=O = 1747; νmax = 2929, 1651, 1252, 1096, 833, 775, 734, 697. MS (70 eV): m/z (%) 378 (M
+
+1, 
100). HRMS (ESI) Calcd. for C21H36NO3Si 378.2464 [M + H]
+
, found 378.2463. 
 
Cis-3-benzyloxy-4-[2-(tert-butyldimethylsilyloxy)ethyl]-1-cyclohexylazetidin-2-one 12c 
Colourless oil. Rf = 0.11 (hexane/EtOAc 9/1). Yield 55%. 
1
H NMR (300 MHz, CDCl3): δ 0.00 and 0.01 (2 
× 3H, 2 × s, Si(CH3)2); 0.86 (9H, s, SiC(CH3)3); 1.04-1.30, 1.34-1.47, 1.52-
1.60 and 1.69-2.02 (12H, 4 × m, (CH2)5CHN and CH2CH2O); 3.32-3.42 
(1H, m, (CH2)5CHN); 3.58-3.83 (2H, m, CH2CH2O); 3.87 (1H, d × d × d, J = 
8.7, 4.5, 4.0 Hz, OCH2CH2CHN); 4.52 (1H, d, J = 4.5 Hz, CHO); 4.65 and 
4.87 (2 × 1H, 2 × d, J = 11.9 Hz, O(HCH)Ph); 7.26-7.32 (5H, m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ -5.4 and -5.3 (2 × SiCH3); 18.3 (SiCquat); 25.2, 
25.25 and 25.33 (3 × CH2); 25.9 (SiC(CH3)3); 30.5 and 31.9 (2 × CH2); 32.6 (CH2CH2O); 52.1 ((CH2)5CHN); 
54.1 (OCH2CH2CHN); 59.8 (CH2CH2O); 72.6 (OCH2Ph); 80.6 (CHO); 127.8, 128.37 and 128.39 (5 x 
HCarom); 137.5 (Carom,quat); 167.3 (C=O). IR (ATR, cm
-1
): νC=O = 1746; νmax = 2929, 1254, 1095, 1056, 832, 
812, 775, 734, 697. MS (70 eV): m/z (%) 418 (M
+
+1, 100). HRMS (ESI) Calcd. for C24H40NO3Si 418.2777 
[M + H]
+
, found 418.2788. 
 
Cis-3-benzyloxy-4-[2-(tert-butyldimethylsilyloxy)ethyl]-1-isobutylazetidin-2-one 12d 
Colourless oil. Rf = 0.05 (hexane/EtOAc 12/1). Yield 5%. 
1
H NMR (300 MHz, CDCl3): δ 0.04 (6H, s, 
Si(CH3)2); 0.88 (3H, d, J = 6.1 Hz, CH3CHCH3); 0.89 (9H, s, SiC(CH3)3); 0.92 
(3H, d, J = 6.1 Hz, CH3CHCH3); 1.82-2.00 (3H, m, CH2CHN and (CH3)2CH); 
2.83 and 3.19 (2 × 1H, 2 × (d × d), J = 14.1, 8.3, 6.0 Hz, (HCH)N); 3.64-
3.78 (2H, m, CH2CH2O); 3.88 (1H, d × d × d, J = 7.0, 5.4, 5.2 Hz, CHN); 
4.66 (1H, d, J = 5.2 Hz, CHO); 4.69 and 4.90 (2 × 1H, 2 × d, J = 11.6 Hz, 
O(HCH)Ph); 7.29-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ -5.3 (Si(CH3)2); 18.4 (SiCquat); 
20.3 and 20.5 (CH3CHCH3); 26.0 (SiC(CH3)3); 27.3 ((CH3)2CH); 31.5 (CH2CHN); 48.0 (CH2N); 55.5 (CHN); 
60.0 (CH2CH2O); 72.8 (OCH2Ph); 81.3(CHO); 127.9 and 128.5 (5 x HCarom); 137.5 (Carom,quat); 168.3 
(C=O). IR (ATR, cm
-1
): νC=O = 1750; νmax = 2955, 1254, 1098, 1054, 833, 776, 732. MS (70 eV): m/z (%) 
392 (M
+
+1, 100). HRMS (ESI) Calcd. for C22H38NO3Si 392.2621 [M + H]
+
, found 392.2632. 
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2-Benzyloxy-N-[3-(tert-butyldimethylsilyloxy)prop-1-en-1-yl]-N-isobutylacetamide 149d 
Yellow oil. Rf = 0.07 (hexane/EtOAc 12/1). Yield 66%. 
1
H NMR (300 MHz, CDCl3): δ 0.06 (6H, s, 
Si(CH3)2); 0.90 (6H, d, J = 6.1 Hz, (CH3)2CH); 0.90 (9H, s, SiC(CH3)3); 
2.01-2.10 (1H, m, (CH3)2CH); 3.51 (2H, d, J = 7.7 Hz, CH2N); 4.19 (2H, d, 
J = 5.3 Hz, CHCH2O); 4.29 and 4.62 (2 × 2H, 2 × s, PhCH2O and CH2CO); 
5.15 (1H, d × d × d, J = 13.8, 5.3, 5.3 Hz, HC=CHCH2); 6.70 (1H, d, J = 
13.8 Hz, HC=CHCH2); 7.28-7.37 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ -5.2 (Si(CH3)2); 18.3 (SiCquat); 20.2 ((CH3)2CH); 25.9 (SiC(CH3)3); 
26.0 ((CH3)2CH); 49.6 (CH2N); 62.1 (CHCH2O); 69.0 and 73.0 (PhCH2O and CH2CO); 110.9 (HC=CHCH2); 
127.6 (HC=CHCH2); 127.8, 128.0 and 128.3 (5 x HCarom); 137.3 (Carom,quat); 168.0 (C=O). IR (ATR, cm
-1
): 
νC=C,C=O = 1686, 1649; νmax = 2929, 1251, 1108, 1061, 834, 775, 697. MS (70 eV): m/z (%) 392 (M
+
+1, 
100). HRMS (ESI) Calcd. for C22H38NO3Si 392.2621 [M + H]
+
, found 392.2634. 
 
5.3.3 Synthesis of 4-(2-hydroxyethyl)azetidin-2-ones 
As a representative example, the synthesis of cis-3-benzyloxy-4-(2-hydroxyethyl)-1-isopropylazetidin-
2-one 184a is described. To an ice-cooled solution of cis-3-benzyloxy-4-[2-(tert-
butyldimethylsilyloxy)ethyl]-1-isopropylazetidin-2-one 12b (0.76 g, 2 mmol, 1 equiv) in 
tetrahydrofuran (20 mL) was added tetra-n-butylammonium fluoride (0.08 g, 2.2 mmol, 1.1 equiv), 
and the resulting solution was stirred at room temperature for 5 hours. Subsequently, the reaction 
mixture was poured into brine (20 mL) and extracted with CH2Cl2 (3 × 20 mL), after which the organic 
fraction was dried (MgSO4), followed by removal of the drying agent and evaporation of the solvent 
in vacuo. Purification by means of column chromatography on silica gel (hexane/EtOAc 1/1) gave 
pure cis-3-benzyloxy-4-(2-hydroxyethyl)-1-isopropylazetidin-2-one 184a in 49% yield. 
 
Cis-3-benzyloxy-4-(2-hydroxyethyl)-1-isopropylazetidin-2-one 184a 
Yellow oil. Rf = 0.49 (hexane/EtOAc 1/1). Yield 49%. 
1
H NMR (300 MHz, CDCl3): δ 1.24 and 1.28 (2 × 
3H, 2 × d, J = 6.9 Hz, (CH3)2CHN); 1.96-2.18 (2H, m, CH2CHN); 2.26 (1H, t, J = 
5.0 Hz, OH); 3.64-3.85 (3H, m, CH2OH and (CH3)2CHN); 3.91 (1H, d × d × d, J = 
9.2, 4.7, 4.5 Hz, CH2CHN); 4.62 (1H, d, J = 4.7 Hz, CHO); 4.73 and 4.99 (2 × 
1H, 2 × d, J = 11.3 Hz, O(HCH)Ph); 7.28-7.40 (5H, m, CHarom). 
13
C NMR (75 
MHz, ref = CDCl3): δ 20.2 and 21.8 ((CH3)2CHN); 32.3 (CH2CHN); 44.3 
((CH3)2CHN); 55.3 (CH2CHN); 59.4 (CH2OH); 72.9 (OCH2Ph); 80.5 (CHO); 
128.05, 128.12 and 128.6 (5 x HCarom); 137.0 (Carom,quat); 167.2 (C=O). IR (ATR, cm
-1
): νC=O = 1726; νOH = 
3418; νmax = 2930, 1340, 1024, 732, 698. MS (70 eV): m/z (%) 264 (M
+
+1, 100). HRMS (ESI) Calcd. for 
C15H22NO3 264.1600 [M + H]
+
, found 264.1598. 
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Cis-3-benzyloxy-1-cyclohexyl-4-(2-hydroxyethyl)azetidin-2-one 184b 
White crystals. Mp 70.0 °C. Rf = 0.18 (hexane/EtOAc 1/1). Yield 60%. 
1
H NMR (300 MHz, CDCl3): δ 
1.06-1.48, 1.52-1.65 and 1.73-1.95 (4H, 2H and 4H, 3 × m, (CH2)5CHN); 1.97-
2.15 (2H, m, CH2CH2O); 2.37 (1H, d, J = 2.8 Hz, OH); 3.36-3.46 (1H, m, 
(CH2)5CHN); 3.63-3.77 (2H, m, CH2OH); 3.91 (1H, d × d × d, J = 9.1, 4.7, 4.4 Hz, 
CHOCHN); 4.61 (1H, d, J = 4.7 Hz, CHO); 4.72 and 4.98 (2 × 1H, 2 × d, J = 11.6 
Hz, O(HCH)Ph); 7.29-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
25.25, 25.28, 25.4, 30.6 and 32.0 ((CH2)5CHN); 32.3 (CH2CH2O); 52.2 
((CH2)5CHN); 55.4 (CHOCHN); 59.4 (CH2OH); 72.8 (OCH2Ph); 80.5 (CHO); 128.06, 128.12 and 128.6 (5 x 
HCarom); 137.0 (Carom,quat); 167.1 (C=O). IR (ATR, cm
-1
): νC=O = 1735; νOH = 3238; νmax = 2932, 1454, 1252, 
1065, 890, 833, 770, 735, 698. MS (70 eV): m/z (%) 304 (M
+
+1, 100). Anal. Calcd. for C18H25NO3: C 
71.26, H 8.31, N 4.62. Found: C 71.13, H 8.50, N 4.63. 
 
5.3.4 Synthesis of 4-(2-mesyloxyethyl)azetidin-2-ones 
As a representative example, the synthesis of cis-3-benzyloxy-1-isopropyl-4-(2-
mesyloxyethyl)azetidin-2-one 17a is described. To an ice-cooled solution of cis-3-benzyloxy-4-(2-
hydroxyethyl)-1-isopropylazetidin-2-one 184a (1.52 g, 5 mmol, 1 equiv) in CH2Cl2 (30 mL) was added 
4-(dimethylamino)pyridine (0.06 g, 0.5 mmol, 0.1 equiv), Et3N (0.56 g, 5.5 mmol, 1.1 equiv) and mesyl 
chloride (0.60 g, 5.25 mmol, 1.05 equiv), after which the mixture was stirred for 3 hours at 0 °C. 
Afterwards, the reaction mixture was washed with brine (2 × 30 mL) and a saturated NaHCO3 
solution (2 × 30 mL). The aqueous phase was extracted with CH2Cl2 (2 × 30 mL), after which the 
organic fraction was dried (MgSO4), followed by removal of the drying agent and evaporation of the 
solvent in vacuo. 
Azetidin-2-ones 17 were obtained in high purity (>95% based on 1H NMR) and were used as such in 
the next reaction step. 
 
Cis-3-benzyloxy-1-isopropyl-4-(2-mesyloxyethyl)azetidin-2-one 17a 
Yellow oil. Yield 89%. 
1
H NMR (300 MHz, CDCl3): δ 1.23 and 1.27 (2 × 3H, 2 × d, J = 6.3 Hz, (CH3)2CHN); 
2.14-2.23 (2H, m, CH2CHN); 2.93 (3H, s, CH3SO3); 3.80 (1H, septet, J = 6.3 
Hz, (CH3)2CHN); 3.91 (1H, d × d × d, J = 8.5, 4.6, 4.1 Hz, CH2CHN); 4.24-4.37 
(2H, m, CH2OSO2); 4.62 (1H, d, J = 4.6 Hz, CHO); 4.68 and 4.93 (2 × 1H, 2 × d, 
J = 11.8 Hz, O(HCH)Ph); 7.28-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 20.2 and 21.8 ((CH3)2CHN); 29.6 (CH2CHN); 37.2 (CH3SO3); 44.4 
((CH3)2CHN); 53.1 (CH2CHN); 66.9 (CH2OSO2); 73.0 (OCH2Ph); 80.6 (CHO); 
128.1, 128.2 and 128.6 (5 x HCarom); 137.2 (Carom,quat); 167.0 (C=O). IR (ATR, cm
-1
): νC=O = 1741; νmax = 
2974, 1351, 1172, 959, 732, 699. MS (70 eV): m/z (%) 342 (M
+
+1, 100). HRMS (ESI) Calcd. for 
C16H24NO5S 342.1375 [M + H]
+
, found 342.1381. 
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Cis-3-benzyloxy-1-cyclohexyl-4-(2-mesyloxyethyl)azetidin-2-one 17b 
Yellow oil. Yield 86%. 
1
H NMR (300 MHz, CDCl3): δ 1.08-1.46, 1.51-1.66 and 1.75-1.93 (4H, 2H and 4H, 
3 × m, (CH2)5CHN); 2.11-2.29 (2H, m, CH2CH2O); 2.94 (3H, s, CH3SO3); 3.37-
3.47 (1H, m, (CH2)5CHN); 3.92 (1H, d × d × d, J = 8.8, 4.7, 4.4 Hz, CHOCHN); 
4.26-4.38 (2H, m, CH2OSO2); 4.62 (1H, d, J = 4.7 Hz, CHO); 4.68 and 4.95 (2 × 
1H, 2 × d, J = 11.5 Hz, O(HCH)Ph); 7.28-7.38 (5H, m, CHarom). 
13
C NMR (75 
MHz, ref = CDCl3): δ 25.2, 25.3, 29.6, 30.6 and 32.0 ((CH2)5CHN and 
CH2CH2O); 37.2 (CH3SO3); 52.2 ((CH2)5CHN); 53.3 (CHOCHN); 67.0 
(CH2OSO2); 72.9 (OCH2Ph); 80.7 (CHO); 128.0, 128.1 and 128.6 (5 x HCarom); 
137.2 (Carom,quat); 166.9 (C=O). IR (ATR, cm
-1
): νC=O = 1740; νmax = 2932, 1352, 1172, 960, 733, 699. MS 
(70 eV): m/z (%) 382 (M
+
+1, 100). HRMS (ESI) Calcd. for C19H28NO5 382.1688 [M + H]
+
, found 
382.1695. 
 
5.3.5 Synthesis of (3R,4S)-3-benzyloxy-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-
yl]azetidin-2-ones 
The synthesis of (3R,4S)-3-benzyloxy-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-ones 192 was 
analogous to the synthesis of cis-4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones 12 and N-[3-
(tert-butyldimethylsilyloxy)prop-1-en-1-yl]acetamides 149 (Section 5.3.2), using (E)-N-[((4S)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylidene]amines 191 as the starting material. 
 
(3R,4S)-3-Benzyloxy-1-isopropyl-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192a 
Colourless oil. Rf = 0.12 (hexane/EtOAc 6/1). Yield 81%. [α]D = +102.8° (c = 0.97, CH2Cl2). 
1
H NMR (300 
MHz, CDCl3): δ 1.29 (6H, d, J = 6.7 Hz, (CH3)2CH); 1.34 and 1.44 (2 × 3H, 2 × s, 
(CH3)2C); 3.62 (1H, d × d, J = 8.2, 6.1 Hz, CHO(HCH)O); 3.69 (1H, d × d, J = 
8.8, 5.0 Hz, CHOCHN); 3.92 (1H, septet, J = 6.7 Hz, (CH3)2CH); 4.16-4.30 (2H, 
m, CHO(HCH)O and CHOCH2O); 4.54 (1H, d, J = 5.0 Hz, COCHO); 4.64 and 
4.92 (2 × 1H, 2 × d, J = 11.9 Hz, O(HCH)Ph); 7.28-7.38 (5H, m, CHarom). 
13
C 
NMR (75 MHz, ref = CDCl3): δ 19.5 and 21.3 ((CH3)2CH); 25.2 and 26.8 
((CH3)2C); 44.4 ((CH3)2CH); 59.8 (CHOCHN); 66.9 (CHOCH2O); 72.8 (OCH2Ph); 77.2 (CHOCH2O); 79.6 
(COCHO); 109.3 ((CH3)2C); 127.8, 128.0 and 128.5 (5 x HCarom); 137.1 (Carom,quat); 166.8 (C=O). IR (ATR, 
cm
-1
): νC=O = 1747; νmax = 2981, 1370, 1209, 1064, 1024, 852, 698. MS (70 eV): m/z (%) 320 (M
+
+1, 
100). HRMS (ESI) Calcd. for C18H26NO4 320.1862 [M + H]
+
, found 320.1867. 
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(3R,4S)-3-Benzyloxy-1-isobutyl-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192b 
White crystals. Mp 103.5 °C. Rf = 0.22 (hexane/EtOAc 6/1). Yield 50%. [α]D = +96.9° (c = 0.40, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.88 and 0.93 (2 × 3H, 2 × d, J = 7.2 Hz, 
(CH3)2CH); 1.33 and 1.42 (2 × 3H, 2 × s, (CH3)2C); 1.92-2.09 (1H, m, (CH3)2CH); 
3.07 and 3.23 (2 × 1H, 2 × (d × d), J = 13.6, 8.3, 6.3 Hz, (HCH)N); 3.63 (1H, d × 
d, J = 8.8, 6.3 Hz, CHO(HCH)O); 3.66 (1H, d × d, J = 8.8, 5.0 Hz, CHN); 4.15 
(1H, d × d, J = 8.8, 6.3 Hz, CHO(HCH)O); 4.32 (1H, d × t, J = 8.8, 6.3 Hz, 
CHOCH2O); 4.62 (1H, d, J = 5.0 Hz, COCHO); 4.64 and 4.92 (2 × 1H, 2 × d, J = 
11.8 Hz, O(HCH)Ph); 7.28-7.39 (5H, m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 20.2 and 20.4 ((CH3)2CH); 
25.1 (CH3CCH3); 26.8 and 27.0 (CH3CCH3 and (CH3)2CH); 48.7 (CH2N); 60.8 (CHN); 66.7 (CHOCH2O); 
72.6 (OCH2Ph); 77.2 (CHOCH2O); 80.3 (COCHO); 109.3 ((CH3)2C); 127.7, 127.9 and 128.4 (5 x HCarom); 
137.2 (Carom,quat); 167.6 (C=O). IR (ATR, cm
-1
): νC=O = 1737; νmax = 2959, 1370, 1209, 1156, 1060, 858, 
698. MS (70 eV): m/z (%) 334 (M
+
+1, 100). Anal. Calcd. for C19H27NO4: C 68.44, H 8.16, N 4.20. Found: 
C 68.70, H 8.10, N 4.32. 
 
(3R,4S)-3-Benzyloxy-1-butyl-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192c 
Light-brown crystals. Mp 98.8 °C. Recrystallization from absolute EtOH. Yield 43%. [α]D = +96.7° (c = 
0.51, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.92 (3H, t, J = 7.3 Hz, CH2CH3); 
1.32 (2H, sextet, J = 7.3 Hz, CH2CH3); 1.33 and 1.43 (2 × 3H, 2 × s, (CH3)2C); 
1.47-1.66 (2H, m, CH2CH2N); 3.21 (1H, d × t, J = 13.8, 7.0 Hz, (HCH)N); 3.44 
(1H, d × t, J = 13.8, 7.0 Hz, (HCH)N); 3.63 (1H, d × d, J = 8.2, 6.5 Hz, 
CHO(HCH)O); 3.64 (1H, d × d, J = 8.8, 4.9 Hz, CHN); 4.15 (1H, d × d, J = 8.2, 
6.5 Hz, CHO(HCH)O); 4.31 (1H, d × t, J = 8.8, 6.5 Hz, CHOCH2O); 4.59 (1H, d, J = 4.9 Hz, COCHO); 4.63 
and 4.91 (2 × 1H, 2 × d, J = 11.6 Hz, O(HCH)Ph); 7.29-7.37 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 13.7 (CH2CH3); 20.2 (CH2CH3); 25.2 and 26.9 ((CH3)2C); 29.5 (CH2CH2N); 41.0 (CH2N); 60.4 
(CHN); 66.9 (CHOCH2O); 72.9 (OCH2Ph); 77.2 (CHOCH2O); 80.3 (COCHO); 109.6 ((CH3)2C); 127.9, 128.1 
and 128.6 (5 x HCarom); 137.1 (Carom,quat); 167.7 (C=O). IR (ATR, cm
-1
): νC=O = 1729; νmax = 2955, 1372, 
1210, 1153, 1072, 1044, 854, 734, 698. MS (70 eV): m/z (%) 334 (M
+
+1, 100). Anal. Calcd. for 
C19H27NO4: C 68.44, H 8.16, N 4.20. Found: C 68.60, H 7.94, N 4.25. 
 
(3R,4S)-3-Benzyloxy-1-cyclohexyl-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192d 
White crystals. Mp 99.8 °C. Recrystallization from absolute EtOH. Yield 65%. [α]D = +109.9° (c = 0.95, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 1.08-1.51 (3H, m, (CH2)5CHN); 1.34 and 
1.44 (2 × 3H, 2 × s, (CH3)2C); 1.60-1.88 (7H, m, (CH2)5CHN); 3.44-3.56 (1H, m, 
(CH2)5CHN); 3.62 (1H, d × d, J = 8.4, 6.0 Hz, CHO(HCH)O); 3.69 (1H, d × d, J = 
8.5, 4.8 Hz, CHOCHN); 4.18 (1H, d × d, J = 8.4, 6.3 Hz, CHO(HCH)O); 4.20-
4.29 (1H, m, CHOCH2O); 4.53 (1H, d, J = 4.8 Hz, COCHO); 4.63 and 4.92 (2 × 
1H, 2 × d, J = 11.9 Hz, O(HCH)Ph); 7.28-7.38 (5H, m, CHarom). 
13
C NMR (75 
MHz, CDCl3): δ 25.16 (CH3CCH3); 25.21 and 25.4 ((CH2)5CHN); 26.8 
(CH3CCH3); 29.8 and 31.1 ((CH2)5CHN); 52.4 ((CH2)5CHN); 60.0 (CHOCHN); 67.0 (CHOCH2O); 72.8 
(OCH2Ph); 77.2 (CHOCH2O); 79.6 (COCHO); 109.4 ((CH3)2C); 127.8, 128.0 and 128.5 (5 x HCarom); 137.1 
(Carom,quat); 167.0 (C=O). IR (ATR, cm
-1
): νC=O = 1724; νmax = 2938, 1214, 1154, 1059, 860, 696. MS (70 
eV): m/z (%) 360 (M
+
+1, 100). Anal. Calcd. for C21H29NO4: C 70.17, H 8.13, N 3.90. Found: C 70.07, H 
7.85, N 3.86. 
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(3R,4S)-3-Benzyloxy-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1-propylazetidin-2-one 192e 
Yellow oil. Rf = 0.12 (hexane/EtOAc 6/1). Yield 70%. [α]D = +95.1° (c = 0.95, CH2Cl2). 
1
H NMR (300 
MHz, CDCl3): δ 0.91 (3H, t, J = 7.4 Hz, CH2CH3); 1.34 and 1.43 (2 × 3H, 2 × s, 
(CH3)2C); 1.50-1.75 (2H, m, CH2CH3); 3.15-3.24 and 3.34-3.43 (2 × 1H, 2 × m, 
(HCH)N); 3.63 (1H, d × d, J = 8.8, 6.1 Hz, CHO(HCH)O); 3.65 (1H, d × d, J = 
8.8, 5.0 Hz, CHN); 4.15 (1H, d × d, J = 8.8, 6.1 Hz, CHO(HCH)O); 4.31 (1H, d × 
t, J = 8.8, 6.1 Hz, CHOCH2O); 4.60 (1H, d, J = 5.0 Hz, COCHO); 4.64 and 4.92 
(2 × 1H, 2 × d, J = 12.1 Hz, O(HCH)Ph); 7.27-7.39 (5H, m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 11.5 
(CH2CH3); 20.8 (CH2CH3); 25.1 and 26.8 ((CH3)2C); 42.8 (CH2N); 60.4 (CHN); 66.8 (CHOCH2O); 72.7 
(OCH2Ph); 77.2 (CHOCH2O); 80.4 (COCHO); 109.3 ((CH3)2C); 127.7, 127.9 and 128.5 (5 x HCarom); 137.2 
(Carom,quat); 167.4 (C=O). IR (ATR, cm
-1
): νC=O = 1751; νmax = 2934, 1371, 1210, 1153, 1064, 850, 698. MS 
(70 eV): m/z (%) 320 (M
+
+1, 100). HRMS (ESI) Calcd. for C18H26NO4 320.1862 [M + H]
+
, found 
320.1869. 
 
(3R,4S)-3-Benzyloxy-1-isopentyl-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192f 
White crystals. Mp 93.9 °C. Recrystallization from absolute EtOH. Yield 50%. [α]D = +106.6° (c = 0.92, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ 0.91 (6H, d, J = 6.1 Hz, (CH3)2CH); 1.34 
and 1.43 (2 × 3H, 2 × s, (CH3)2C); 1.39-1.58 (3H, m, CH2CH2N and (CH3)2CH); 
3.21 (1H, d × d × d, J = 14.3, 6.7, 6.7 Hz, (HCH)N); 3.48 (1H, d × d × d, J = 
14.3, 7.0, 7.0 Hz, (HCH)N); 3.62-3.66 (2H, m, CHN and CHO(HCH)O); 4.15 
(1H, d × d, J = 7.7, 7.7 Hz, CHO(HCH)O); 4.31 (1H, d × d × d, J = 7.7, 7.6, 7.6 
Hz, CHOCH2O); 4.58 (1H, d, J = 5.0 Hz, COCHO); 4.63 and 4.91 (2 × 1H, 2 × d, 
J = 11.6 Hz, O(HCH)Ph); 7.30-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 22.3 and 22.5 
((CH3)2CH); 25.2 (CH3CCH3); 25.9 ((CH3)2CH); 26.9 (CH3CCH3); 36.1 (CH2CH2N); 39.6 (CH2N); 60.2 (CHN); 
66.9 (CHOCH2O); 72.9 (OCH2Ph); 77.2 (CHOCH2O); 80.2 (COCHO); 109.6 (CH3CCH3); 127.9, 128.1 and 
128.6 (5 x HCarom); 137.1 (Carom,quat); 167.6 (C=O). IR (ATR, cm
-1
): νC=O = 1727; νmax = 2958, 1370, 1235, 
1210, 1152, 1074, 853, 733, 698. MS (70 eV): m/z (%) 348 (M
+
+1, 100). Anal. Calcd. for C20H29NO4: C 
69.14, H 8.41, N 4.03. Found: C 69.16, H 8.44, N 4.01. 
 
5.3.6 Synthesis of (3R,4S)-3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]azetidin-2-
ones 
As a representative example, the synthesis of (3R,4S)-3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-
isopropylazetidin-2-one 193a is described. To a solution of (3R,4S)-3-benzyloxy-1-isopropyl-4-[(4S)-
2,2-dimethyl-1,3-dioxolan-4-yl]azetidin-2-one 192a (3.19 g, 10 mmol, 1 equiv) in THF/H2O (1/1, 100 
mL) was added pTsOH·H2O (1.72 g, 10 mmol, 1 equiv) in a single portion. After a reflux period of 4 
hours, the resulting reaction mixture was allowed to cool to room temperature and was then 
neutralized with solid NaHCO3. The mixture was extracted with EtOAc (3 × 40 mL), the combined 
organic layers was dried (MgSO4), and the solvent was removed under reduced pressure. In the next 
step, palladium on activated carbon (20% w/w) was added to a solution of the latter diol (2.79 g, 10 
mmol, 1 equiv) in methanol (60 mL) and the resulting mixture was placed in a Parr apparatus. The 
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inside of the Parr apparatus was then degassed and filled with hydrogen gas, after which the mixture 
was stirred for 18 hours at room temperature while applying 5 bar of hydrogen gas. Filtration of the 
heterogeneous mixture through Celite® and evaporation of the solvent in vacuo afforded crude 
(3R,4S)-3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-isopropylazetidin-2-one 193a, which was purified by 
means of recrystallization from EtOAc/hexane (30/1). 
 
(3R,4S)-3-Hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-isopropylazetidin-2-one 193a 
White crystals. Mp 85.0 °C. Recrystallization from EtOAc/hexane (30/1). Yield 83%. [α]D = +171.5° (c = 
0.78, MeOH). 
1
H NMR (300 MHz, (CD3)2SO): δ 1.16 and 1.23 (2 × 3H, 2 × d, J = 6.7 
Hz, (CH3)2CH); 3.29-3.36 (1H, m, (HCH)OH); 3.46-3.60 (3H, m, (HCH)OH, CHOCHN, 
CH2CHO); 3.66 (1H, septet, J = 6.7 Hz, (CH3)2CH); 4.53 (1H, d × d, J = 7.7, 4.4 Hz, 
COCHO); 4.57 (1H, t, J = 5.5 Hz, CH2OH); 4.77 (1H, d, J = 5.5 Hz, CH2CHOH); 5.91 (1H, 
d, J = 7.7 Hz, COCHOH). 
13
C NMR (75 MHz, ref = (CD3)2SO): δ 20.5 and 21.8 
((CH3)2CH); 45.2 ((CH3)2CH); 59.6 (CHOCHN); 63.7 (CH2OH); 72.5 (CH2CHO); 74.5 (COCHO) 169.0 (C=O). 
IR (ATR, cm
-1
): νOH = 3237; νC=O = 1706; νmax = 1401, 1226, 1087, 814, 708. MS (70 eV): m/z (%) 190 
(M
+
+1, 100). Anal. Calcd. for C8H15NO4: C 50.78, H 7.99, N 7.40. Found: C 51.00, H 7.91, N 7.53. 
 
(3R,4S)-3-Hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-isobutylazetidin-2-one 193b 
White crystals. Mp 98.3 °C. Recrystallization from EtOAc/hexane (30/1). Yield 74%. [α]D = +152.8° (c = 
0.93, MeOH). 
1
H NMR (300 MHz, (CD3)2SO): δ 0.76 and 0.82 (2 × 3H, 2 × d, J = 7.1 
Hz, (CH3)2CH); 1.94 (1H, nonet, J = 7.1 Hz, (CH3)2CH); 2.98 and 3.01 (2 × 1H, 2 × (d × 
d), J = 13.6, 7.1 Hz, (HCH)N); 3.28-3.36 (1H, m, (HCH)OH); 3.46 (1H, d × d × d, J = 
11.0, 5.7, 3.9 Hz, (HCH)OH); 3.51 (1H, d × d, J = 8.3, 5.0 Hz, CHN); 3.60-3.68 (1H, m, 
CH2CHO); 4.56 (1H, t, J = 5.7 Hz, CH2OH); 4.65 (1H, d × d, J = 7.7, 5.0 Hz, COCHO); 
4.75 (1H, d, J = 5.5 Hz, CH2CHOH); 5.92 (1H, d, J = 7.7 Hz, COCHOH). 
13
C NMR (75 MHz, ref = (CD3)2SO): 
δ 20.5 and 20.9 ((CH3)2CH); 26.8 ((CH3)2CH); 49.0 (CH2N); 59.8 (CHN); 63.7 (CH2OH); 72.7 (CH2CHO); 
75.0 (COCHO), 169.8 (C=O). IR (ATR, cm
-1
): νOH = 3284; νC=O = 1712; νmax = 2951, 1425, 1166, 1082, 
996, 831. MS (70 eV): m/z (%) 204 (M
+
+1, 100). Anal. Calcd. for C9H17NO4: C 53.19, H 8.43, N 6.89. 
Found: C 53.37, H 8.13, N 6.49. 
 
(3R,4S)-1-Butyl-3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]azetidin-2-one 193c 
Yellow oil. Rf = 0.06 (EtOAc). Yield 63%. [α]D = +185.6° (c = 0.72, MeOH). 
1
H NMR (300 MHz, (CD3)2SO): 
δ 0.84 (3H, t, J = 7.4 Hz, CH2CH3); 1.12-1.29 (2H, m, CH2CH3); 1.47 (2H, pentet, J = 
7.3 Hz, CH2CH2N); 3.05-3.16 (1H, m, (HCH)N); 3.22-3.37 (2H, m, (HCH)N and 
(HCH)OH); 3.46 (1H, d × d × d, J = 11.1, 5.5, 3.4 Hz, (HCH)OH); 3.50 (1H, d × d, J = 
8.6, 4.7 Hz, CHN); 3.59-3.67 (1H, m, CH2CHO); 4.60 (1H, t, J = 5.5 Hz, CH2OH); 4.61 
(1H, d × d, J = 7.6, 4.7 Hz, COCHO); 4.80 (1H, d, J = 5.5 Hz, CH2CHOH); 5.93 (1H, d, J 
= 7.6 Hz, COCHOH). 
13
C NMR (75 MHz, ref = (CD3)2SO): δ 14.1 (CH2CH3); 20.1 (CH2CH3); 29.5 
(CH2CH2N); 40.9 (CH2N); 59.4 (CHN); 63.7 (CH2OH); 72.7 (CH2CHO); 75.0 (COCHO), 169.6 (C=O). IR 
(ATR, cm
-1
): νOH = 3330; νC=O = 1719; νmax = 2955, 1372, 1210, 1153, 1044, 854, 734, 698. MS (70 eV): 
m/z (%) 204 (M
+
+1, 100). HRMS (ESI) Calcd. for C9H18NO4 204.1236 [M + H]
+
, found 204.1232. 
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(3R,4S)-1-Cyclohexyl-3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]azetidin-2-one 193d 
White crystals. Mp 101.3 °C. Recrystallization from EtOAc/hexane (30/1). Yield 88%. [α]D = +218.3° (c 
= 0.62, MeOH). 
1
H NMR (300 MHz, (CD3)2SO): δ 0.97-1.22 and 1.49-1.85 (3H and 
7H, 2 × m, (CH2)5CHN); 3.19-3.28 (1H, m, (CH2)5CHN); 3.32 (1H, d × d, J = 11.3, 5.8 
Hz, (HCH)OH); 3.44-3.61 (3H, m, (HCH)OH, CHOCHN and CH2CHO); 4.52 (1H, d × d, J 
= 7.7, 5.0 Hz, COCHO); 4.58 (1H, t, J = 5.8 Hz, CH2OH); 4.76 (1H, d, J = 4.9 Hz, 
CH2CHOH); 5.91 (1H, d, J = 7.7 Hz, COCHOH). 
13
C NMR (75 MHz, ref = (CD3)2SO): δ 
25.3, 25.6, 25.7, 30.5 and 31.2 ((CH2)5CHN); 53.3 ((CH2)5CHN); 59.4 (CHOCHN); 63.7 
(CH2OH); 72.6 (CH2CHO); 74.4 (COCHO); 169.0 (C=O). IR (ATR, cm
-1
): νOH = 3197; νC=O = 1704; νmax = 
2933, 1450, 1150, 1055, 699, 674. MS (70 eV): m/z (%) 230 (M
+
+1, 100). Anal. Calcd. for C11H19NO4: C 
57.62, H 8.35, N 6.11. Found: C 57.34, H 8.15, N 5.98. 
 
(3R,4S)-3-Hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-propylazetidin-2-one 193e 
Yellow oil. Rf = 0.08 (EtOAc). Yield 68%. [α]D = +229.6° (c = 0.55, MeOH). 
1
H NMR (300 MHz, (CD3)2SO): 
δ 0.79 (3H, t, J = 7.4 Hz, CH2CH3); 1.40-1.60 (2H, m, CH2CH3); 3.04-3.12 and 3.15-
3.26 (2 × 1H, 2 × m, (HCH)N); 3.27-3.36 (1H, m, (HCH)OH); 3.47 (1H, d × d × d, J = 
11.0, 5.5, 3.3 Hz, (HCH)OH); 3.50 (1H, d × d, J = 8.3, 4.7 Hz, CHN); 3.59-3.67 (1H, m, 
CH2CHO); 4.57 (1H, t, J = 5.5 Hz, CH2OH); 4.62 (1H, d × d, J = 7.7, 4.7 Hz, COCHO); 
4.77 (1H, d, J = 5.5 Hz, CH2CHOH); 5.92 (1H, d, J = 7.7 Hz, COCHOH). 
13
C NMR (75 MHz, ref = (CD3)2SO): 
δ 11.9 (CH2CH3); 20.8 (CH2CH3); 43.1 (CH2N); 59.4 (CHN); 63.7 (CH2OH); 72.6 (CH2CHO); 75.0 (COCHO); 
169.7 (C=O). IR (ATR, cm
-1
): νOH = 3319; νC=O = 1719; νmax = 2935, 1419, 1070, 1026. MS (70 eV): m/z 
(%) 190 (M
+
+1, 100). HRMS (ESI) Calcd. for C8H16NO4 190.1079 [M + H]
+
, found 190.1077. 
 
(3R,4S)-3-Hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-isopentylazetidin-2-one 193f 
Colourless oil. Rf = 0.07 (EtOAc). Yield 93%. [α]D = +163.9° (c = 0.52, MeOH). 
1
H NMR (300 MHz, 
CDCl3): δ 0.90 (6H, d, J = 6.1 Hz, (CH3)2CH); 1.43-1.59 (3H, m, CH2CH2N and 
(CH3)2CH); 3.10 (1H, d × d × d, J = 14.2, 6.9, 6.9 Hz, (HCH)N); 3.57 (1H, d × d × d, J = 
14.2, 7.5, 7.4 Hz, (HCH)N); 3.65-3.82 (3H, m, CHN and CH2OH); 4.02-4.06 (1H, m, 
CH2CHO); 4.85 (1H, d, J = 4.4 Hz, COCHO). 
13
C NMR (75 MHz, ref = CDCl3): δ 22.1 
and 22.5 ((CH3)2CH); 25.8 ((CH3)2CH); 35.7 (CH2CH2N); 40.2 (CH2N); 59.4 (CHN); 64.1 
(CH2OH); 71.7 (CH2CHO); 74.6 (COCHO); 170.6 (C=O). IR (ATR, cm
-1
): νOH = 3326; 
νC=O = 1720; νmax = 2955, 1420, 1072, 1034. MS (70 eV): m/z (%) 218 (M
+
+1, 100). HRMS (ESI) Calcd. 
for C10H20NO4 218.1392 [M + H]
+
, found 218.1390. 
 
5.4 Synthesis of 1-(1-aryl-2-chloro-3-hydroxypropyl)aziridines 
As a representative example, the synthesis of anti-1-[2-chloro-3-hydroxy-1-(4-
methylphenyl)propyl]aziridine 5a is described. To an ice-cooled solution of trans-3-chloro-1-(2-
chloroethyl)-4-(4-methylphenyl)azetidin-2-one 2a (2.07 g, 8 mmol, 1 equiv) in THF (50 mL) was added 
LiAlH4 (0.30 g, 8 mmol, 1 molar equiv) in small portions. Subsequently, the resulting suspension was 
stirred at room temperature for 91 hours, after which water (10 mL) was added cautiously at 0 °C in 
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order to neutralize the excess of LiAlH4. Afterwards, the mixture was filtered through Celite®, and the 
filtrate was dried over MgSO4. Removal of the drying agent through filtration and evaporation of the 
solvent in vacuo afforded anti-1-[2-chloro-3-hydroxy-1-(4-methylphenyl)propyl]-aziridine 5a, which 
was purified in 40% yield by column chromatography on silica gel (hexane/EtOAc 3/2). 
 
Anti-1-[2-chloro-3-hydroxy-1-(4-methylphenyl)propyl]aziridine 5a 
White crystals. Mp 68.7 °C. Rf = 0.06 (hexane/EtOAc 3/2). Yield 40%. 
1
H NMR (300 MHz, CDCl3): δ 1.05 
(1H, d × d, J = 6.5, 4.4 Hz, (HCH)N); 1.76 (1H, d × d, J = 5.7, 4.1 Hz, (HCH)N); 1.80 
(1H, d × d, J = 6.5, 4.1 Hz, (HCH)N); 2.18 (1H, d × d, J = 5.7, 4.4 Hz, (HCH)N); 2.36 
(3H, s, CH3); 3.00 (1H, d, J = 4.4 Hz, CHN); 3.77–3.84 (1H, m, (HCH)OH); 4.08 (1H, 
d, J = 12.7 Hz, (HCH)OH); 4.16–4.22 (2H, m, CHCl and OH); 7.18 and 7.28 (2 × 2H, 
2 × d, J = 8.2 Hz, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 21.2 (CH3); 25.2 and 31.6 (2 × CH2N); 63.8 
(CH2OH); 66.1 (CHCl); 76.9 (CHN); 127.7 and 129.2 (4 x HCarom); 136.5 and 137.8 (2 x Carom,quat). IR 
(ATR, cm
-1
): νOH = 3188; νmax = 2898, 1312, 1258, 1048, 1008, 856, 811, 690. MS (70 eV): m/z (%) 
226/8 (M
+
+1, 100). Anal. Calcd. for C12H16ClNO: C 63.85, H 7.14, N 6.21. Found: C 63.62, H 7.54, N 
6.41. 
 
Anti-1-(2-chloro-3-hydroxy-1-phenylpropyl)aziridine 5b 
White crystals. Mp 73.5 °C. Rf = 0.10 (hexane/EtOAc 3/2). Yield 55%. 
1
H NMR (300 MHz, CDCl3): δ 1.06 
(1H, d × d, J = 6.9, 4.6 Hz, (HCH)N); 1.77 (1H, d × d, J = 5.7, 4.4 Hz, (HCH)N); 1.81 
(1H, d × d, J = 6.9, 4.4 Hz, (HCH)N); 2.20 (1H, d × d, J = 5.7, 4.6 Hz, (HCH)N); 3.03 
(1H, d, J = 6.4 Hz, CHN); 3.80–3.84 (1H, m, (HCH)OH); 4.05-4.14 (2H, m, (HCH)OH 
and OH); 4.22 (1H, d × d, J = 6.4, 3.5 Hz, CHCl); 7.29–7.42 (5H, m, CHarom). 
13
C NMR 
(75 MHz, CDCl3): δ 25.3 and 31.6 (2 × CH2N); 63.7 (CH2OH); 66.0 (CHCl); 77.1 (CHN); 127.8, 128.0, 
128.5 (5 x HCarom); 139.5 (Carom,quat). IR (ATR, cm
-1
): νOH = 3322; νmax = 2869, 1453, 1257, 1047, 1029, 
756, 700. MS (70 eV): m/z (%) 212/4 (M
+
+1, 100). Anal. Calcd. for C11H14ClNO: C 62.41, H 6.67, N 6.62. 
Found: C 62.31, H 6.96, N 6.38. 
 
5.5 Synthesis of 3-aryl-2-(ethylamino)propan-1-ols 
As a representative example, the synthesis of 2-(N-ethylamino)-3-(4-methylphenyl)propan-1-ol 127a 
is described. To an ice-cooled solution of trans-3-chloro-1-(2-chloroethyl)-4-(4-
methylphenyl)azetidin-2-one 2a (0.52 g, 2 mmol, 1 equiv) in THF (30 mL) was added LiAlH4 (0.23 g, 6 
mmol, 3 molar equiv) in small portions. Subsequently, the resulting suspension was heated under 
reflux for 48 hours, after which water (5 mL) was added cautiously at 0 °C in order to neutralize the 
excess of LiAlH4. Afterwards, the mixture was filtered through Celite®, and the filtrate was dried over 
MgSO4. Removal of the drying agent through filtration and evaporation of the solvent in vacuo 
HO
N
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afforded 2-(N-ethylamino)-3-(4-methylphenyl)propan-1-ol 127a, which was purified in 61% yield by 
recrystallization from EtOAc/hexane (30/1). 
 
2-(N-Ethylamino)-3-(4-methylphenyl)propan-1-ol 127a 
White crystals. Mp 102.3 °C. Recrystallization from EtOAc/hexane (30/1). Yield 61%. 
1
H NMR (300 
MHz, CDCl3): δ 1.05 (3H, t, J = 7.2 Hz, CH2CH3); 1.80 (2H, s(broad), OH and NH); 
2.33 (3H, s, CquatCH3); 2.59–2.78 (4H, m, CH2CH3 and CH2Cquat); 2.84–2.92 (1H, m, 
CHN); 3.29 and 3.60 (2 × 1H, 2 × (d × d), J = 10.5, 5.5, 3.9 Hz, (HCH)OH); 7.06 and 
7.11 (2 × 2H, 2 × d, J = 8.0 Hz, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 15.6 (CH2CH3); 
21.0 (CquatCH3); 37.7 (CH2Cquat); 41.2 (CH2CH3); 60.0 (CHN); 62.4 (CH2OH); 129.0 and 129.3 (4 x HCarom); 
135.5 and 135.9 (2 x Carom,quat). IR (ATR, cm
-1
): νOH,NH = 3254; νmax = 2821, 1445, 1121, 1074, 1038, 947, 
931, 802. MS (70 eV): m/z (%) 194 (M
+
+1, 100). Anal. Calcd. for C12H19NO: C 74.57, H 9.91, N 7.25. 
Found: C 74.24, H 10.26, N 7.09. 
 
3-(4-Chlorophenyl)-2-(N-ethylamino)propan-1-ol 127c 
White crystals. Mp 101.3 °C. Recrystallization from EtOAc/hexane (30/1). Yield 65%. 
1
H NMR (300 
MHz, CDCl3): δ 1.06 (3H, t, J = 7.2 Hz, CH2CH3); 1.87 (2H, s(broad), OH and NH); 
2.59–2.79 (4H, m, CH2CH3 and CH2Cquat); 2.83–2.91 (1H, m, CHN); 3.28 and 3.59 
(2 × 1H, 2 × (d × d), J = 10.6, 5.2, 3.9 Hz, (HCH)OH); 7.12 and 7.27 (2 × 2H, 2 × d, 
J = 8.0 Hz, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 15.5 (CH2CH3); 37.4 (CH2Cquat); 
41.3 (CH2CH3); 60.0 (CHN); 62.2 (CH2OH); 128.7 and 130.5 (4 x HCarom); 132.2 and 137.1 (2 x Carom,quat). 
IR (ATR, cm
-1
): νOH,NH = 3268; νmax = 2888, 1482, 1114, 1099, 838, 802. MS (70 eV): m/z (%) 214/6 
(M
+
+1, 100). Anal. Calcd. for C11H16ClNO: C 61.82, H 7.55, N 6.55. Found: C 61.72, H 7.43, N 6.50. 
 
2-(N-Ethylamino)-3-(3-methoxyphenyl)propan-1-ol 127d 
White crystals. Mp 101.6 °C. Recrystallization from EtOAc/hexane (30/1). Yield 68%. 
1
H NMR (300 
MHz, CDCl3): δ 1.06 (3H, t, J = 6.9 Hz, CH2CH3); 2.01 (2H s(broad), OH and 
NH); 2.57–2.81 (4H, m, CH2CH3 and CH2Cquat); 2.88–2.95 (1H, m, CHN); 3.32 
and 3.61 (2 × 1H, 2 × (d × d), J = 10.5, 5.5, 3.8 Hz, (HCH)OH); 3.80 (3H, s, 
CH3O); 6.73–6.79 and 7.19–7.25 (3H and 1H, 2 × m, CHarom). 
13
C NMR (75 
MHz, CDCl3): δ 15.5 (CH2CH3); 38.1 (CH2Cquat); 41.4 (CH2CH3); 55.1 (CH3O); 60.1 (CHN); 62.5 (CH2OH); 
111.7, 115.0, 121.6, 129.6 (4 x HCarom); 140.3 (CH2Cquat); 159.8 (OCarom,quat). IR (ATR, cm
-1
): νOH,NH = 
3272; νmax = 2805, 1586, 1488, 1252, 1152, 1030, 797, 779, 697. MS (70 eV): m/z (%) 210 (M
+
+1, 100). 
Anal. Calcd. for C12H19NO2: C 68.87, H 9.15, N 6.69. Found: C 69.01, H 9.23, N 6.50. 
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5.6 Synthesis of azetidines 
5.6.1 Synthesis of 2-(2-hydroxyethyl)azetidines 
As a representative example, the synthesis of cis-2-(2-hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 
151a is described. To a solution of aluminium(III) chloride (1.07 g, 8 mmol, 1 equiv) in dry Et2O (30 
mL) was added carefully lithium aluminium hydride (0.91 g, 24 mmol, 3 molar equiv) at 0 °C. The 
reaction mixture was stirred at room temperature for 1 hour. Subsequently, a solution of cis-4-[2-
(tert-butyldimethylsilyloxy)ethyl]-1-isopropyl-3-phenoxyazetidin-2-one 12a (2.91 g, 8 mmol, 1 equiv) 
in dry Et2O (15 mL) was added slowly, and after the addition was complete, the reaction mixture was 
stirred for 2 hours at 0 °C, after which water (10 mL) was added cautiously at 0 °C in order to 
neutralize the excess of LiAlH4. Afterwards, the reaction mixture was filtered and extracted with Et2O 
(3 × 25 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent afforded a 
mixture of cis-2-[2-(tert-butyldimethylsilyloxy)ethyl]-1-isopropyl-3-phenoxyazetidine and cis-2-(2-
hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 151a. In the next step, TBAF (2.30 g, 8.8 mmol, 1.1 
equiv) was added to an ice-cooled solution of the latter reaction mixture in THF (30 mL), and the 
resulting solution was stirred at room temperature for 5 hours. Subsequently, the reaction mixture 
was poured into brine and extracted with CH2Cl2 (3 × 25 mL), after which the organic fraction was 
dried (MgSO4), followed by removal of the drying agent and evaporation of the solvent in vacuo. 
Purification by means of column chromatography on silica gel (CH2Cl2/MeOH 95/5) afforded pure cis-
2-(2-hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 151a in 48% yield. 
 
Cis-2-(2-hydroxyethyl)-1-isopropyl-3-phenoxyazetidine 151a 
White crystals. Mp 70.2 °C. Rf = 0.10 (CH2Cl2/MeOH 95/5). Yield 48%. 
1
H NMR (300 MHz, CDCl3): δ 
0.96 and 1.07 (2 × 3H, 2 × d, J = 6.2 Hz, (CH3)2CHN); 1.83-1.92 and 2.18-2.35 (2 
× 1H, 2 × m, (HCH)CHN); 2.56 (1H, septet, J = 6.2 Hz, (CH3)2CHN); 3.28 (1H, d × 
d, J = 9.9, 7.7 Hz, (HCH)N); 3.62 (1H, d × d × d, J = 9.9, 2.9, 1.1 Hz, (HCH)N); 
3.70-3.79 (2H, m, (HCH)OH and CH2CHN); 4.07 (1H, d × d × d, J = 11.7, 8.1, 2.9 
Hz, (HCH)OH); 4.91 (1H, d × d × d, J = 7.7, 7.7, 2.9 Hz, CHOPh); 6.76-6.79, 6.93-
6.98 and 7.23-7.29 (5H, 3 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 20.1 and 21.0 ((CH3)2CHN); 32.2 
(CH2CHN); 56.7 (CH2N); 57.7 ((CH3)2CHN); 60.8 (CH2OH); 66.0 (CH2CHN); 68.8 (CHO); 114.9, 121.1 and 
129.5 (5 x HCarom); 157.2 (OCarom,quat). IR (ATR, cm
-1
): νOH = 3360; νmax = 2966, 2932, 1587, 1495, 1239, 
1116, 690. MS (70 eV): m/z (%) 236 (M
+
+1, 100). Anal. Calcd. for C14H21NO2: C 71.46, H 8.99, N 5.95. 
Found: C 71.72, H 9.31, N 5.88. 
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Cis-3-benzyloxy-2-(2-hydroxyethyl)-1-isopropylazetidine 151b 
White crystals. Mp 76.3 °C. Rf = 0.10 (CH2Cl2/MeOH 95/5). Yield 49%. 
1
H NMR (300 MHz, CDCl3): δ 
0.93 and 1.01 (2 × 3H, 2 × d, J = 6.2 Hz, (CH3)2CHN); 1.76-1.85 and 2.15-2.27 
(2 × 1H, 2 × m, (HCH)CHN); 2.47 (1H, septet, J = 6.2 Hz, (CH3)2CHN); 3.04 (1H, 
d × d, J = 9.4, 6.6 Hz, (HCH)N); 3.49-3.63 (2H, m, (HCH)N and CH2CHN); 3.72 
(1H, d × d × d, J = 10.4, 5.1, 4.3 Hz, (HCH)OH); 3.91 (1H, d × d × d, J = 10.4, 
10.2, 3.0 Hz, (HCH)OH); 4.25 (1H, d × d × d, J = 6.6, 6.6, 2.8 Hz, CHO); 4.39 
and 4.58 (2 × 1H, 2 × d, J = 11.8 Hz, O(HCH)Ph); 7.28-7.37 (5H, m, CHarom). 
13
C 
NMR (75 MHz, ref = CDCl3): δ 20.2 and 21.1 ((CH3)2CHN); 32.5 (CH2CHN); 56.3 (CH2N); 57.6 
((CH3)2CHN); 60.8 (CH2OH); 67.0 (CH2CHN); 70.5 (CHO); 70.9 (OCH2Ph); 127.8, 128.4 and 128.4 (5 x 
HCarom); 137.7 (Carom,quat). IR (ATR, cm
-1
): νOH = 3380; νmax = 2963, 1454, 1351, 1198, 1119, 1056, 1028, 
733. MS (70 eV): m/z (%) 250 (M
+
+1, 100). Anal. Calcd. for C15H23NO2: C 72.25, H 9.30, N 5.62. Found: 
C 72.17, H 9.44, N 5.61. 
 
Cis-3-benzyloxy-1-cyclohexyl-2-(2-hydroxyethyl)azetidine 151c 
White crystals. Mp 93.3 °C. Recrystallization from EtOAc/hexane (25/1). Yield 50%. 
1
H NMR (300 
MHz, CDCl3): δ 0.88-1.28 and 1.61-1.80 (5H and 6H, 2 × m, (CH2)5CHN and 
(HCH)CH2O); 2.05-2.15 (1H, m, (CH2)5CHN); 2.17-2.26 (1H, m, (HCH)CH2O); 
3.02 and 3.55 (2 × 1H, 2 × (d × d), J = 9.5, 6.5, 2.8 Hz, (HCH)N); 3.57-3.59 (1H, 
m, OCH2CH2CHN); 3.71 and 3.92 (2 × 1H, 2 × (d × d × d), J = 10.3, 10.2, 5.1, 
5.1, 3.1 Hz, (HCH)OH); 4.26 (1H, d × d × d, J = 6.6, 6.5, 2.8 Hz, CHO); 4.38 and 
4.58 (2 × 1H, 2 × d, J = 11.9 Hz, O(HCH)Ph); 7.28-7.37 (5H, m, CHarom). 
13
C 
NMR (75 MHz, ref = CDCl3): δ 24.7, 24.8, 25.9, 30.4 and 31.5 ((CH2)5CHN); 
32.7 (CH2CH2O); 56.1 (CH2N); 61.0 (CH2OH); 66.3 ((CH2)5CHN); 66.9 (OCH2CH2CHN); 71.0 (OCH2Ph); 
71.1 (CHO); 127.8, 128.48 and 128.49 (5 x HCarom); 137.8 (Carom,quat). IR (ATR, cm
-1
): νOH = 3147; νmax = 
2929, 2854, 1355, 1182, 1116, 1046, 1017, 736, 698. MS (70 eV): m/z (%) 290 (M
+
+1, 100). Anal. 
Calcd. for C18H27NO2: C 74.70, H 9.40, N 4.84. Found: C 74.52, H 9.54, N 4.84. 
 
5.6.2 Synthesis of 2-(2-mesyloxyethyl)azetidines 
The synthesis of 2-(2-mesyloxyethyl)azetidines 13 was analogous to the synthesis of 4-(2-
mesyloxyethyl)azetidin-2-ones 17 (Section 5.3.4), using 2-(2-hydroxyethyl)azetidines 151 as the 
starting material. 
Due to the high intrinsic reactivity of azetidines 13, no accurate HRMS data could be obtained. 
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Cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a 
Colourless oil. Yield 90%. 
1
H NMR (300 MHz, CDCl3): δ 0.93 and 1.03 (2 × 3H, 2 × d, J = 6.1 Hz, 
(CH3)2CHN); 2.01-2.12 (1H, m, (HCH)CHN); 2.44-2.65 (2H, m, (CH3)2CHN and 
(HCH)CHN); 2.96 (3H, s, CH3SO3); 3.19 (1H, d × d, J = 9.4, 6.1 Hz, (HCH)N); 
3.50 (1H, d × d × d, J = 9.4, 1.9, 1.1 Hz, (HCH)N); 3.63 (1H, d × d × d, J = 10.1, 
6.3, 3.4 Hz, CH2CHN); 4.25-4.40 (2H, m, CH2O); 4.83 (1H, d × d × d, J = 6.3, 
6.1, 1.9 Hz, CHOPh); 6.76-6.79, 6.88-7.03 and 7.23-7.34 (5H, 3 × m, CHarom).
 
13
C NMR (75 MHz, ref = CDCl3): δ 20.0 and 21.1 ((CH3)2CHN); 30.2 (CH2CHN); 37.3 (CH3SO3); 56.8 
(CH2N); 57.9 ((CH3)2CHN); 64.0 (CH2CHN); 67.8 (CH2O); 68.0 (CHO); 115.1, 121.3 and 129.7 (5 x 
HCarom); 157.1 (OCarom,quat). IR (ATR, cm
-1
): νmax = 2966, 2939, 2872, 1492, 1352, 1234, 1171, 967, 930, 
754, 692. MS (70 eV): m/z (%) 314 (M
+
+1, 100). 
 
Cis-3-benzyloxy-1-isopropyl-2-(2-mesyloxyethyl)azetidine 13b 
Colourless oil. Yield 88%. 
1
H NMR (300 MHz, CDCl3): δ 0.93 and 0.98 (2 × 3H, 2 × d, J = 6.3 Hz, 
(CH3)2CHN); 1.90-2.01 (1H, m, (HCH)CHN); 2.38-2.53 (2H, m, (CH3)2CHN and 
(HCH)CHN); 2.91 (3H, s, CH3SO3); 2.93-3.01 (1H, m, (HCH)N); 3.35-3.55 (2H, 
m, (HCH)N and CH2CHN); 4.15 (1H, d × d × d, J = 6.0, 6.0, 1.7 Hz, CHO); 4.21-
4.35 (2H, m, CH2CH2O); 4.36 and 4.61 (2 × 1H, 2 × d, J = 12.1 Hz, O(HCH)Ph); 
7.28-7.37 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 20.1 and 21.2 
((CH3)2CHN); 30.1 (CH2CHN); 37.1 (CH3SO3); 56.5 (CH2N); 57.9 ((CH3)2CHN); 
64.4 (CH2CHN); 68.3 (CH2CH2O); 69.6 (CHO); 70.8 (OCH2Ph); 127.76, 127.83 and 128.4 (5 x HCarom); 
138.0 (Carom,quat). IR (ATR, cm
-1
): νmax = 2964, 2931, 2855, 1352, 1172, 960, 925, 813, 735, 698. MS (70 
eV): m/z (%) 328 (M
+
+1, 100). 
 
Cis-3-benzyloxy-1-cyclohexyl-2-(2-mesyloxyethyl)azetidine 13c 
Yellow oil. Yield 85%. 
1
H NMR (300 MHz, CDCl3): δ 0.99-1.25 and 1.59-1.74 (6H and 4H, 2 × m, 
(CH2)5CHN); 1.90-2.01 and 2.03-2.13 (2 × 1H, 2 × m, (HCH)CH2O); 2.41-2.53 
(1H, m, (CH2)5CHN); 2.90 (3H, s, CH3SO3); 2.94-2.98 (1H, m, (HCH)N); 3.44-
3.51 (2H, m, (HCH)N and OCH2CH2CHN); 4.16 (1H, d × d × d, J = 6.1, 6.1, 1.1 
Hz, CHO); 4.21-4.35 (2H, m, CH2CH2O); 4.36 and 4.61 (2 × 1H, 2 × d, J = 11.9 
Hz, O(HCH)Ph); 7.28-7.39 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
24.6, 24.7, 25.8, 30.1 and 30.2 ((CH2)5CHN); 31.4 (CH2CH2O); 37.1 (CH3SO3); 
56.2 (CH2N); 64.3 (CH2CH2O); 66.4 ((CH2)5CHN); 68.4 (OCH2CH2CHN); 70.0 (OCH2Ph); 70.9 (CHO); 
127.8, 127.9 and 128.4 (5 x HCarom); 138.0 (Carom,quat). IR (ATR, cm
-1
): νmax = 3029, 2927, 2853, 1350, 
1172, 969, 921, 812, 734, 699. MS (70 eV): m/z (%) 368 (M
+
+1, 100). 
 
5.7 Synthesis of piperidines 
5.7.1 Synthesis of 4-acetoxy-5,5-dimethylpiperidines 
As a representative example, the synthesis of cis-4-acetoxy-1-isopropyl-5,5-dimethyl-3-
phenoxypiperidine 139c is described. To a solution of cis-2-(2-bromo-1,1-dimethylethyl)-1-isopropyl-
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3-phenoxyazetidine 8c (3.26 g, 10 mmol, 1 equiv) in DMSO (50 mL) was added NaOAc (8.20 g, 100 
mmol, 10 equiv) at room temperature. After stirring at 100 °C for 18 hours, the reaction mixture was 
poured into water (40 mL) and extracted with Et2O (3 × 25 mL). Afterwards, the organic phase was 
washed intensively with brine (4 × 30 mL). Drying (MgSO4), filtration of the drying agent, and removal 
of the solvent afforded cis-4-acetoxy-1-isopropyl-5,5-dimethyl-3-phenoxypiperidine 139c, which was 
further purified in 62% yield by column chromatography on silica gel (hexane/EtOAc 14/1). 
 
Cis-4-acetoxy-1-allyl-3-benzyloxy-5,5-dimethylpiperidine 139a 
Colourless oil. Rf = 0.08 (hexane/EtOAc 10/1). Yield 64%. 
1
H NMR (300 MHz, CDCl3): δ 0.88 and 1.07 (2 
× 3H, 2 × s, C(CH3)(CH3)); 2.06 (1H, d, J = 11.0 Hz, N(HCH)Cquat); 2.11 (3H, s, 
CH3C=O); 2.22-2.26 (2H, m, N(HCH)Cquat and N(HCH)CHO); 2.76-2.78 (1H, m, 
N(HCH)CHO); 2.95 and 3.04 (2 × 1H, 2 × (d × d), J = 13.8, 6.3, 6.1 Hz, 
N(HCH)CH=CH2); 3.80 (1H, d × d × d, J = 10.5, 4.7, 3.0 Hz, CHOBn); 4.43 and 4.65 
(2 × 1H, 2 × d, J = 11.9 Hz, (HCH)O); 5.10-5.20 (3H, m, CHOC=O and CH2=CH), 
5.81 (1H, m, CH2=CH); 7.23-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): 
δ 21.0 (CH3C=O); 24.4 and 24.9 (C(CH3)(CH3)); 35.2 (C(CH3)2); 53.3 (NCH2CHO); 
59.9 (NCH2Cquat); 61.4 (NCH2CH=CH2); 70.8 (CH2O); 73.0 (CHOBn); 73.6 
(CHOC=O); 117.5 (CH2=CH); 127.6, 127.8 and 128.4 (5 x HCarom); 135.6 (CH2=CH); 138.5 (Carom,quat); 
170.5 (C=O). IR (ATR, cm
-1
): νC=O = 1739; νmax = 2955, 1371, 1236, 1117, 1091, 1018, 735, 698. MS 
(70eV): m/z (%) 318 (M
+
+1, 100). Anal. Calcd. for C19H27NO3: C 71.89, H 8.57, N 4.41. Found: C 72.08, 
H 8.43, N 4.29. 
 
Cis-4-acetoxy-3-benzyloxy-1-tert-butyl-5,5-dimethylpiperidine 139b 
Colourless oil. Rf = 0.11 (hexane/EtOAc 6/1). Yield 71%. 
1
H NMR (300 MHz, CDCl3): δ 0.87 (3H, s, 
C(CH3)(CH3)); 1.03 (9H, s, C(CH3)3); 1.05 (3H, s, C(CH3)(CH3)); 2.11 (3H, s, 
CH3C=O); 2.18 (1H, d, J = 11.0 Hz, N(HCH)Cquat); 2.28-2.32 (2H, m, N(HCH)Cquat 
and N(HCH)CHO); 2.87-2.95 (1H, m, N(HCH)CHO); 3.72 (1H, d × d × d, J = 10.4, 
4.7, 3.0 Hz, CHOBn); 4.40 and 4.66 (2 × 1H, 2 × d, J = 11.6 Hz, (HCH)O); 5.09 (1H, 
s(broad), CHOC=O); 7.28-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
21.1 (CH3C=O); 24.4 and 24.8 (C(CH3)(CH3)); 26.6 (C(CH3)3); 35.1 (C(CH3)2); 46.4 
(NCH2CHO); 53.0 (NCH2Cquat); 53.3 (C(CH3)3); 70.9 (CH2O); 73.9 (CHOC=O); 74.4 
(CHOBn); 127.6, 127.9 and 128.4 (5 x HCarom); 138.6 (Carom,quat); 170.7 (C=O). IR (ATR, cm
-1
): νC=O = 
1737; νmax = 2968, 1370, 1239, 1223, 1208, 1100, 980, 735, 697. MS (70eV): m/z (%) 334 (M
+
+1, 100). 
Anal. Calcd. for C20H31NO3: C 72.04, H 9.37, N 4.20. Found: C 71.83, H 9.65, N 4.12. 
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Cis-4-acetoxy-1-isopropyl-5,5-dimethyl-3-phenoxypiperidine 139c 
Colourless oil. Rf = 0.09 (hexane/EtOAc 14/1). Yield 62%. 
1
H NMR (300 MHz, CDCl3): δ 0.92 (3H, s, 
C(CH3)(CH3)); 1.01 (6H, d, J = 6.6 Hz, NCH(CH3)2); 1.13 (3H, s, C(CH3)(CH3)); 2.09 
(3H, s, CH3C=O); 2.14 and 2.34 (2 × 1H, 2 × d, J = 11.3 Hz, N(HCH)Cquat); 2.61 (1H, d 
× d, J = 10.2, 10.0 Hz, N(HCH)CHO); 2.72-2.85 (2H, m, N(HCH)CHO and NCH(CH3)2); 
4.60 (1H, d × d × d, J = 10.0, 4.5, 3.2 Hz, CHOPh); 5.05 (1H, s(broad), CHOC=O); 
6.81-6.95 and 7.21-7.28 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 17.8 and 
18.4 (NCH(CH3)(CH3)); 20.9 (CH3C=O); 23.8 and 24.8 (C(CH3)(CH3)); 35.3 (C(CH3)2); 
48.7 (NCH2CHO); 54.2 (NCH(CH3)2); 55.1 (NCH2Cquat); 72.8 (CHOPh); 75.1 
(CHOC=O); 116.1, 121.2 and 129.5 (5 x HCarom); 157.8 (OCarom,quat); 170.5 (C=O). IR (ATR, cm
-1
): νC=O = 
1742; νmax = 2963, 1598, 1493, 1372, 1226, 1166, 1050, 1036, 752. MS (70 eV): m/z (%) 306 (M
+
+1, 
100). Anal. Calcd. for C18H27NO3: C 70.79, H 8.91, N 4.59. Found: C 70.62, H 9.14, N 4.77. 
 
Cis-4-acetoxy-1-cyclohexyl-5,5-dimethyl-3-phenoxypiperidine 139d 
Colourless oil. Rf = 0.20 (hexane/EtOAc 19/1). Yield 72%. 
1
H NMR (300 MHz, CDCl3): δ 0.91 and 1.13 (2 
× 3H, 2 × s, C(CH3)(CH3)); 1.16-1.31, 1.55-1.65 and 1.68-1.87 (10H, 3 × m, 
(CH2)5CHN); 2.09 (3H, s, CH3C=O); 2.19 (1H, d, J = 11.3 Hz, N(HCH)Cquat); 2.27-2.38 
(1H, m, (CH2)5CHN); 2.42 (1H, d, J = 11.3 Hz, N(HCH)Cquat); 2.68 and 2.87 (2 × 1H, 2 
× (d × d), J = 10.2, 9.7, 4.1 Hz, N(HCH)CHO); 4.59 (1H, d × d × d, J = 9.7, 4.1, 3.3 Hz, 
CHOPh); 5.04 (1H, s(broad), CHOC=O); 6.79-6.97 and 7.15-7.29 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 20.9 (CH3C=O); 23.8 and 24.8 (C(CH3)(CH3)); 25.9, 26.0, 
26.4, 28.6 and 29.1 ((CH2)5CHN); 35.4 (C(CH3)2); 49.1 (NCH2CHO); 56.0 (NCH2Cquat); 
63.4 ((CH2)5CHN); 72.9 (CHOPh); 75.2 (CHOC=O); 116.1, 121.2 and 129.5 (5 x 
HCarom); 157.8 (OCarom,quat); 170.5 (C=O). IR (ATR, cm
-1
): νC=O = 1744; νmax = 2929, 2853, 1599, 1493, 
1373, 1243, 1051. MS (70 eV): m/z (%) 346 (M
+
+1, 100). Anal. Calcd. for C21H31NO3: C 73.01, H 9.04, N 
4.05. Found: C 72.83, H 9.39, N 4.26. 
 
5.7.2 Synthesis of 4-hydroxy-5,5-dimethylpiperidines 
As a representative example, the synthesis of cis-4-hydroxy-1-isopropyl-5,5-dimethyl-3-
phenoxypiperidine 140c is described. To a solution of cis-4-acetoxy-1-isopropyl-5,5-dimethyl-3-
phenoxypiperidine 139c (3.05 g, 10 mmol, 1 equiv) in methanol (50 mL) was added LiOH·H2O (1.26 g, 
30 mmol, 3 equiv). After a reflux period of 15 hours, the solvent was removed in vacuo and the 
residue was washed with Et2O (1 × 30 mL) and water (2 × 30 mL). The aqueous phase was extracted 
with Et2O (2 × 25 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent in 
vacuo afforded cis-4-hydroxy-1-isopropyl-5,5-dimethyl-3-phenoxypiperidine 140c, which was further 
purified in 86% yield by column chromatography on silica gel (hexane/EtOAc 9/1). 
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Cis-1-allyl-3-benzyloxy-4-hydroxy-5,5-dimethylpiperidine 140a 
Colourless oil. Rf = 0.05 (hexane/EtOAc 6/1). Yield 62%. 
1
H NMR (300 MHz, CDCl3): δ 1.00 (6H, s, 
C(CH3)2); 2.14 (2H, s, NCH2Cquat); 2.23-2.35 (1H, m, N(HCH)CHO); 2.72 (1H, d × d, 
J = 9.4, 4.5 Hz, N(HCH)CHO); 2.93 and 3.02 (2 × 1H, 2 × (d × d), J = 13.8, 5.9, 5.7 
Hz, N(HCH)CH=CH2); 3.53 (1H, s(broad), CHOH); 3.80 (1H, d × d × d, J = 10.1, 4.5, 
3.2 Hz, CHOBn); 4.58 (2H, s, CH2O); 5.10-5.20 (2H, m, CH2=CH); 5.81 (1H, m, 
CH2=CH); 7.27-7.38 (5H, m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 24.2 and 24.8 
(C(CH3)(CH3)); 35.3 (C(CH3)2); 51.8 (NCH2CHO); 59.1 (NCH2Cquat); 61.3 
(NCH2CH=CH2); 70.5 (CH2O); 72.8 (CHOH); 74.8 (CHOBn); 117.2 (CH2=CH); 127.5, 
127.7 and 128.3 (5 x HCarom); 135.5 (CH2=CH); 138.1 (Carom,quat). IR (ATR, cm
-1
): νOH = 3558; νmax = 2949, 
2809, 1112, 1072, 988, 917, 735, 697. MS (70 eV): m/z (%) 276 (M
+
+1, 100). Anal. Calcd. for 
C17H25NO2: C 74.14, H 9.15, N 5.09. Found: C 74.01, H 9.32, N 4.93. 
 
Cis-3-benzyloxy-1-tert-butyl-4-hydroxy-5,5-dimethylpiperidine 140b 
Yellow oil. Rf = 0.10 (hexane/EtOAc 4/1). Yield 66%. 
1
H NMR (300 MHz, CDCl3): δ 0.97 and 0.99 (2 × 
3H, 2 × s, C(CH3)(CH3)); 1.02 (9H, s, C(CH3)3); 2.19 and 2.27 (2 × 1H, 2 × d, J = 
11.0 Hz, N(HCH)Cquat); 2.26-2.42 and 2.77-2.88 (2 × 1H, 2 × m, N(HCH)CHO); 3.51 
(1H, d, J = 2.2 Hz, CHOH); 3.69-3.75 (1H, m, CHOBn); 4.56 and 4.58 (2 × 1H, 2 × 
d, J = 11.6 Hz, (HCH)O); 7.25-7.38 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 24.3 and 24.9 (C(CH3)(CH3)); 26.5 (C(CH3)3); 35.4 (C(CH3)2); 45.0 
(NCH2CHO); 52.4 (NCH2Cquat); 53.5 (C(CH3)3); 70.8 (CH2O); 73.2 (CHOH); 76.2 
(CHOBn); 127.8, 127.9 and 128.6 (5 x HCarom); 138.3 (Carom,quat). IR (ATR, cm
-1
): νOH = 3404; νmax = 2966, 
2928, 2867, 1363, 1098, 1070, 1027, 734, 697. MS (70 eV): m/z (%) 292 (M
+
+1, 100). Anal. Calcd. for 
C18H29NO2: C 74.18, H 10.03, N 4.81. Found: C 74.44, H 10.29, N 4.62. 
 
Cis-4-hydroxy-1-isopropyl-5,5-dimethyl-3-phenoxypiperidine 140c 
White crystals. Mp 82.5 °C. Rf = 0.11 (hexane/EtOAc 9/1). Yield 86%. 
1
H NMR (300 MHz, CDCl3): δ 0.99 
and 1.00 (2 × 3H, 2 × d, J = 6.3 Hz, NCH(CH3)(CH3)); 1.02 and 1.08 (2 × 3H, 2 × s, 
C(CH3)(CH3)); 2.07 and 2.41 (2 × 1H, 2 × d, J = 11.1 Hz, N(HCH)Cquat); 2.24 (1H, 
s(broad), OH); 2.61 (1H, d × d, J = 10.2, 9.8 Hz, N(HCH)CHO); 2.67-2.83 (2H, m, 
NCH(CH3)2 and N(HCH)CHO); 3.62 (1H, d, J = 3.0 Hz, CHOH); 4.58 (1H, d × d × d, J = 
9.8, 4.6, 3.0 Hz, CHOPh); 6.87-7.00 and 7.27-7.32 (5H, 2 × m, CHarom). 
13
C NMR (75 
MHz, CDCl3): δ 17.5 and 18.6 (NCH(CH3)(CH3)); 24.1 and 24.8 (C(CH3)(CH3)); 35.5 (C(CH3)2); 47.3 
(NCH2CHO); 53.9 (NCH2Cquat); 54.2 (NCH(CH3)2); 74.0 (CHOH); 74.6 (CHOPh); 116.2, 121.5 and 129.6 (5 
x HCarom); 157.2 (OCarom,quat). IR (ATR, cm
-1
): νOH = 3197; νmax = 2958 1596, 1496, 1237, 1174, 981, 749. 
MS (70 eV): m/z (%) 264 (M
+
+1, 100). Anal. Calcd. for C16H25NO2: C 72.96, H 9.57, N 5.32. Found: C 
72.94, H 9.77, N 5.27. 
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Cis-1-cyclohexyl-4-hydroxy-5,5-dimethyl-3-phenoxypiperidine 140d 
Colourless oil. Rf = 0.19 (hexane/EtOAc 14/1). Yield 71%. 
1
H NMR (300 MHz, CDCl3): δ 1.01 and 1.08 (2 
× 3H, 2 × s, 2 × CH3); 1.12-1.29, 1.56-1.63 and 1.68-1.81 (10H, 3 × m, (CH2)5CHN); 
2.11 (1H, d, J = 11.0 Hz, N(HCH)Cquat); 2.20-2.34 (1H, m, (CH2)5CHN); 2.49 (1H, d, J = 
11.0 Hz, N(HCH)Cquat); 2.68 and 2.80 (2 × 1H, 2 × (d × d), J = 10.2, 9.9, 4.4 Hz, 
N(HCH)CHO); 3.61 (1H, d, J = 2.6 Hz, CHOH); 4.56 (1H, d × d × d, J = 9.9, 4.4, 2.6 Hz, 
CHOPh); 6.92-6.98, 7.24-7.30 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 24.1 
and 24.8 (C(CH3)(CH3)); 26.0, 26.1, 26.4, 29.3 and 29.7 ((CH2)5CHN); 35.6 (C(CH3)2); 
47.7 (NCH2CHO); 54.8 (NCH2Cquat); 63.5 ((CH2)5CHN); 74.1 (CHOH); 74.7 (CHOPh); 
116.2, 121.5 and 129.6 (5 x HCarom); 157.2 (OCarom,quat). IR (ATR, cm
-1
): νOH = 3589; νmax = 2926, 2853, 
1599, 1493, 1235, 1040, 982, 751. MS (70 eV): m/z (%) 304 (M
+
+1, 100). Anal. Calcd. for C19H29NO2: C 
75.21, H 9.63, N 4.62. Found: C 75.36, H 9.82, N 4.77. 
 
5.7.3 Synthesis of 4-bromopiperidines 
As a representative example, the synthesis of cis-4-bromo-1-isopropyl-3-phenoxypiperidine 154a is 
described. To a solution of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a (1.72 g, 5.5 
mmol, 1 equiv) in acetonitrile (30 mL) was added LiBr (0.96 g, 11 mmol, 2 equiv) at room 
temperature. After a reflux period of 15 hours, the solvent was removed in vacuo, and the residue 
was washed with CH2Cl2 (1 × 30 mL) and water (2 × 30 mL). The aqueous phase was extracted with 
CH2Cl2 (2 × 25 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent in vacuo 
afforded cis-4-bromo-1-isopropyl-3-phenoxypiperidine 154a, which was further purified in 47% yield 
by column chromatography on silica gel (hexane/ EtOAc 9/1). 
 
Cis-4-bromo-1-isopropyl-3-phenoxypiperidine 154a 
Light-yellow oil. Rf = 0.10 (hexane/EtOAc 9/1). Yield 47%. 
1
H NMR (300 MHz, CDCl3): δ 1.06 (6H, d, J = 
6.6 Hz, (CH3)2CHN); 2.17-2.23 (2H, m, NCH2CH2); 2.60 (1H, d × t, J = 11.4, 4.0 Hz, 
N(HCH)CH2); 2.70-2.89 (4H, m, N(HCH)CH2, NCH2CHO and (CH3)2CHN); 4.31 (1H, d × d 
× d, J = 8.5, 4.0, 3.7 Hz, CHO); 4.64 (1H, d(broad), J = 3.7 Hz, CHBr); 6.96-7.01 and 
7.28-7.33 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 18.1 and 18.3 ((CH3)2CHN); 
32.8 (NCH2CH2); 43.9 (NCH2CH2); 48.1 (NCH2CHO); 53.5 (CHBr); 54.5 ((CH3)2CHN); 
74.8 (CHO); 117.0, 121.9 and 129.6 (5 x HCarom); 156.9 (OCarom,quat). IR (ATR, cm
-1
): νmax = 2964, 2828, 
2360, 1587, 1492, 1237, 1168, 1059, 752, 690. MS (70 eV): m/z (%) 298/300 (M
+
+1, 100). HRMS (ESI) 
Calcd. for C14H21BrNO 298.0807 [M + H]
+
, found 298.0797. 
 
 
 
 
N
O
OH
N
O
Br
Chapter 5  Experimental Part 
116 
 
Cis-3-benzyloxy-4-bromo-1-isopropylpiperidine 154b 
White crystals. Mp 79.9 °C. Recrystallization from absolute EtOH. Yield 62%. 
1
H NMR (300 MHz, 
CDCl3): δ 1.03 and 1.04 (2 × 3H, 2 × d, J = 6.6 Hz, (CH3)2CHN); 2.02-2.21 (2H, m, 
NCH2CH2); 2.52-2.69 (4H, m, 2 × NCH2); 2.76 (1H, septet, J = 6.6 Hz, (CH3)2CHN); 
3.47 (1H, d × d × d, J = 8.3, 3.9, 3.9 Hz, CHO); 4.52 (1H, d, J = 11.9 Hz, O(HCH)Ph); 
4.62 (1H, s(broad), CHBr); 4.69 (1H, d, J = 11.9 Hz, O(HCH)Ph); 7.28-7.40 (5H, m, 
CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 18.2 and 18.4 ((CH3)2CHN); 32.7 
(NCH2CH2); 44.0 and 48.6 (2 × NCH2); 54.5 and 54.7 (CHBr and (CH3)2CHN); 70.4 
(OCH2); 75.2 (CHO); 127.9, 128.0 and 128.5 (5 x HCarom); 138.0 (Carom,quat). IR (ATR, cm
-1
): νmax = 3400, 
3028, 2962, 2824, 1165, 1134, 1116, 1094, 1023, 1004, 750, 697. MS (70 eV): m/z (%) 312/314 (M
+
+1, 
100). Anal. Calcd. for C15H22BrNO: C 57.70, H 7.10, N 4.49. Found: C 58.10, H 7.34, N 4.48. 
 
Cis-3-benzyloxy-4-bromo-1-cyclohexylpiperidine 154c 
White crystals. Mp 76.6 °C. Rf = 0.06 (hexane/EtOAc 4/1). Yield 65%. 
1
H NMR (300 MHz, CDCl3): δ 
1.05-1.25, 1.60-1.65 and 1.78-1.80 (10H, 3 × m, (CH2)5CHN); 2.01-2.20 (2H, m, 
NCH2CH2); 2.27-2.37 (1H, m, CHN); 2.54-2.62 (1H, m, N(HCH)CH2); 2.66-2.78 (3H, 
m, N(HCH)CH2 and NCH2CHO); 3.46 (1H, d × d × d, J = 8.3, 3.9, 3.6 Hz, CHO); 4.53 
(1H, d, J = 12.1 Hz, O(HCH)Ph); 4.62 (1H, d(broad), J = 3.6 Hz, CHBr); 4.68 (1H, d, J 
= 12.1 Hz, O(HCH)Ph); 7.28-7.39 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
26.1, 26.4, 28.7 and 29.0 ((CH2)5CHN); 32.9 (NCH2CH2); 44.4 (NCH2CH2); 49.1 
(NCH2CHO); 54.8 (CHBr); 63.8 (CHN); 70.3 (OCH2); 75.3 (CHO); 127.8, 128.0 and 
128.5 (5 x HCarom); 138.1 (Carom,quat). IR (ATR, cm
-1
): νmax = 3062, 3030, 2926, 2852, 1451, 1202, 1116, 
1099, 1026, 948, 734, 696. MS (70 eV): m/z (%) 352/354 (M
+
+1, 100). Anal. Calcd. for C18H26BrNO: C 
61.36, H 7.44, N 3.98. Found: C 61.57, H 7.77, N 4.10. 
 
5.7.4 Synthesis of 4-acetoxypiperidines 
As a representative example, the synthesis of cis-4-acetoxy-1-isopropyl-3-phenoxypiperidine 157a is 
described. To a solution of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a (3.13 g, 10 
mmol, 1 equiv) in acetonitrile (50 mL) was added NaOAc (1.64 g, 20 mmol, 2 equiv) at room 
temperature. After a reflux period of 15 hours, the solvent was removed in vacuo and the residue 
was washed with CH2Cl2 (1 × 30 mL) and water (2 × 30 mL). The aqueous phase was extracted with 
CH2Cl2 (2 × 25 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent in vacuo 
afforded cis-4-acetoxy-1-isopropyl-3-phenoxypiperidine 157a, which was further purified in 63% yield 
by column chromatography on silica gel (hexane/EtOAc 2/1). 
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Cis-4-acetoxy-1-isopropyl-3-phenoxypiperidine 157a 
Colourless oil. Rf = 0.09 (hexane/EtOAc 2/1). Yield 63%. 
1
H NMR (300 MHz, CDCl3): δ 1.04 (6H, d, J = 
6.1 Hz, (CH3)2CHN); 1.76-1.86 (1H, m, NCH2(HCH)); 2.06 (3H, s, CH3CO); 1.98-2.14 
(1H, m, NCH2(HCH)); 2.51-2.64 (2H, m, NCH2CH2); 2.77-2.89 (3H, m, (CH3)2CHN and 
NCH2CHO); 4.49 (1H, d × d × d, J = 5.9, 5.9, 2.9 Hz, CHOPh); 5.18-5.20 (1H, m, 
CHOCO); 6.91-6.98 and 7.23-7.29 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, CDCl3): δ 
17.8 and 18.6 ((CH3)2CHN); 21.2 (CH3CO); 28.4 (NCH2CH2); 44.5 (NCH2CH2); 48.1 
(NCH2CHO); 54.3 ((CH3)2CHN); 69.5 (CHOCO); 74.2 (CHOPh); 116.6, 121.4 and 129.5 
(5 x HCarom); 157.8 (OCarom,quat); 170.5 (C=O). IR (ATR, cm
-1
): νC=O = 1736; νmax = 2964, 1492, 1234, 1176, 
1047, 752, 692. MS (70 eV): m/z (%) 278 (M
+
+1, 100). HRMS (ESI) Calcd. for C16H24NO3 278.1756 [M + 
H]
+
, found 278.1755. 
 
Cis-4-acetoxy-3-benzyloxy-1-isopropylpiperidine 157b 
Light-yellow oil. Rf = 0.05 (hexane/EtOAc 2/1). Yield 55%. 
1
H NMR (300 MHz, CDCl3): δ 1.03 and 1.04 
(2 × 3H, 2 × d, J = 6.3 Hz, (CH3)2CHN); 1.66-1.77 and 1.91-2.00 (2 × 1H, 2 × m, 
NCH2(HCH)); 2.10 (3H, s, CH3CO); 2.44-2.53 (2H, m, NCH2CH2); 2.57-2.66 (2H, m, 
NCH2CHO); 2.77 (1H, septet, J = 6.3 Hz, (CH3)2CHN); 3.61 (1H, d × d × d, J = 8.1, 
3.9, 3.9 Hz, NCH2CHO); 4.52 and 4.65 (2 × 1H, 2 × d, J = 12.1 Hz, O(HCH)Ph); 5.26 
(1H, s(broad), CHOCO); 7.28-7.39 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): 
δ 18.0 and 18.6 ((CH3)2CHN); 21.4 (CH3CO); 28.6 (NCH2CH2); 44.1 (NCH2CH2); 48.7 
(NCH2CHO); 54.5 ((CH3)2CHN); 68.5 (CHOCO); 71.0 (OCH2); 74.9 (NCH2CHO); 
127.7, 127.9 and 128.5 (5 x HCarom); 138.4 (Carom,quat); 170.7 (C=O). IR (ATR, cm
-1
): νC=O = 1735; νmax = 
2963, 1369, 1241, 1092, 967, 736, 698. MS (70 eV): m/z (%) 292 (M
+
+1, 100). HRMS (ESI) Calcd. for 
C17H26NO3 292.1913 [M + H]
+
, found 292.1916. 
 
Cis-4-acetoxy-3-benzyloxy-1-cyclohexylpiperidine 157c 
Attempts to purify this compound failed. Spectral data are based on 
1
H NMR and 
13
C NMR of the 
crude reaction mixture (purity of 157c: ~85%), and no HRMS analysis was performed. 
 
Colourless oil. Yield 66%. 
1
H NMR (300 MHz, CDCl3): δ 1.05-1.33, 1.57-1.65 and 1.70-1.84 (4H, 1H and 
6H, 3 × m, (CH2)5CHN and NCH2(HCH)); 1.88-1.99 (1H, m, NCH2(HCH)); 2.10 (3H, 
s, CH3CO); 2.29-2.38 (1H, m, CHN); 2.53-2.57 (2H, m, NCH2CH2); 2.64-2.73 (2H, 
m, NCH2CHO); 3.60 (1H, d × d × d, J = 8.4, 4.0, 4.0 Hz, NCH2CHO); 4.52 and 4.64 
(2 × 1H, 2 × d, J = 12.1 Hz, O(HCH)Ph); 5.25 (1H, s(broad), CHOCO); 7.23-7.36 
(5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 21.4 (CH3CO); 22.7, 26.1, 26.4 
and 28.6 (4 × CH2); 29.0 (NCH2CH2); 31.7 (CH2); 44.4 (NCH2CH2); 49.1 (NCH2CHO); 
63.7 (CHN); 68.5 (CHOCO); 70.9 (OCH2); 74.9 (NCH2CHO); 127.7, 127.9 and 128.4 
(5 x HCarom); 138.4 (Carom,quat); 170.7 (C=O). IR (ATR, cm
-1
): νC=O = 1737; νmax = 
2926, 1371, 1240, 1093, 1021, 735, 698. MS (70 eV): m/z (%) 332 (M
+
+1, 100). 
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5.7.5 Synthesis of 4-hydroxypiperidines 
5.7.5.1 Synthesis of 4-hydroxypiperidines via 4-acetoxypiperidines 
As a representative example, the synthesis of cis-4-hydroxy-1-isopropyl-3-phenoxypiperidine 158a is 
described. To a solution of cis-4-acetoxy-1-isopropyl-3-phenoxypiperidine 157a (1.66 g, 6 mmol, 1 
equiv) in methanol (40 mL) was added K2CO3 (1.66 g, 12 mmol, 2 equiv). After a reflux period of 1 
hour, the solvent was removed in vacuo, and the residue was washed with Et2O (1 × 30 mL) and 
water (2 × 30 mL). The aqueous phase was extracted with Et2O (2 × 25 mL). Drying (MgSO4), filtration 
of the drying agent, and removal of the solvent in vacuo afforded cis-4-hydroxy-1-isopropyl-3-
phenoxypiperidine 158a, which was further purified in 56% yield by column chromatography on silica 
gel (hexane/EtOAc 1/2). 
 
Cis-4-hydroxy-1-isopropyl-3-phenoxypiperidine 158a 
Colourless oil. Rf = 0.05 (hexane/EtOAc 1/2). Yield 56%. 
1
H NMR (300 MHz, CDCl3): δ 1.04 (6H, d, J = 
6.6 Hz, (CH3)2CHN); 1.77-1.88 and 1.94-2.03 (2 × 1H, 2 × m, NCH2(HCH)); 2.48-2.70 
(4H, m, NCH2CH2, N(HCH)CHO and OH); 2.75-2.85 (2H, m, N(HCH)CHO and 
(CH3)2CHN); 4.11-4.15 (1H, m, CHOH); 4.43 (1H, d × d × d, J = 9.0, 4.4, 3.1 Hz, 
NCH2CHO); 6.95-7.00 and 7.26-7.33 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 18.0 and 18.5 ((CH3)2CHN); 30.6 (NCH2CH2); 43.2 (NCH2CH2); 46.6 
(NCH2CHO); 54.5 ((CH3)2CHN); 66.4 (CHOH); 76.1 (CHOPh); 116.3, 121.6 and 129.7 (5 x HCarom); 157.2 
(OCarom,quat). IR (ATR, cm
-1
): νOH = 3406; νmax = 2964, 1596, 1493, 1239, 1173, 965, 752, 730, 691. MS 
(70 eV): m/z (%) 236 (M
+
+1, 100). HRMS (ESI) Calcd. for C14H22NO2 236.1651 [M + H]
+
, found 
236.1653. 
 
Cis-3-benzyloxy-4-hydroxy-1-isopropylpiperidine 158b 
Colourless oil. Rf = 0.03 (hexane/EtOAc 1/3). Yield 70%. 
1
H NMR (300 MHz, CDCl3): δ 1.02 and 1.04 (2 
× 3H, 2 × d, J = 6.7 Hz, (CH3)2CHN); 1.63-1.74 and 1.86-1.95 (2 × 1H, 2 × m, 
NCH2(HCH)); 2.34 (1H, s(broad), OH); 2.39-2.45 (1H, m, N(HCH)CH2); 2.49-2.64 (3H, 
m, N(HCH)CH2 and NCH2CHO); 2.76 (1H, septet, J = 6.7 Hz, (CH3)2CHN); 3.58 (1H, d 
× d × d, J = 8.5, 4.1, 4.1 Hz, NCH2CHO); 3.98 (1H, s(broad), CHOH); 4.58 and 4.63 (2 
× 1H, 2 × d, J = 12.1 Hz, O(HCH)Ph); 7.28-7.38 (5H, m, CHarom). 
13
C NMR (75 MHz, 
ref = CDCl3): δ 18.0 and 18.6 ((CH3)2CHN); 30.5 (NCH2CH2); 43.3 (NCH2CH2); 47.4 (NCH2CHO); 54.5 
((CH3)2CHN); 66.1 (CHOH); 70.8 (OCH2); 76.9 (NCH2CHO); 127.86, 127.91 and 128.6 (5 x HCarom); 138.3 
(Carom,quat). IR (ATR, cm
-1
): νOH = 3445; νmax = 2963, 1384, 1175, 1091, 963, 735, 697. MS (70 eV): m/z 
(%) 250 (M
+
+1, 100). HRMS (ESI) Calcd. for C15H24NO2 250.1807 [M + H]
+
, found 250.1812. 
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Cis-3-benzyloxy-1-cyclohexyl-4-hydroxypiperidine 158c 
Attempts to purify this compound failed. Spectral data are based on 
1
H NMR and 
13
C NMR of the 
crude reaction mixture (purity of 158c: ~80%), and no HRMS analysis was performed. 
 
Colourless oil. Yield 60%. 
1
H NMR (300 MHz, CDCl3): δ 1.05-1.29, 1.53-1.73 and 1.74-1.92 (5H, 1H and 
6H, 3 × m, (CH2)5CHN and NCH2CH2); 2.28-2.38 (1H, m, CHN); 2.44-2.51 (1H, m, 
N(HCH)CH2); 2.56-2.71 (3H, m, N(HCH)CH2 and NCH2CHO); 3.58 (1H, d × d × d, J = 
8.5, 4.1, 4.1 Hz, NCH2CHO); 3.97 (1H, s(broad), CHOH); 4.57 and 4.62 (2 × 1H, 2 × 
d, J = 11.8 Hz, O(HCH)Ph); 7.25-7.35 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 26.1, 26.2, 26.4, 28.5 and 29.1 ((CH2)5CHN); 30.6 (NCH2CH2); 43.7 
(NCH2CH2); 47.7 (NCH2CHO); 63.9 (CHN); 66.1 (CHOH); 70.8 (OCH2); 76.8 
(NCH2CHO); 127.8, 127.9 and 128.6 (5 x HCarom); 138.3 (Carom,quat). IR (ATR, cm
-1
): 
νOH = 3428; νmax = 2925, 2852, 1451, 1091, 1074, 966, 734, 697. MS (70 eV): m/z (%) 290 (M
+
+1, 100). 
 
5.7.5.2 Synthesis of 4-hydroxypiperidines via enzymatic reduction of piperidin-4-
ones 
5.7.5.2.1 Synthesis of (4S)-3-benzyloxy-4-hydroxy-1-isopropylpiperidines 
3-Benzyloxy-1-isopropylpiperidin-4-one 15b (250 mg, 50 mM), NADH (71 mg, 5 mM), 
isopropylalcohol (1 mL) and an S-specific alcohol dehydrogenase
111
 (100 mg) were dissolved in MES-
buffer (19 mL, 50 mM, pH 6.5). The mixture was incubated overnight in a thermoshaker (Eppendorf) 
at 300 rpm and 30 °C, yielding (3S,4S)-3-benzyloxy-4-hydroxy-1-isopropylpiperidine 176 and (3R,4S)-
3-benzyloxy-4-hydroxy-1-isopropylpiperidine 177 in quantitative yield (ratio 1/1, based on 1H NMR). 
 
(3S,4S)-3-Benzyloxy-4-hydroxy-1-isopropylpiperidine 176 
Colourless oil. Rf = 0.04 (hexane/EtOAc 1/3). Yield 45%. [α]D = +27.7° (c = 1.01, CH2Cl2). ee = 98.8%. 
1
H 
NMR (300 MHz, CDCl3): δ 1.03 (6H, d, J = 6.1 Hz, (CH3)2CHN); 1.59 (1H, d × d × d × 
d, J = 17.2, 11.2, 5.9, 3.6 Hz, NCH2(HCH)); 1.94-2.05 (2H, m, NCH2(HCH) and 
N(HCH)CHO); 2.20 (1H, d × d, J = 11.2, 10.7 Hz, N(HCH)CH2); 2.74-2.85 (2H, m, 
(CH3)2CHN and N(HCH)CH2); 3.11 (1H, d(broad), J = 11.0 Hz, N(HCH)CHO); 3.35-
3.49 (2H, m, NCH2CHO and CHOH); 4.56 and 4.70 (2 × 1H, 2 × d, J = 11.6 Hz, 
(HCH)O); 7.30-7.37 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 18.2 and 18.4 
((CH3)2CHN); 31.5 (NCH2CH2); 46.6 (NCH2CH2); 50.8 (NCH2CHO); 54.4 ((CH3)2CHN); 72.0 (OCH2Ph); 73.2 
and 81.5 (CHOH and CHOPh); 127.9 and 128.6 (5 x HCarom); 138.5 (Carom,quat). IR (ATR, cm
-1
): νOH = 3445; 
νmax = 2963, 1384, 1175, 1091, 963, 735, 697. MS (70 eV): m/z (%) 250 (M
+
+1, 100). HRMS (ESI) Calcd. 
for C15H24NO2 250.1807 [M + H]
+
, found 250.1812. 
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(3R,4S)-3-Benzyloxy-4-hydroxy-1-isopropylpiperidine 177 
Colourless oil. Rf = 0.03 (hexane/EtOAc 1/3). Yield 43%. [α]D = +7.6° (c = 0.95, 
CHCl3). ee = 98.8%. The spectral data of (3R,4S)-3-benzyloxy-4-hydroxy-1-
isopropylpiperidine 177 were judged to be identical to those for cis-3-benzyloxy-
4-hydroxy-1-isopropylpiperidine 158b (Section 5.7.5.1). 
 
 
5.7.5.2.2 Synthesis of (4R)-3-benzyloxy-4-hydroxy-1-isopropylpiperidines 
The synthesis of (4R)-3-benzyloxy-4-hydroxy-1-isopropylpiperidines 178 and 179 was analogous to 
the synthesis of (4S)-3-benzyloxy-4-hydroxy-1-isopropylpiperidines 176 and 177 using an R-specific 
alcohol dehydrogenase,
112
 yielding (3S,4R)-3-benzyloxy-4-hydroxy-1-isopropylpiperidine 178 and 
(3R,4R)-3-benzyloxy-4-hydroxy-1-isopropylpiperidine 179 in quantitative yield (ratio 1/1, based on 1H 
NMR). 
 
(3S,4R)-3-Benzyloxy-4-hydroxy-1-isopropylpiperidine 178 
Colourless oil. Rf = 0.03 (hexane/EtOAc 1/3). Yield 49%. [α]D = -7.6° (c = 0.98, 
CHCl3). ee = 96.2%. The spectral data of (3S,4R)-3-benzyloxy-4-hydroxy-1-
isopropylpiperidine 178 were judged to be identical to those for cis-3-benzyloxy-
4-hydroxy-1-isopropylpiperidine 158b (Section 5.7.5.1). 
 
 
(3R,4R)-3-Benzyloxy-4-hydroxy-1-isopropylpiperidine 179 
Colourless oil. Rf = 0.04 (hexane/EtOAc 1/3). Yield 44%. [α]D = -27.7° (c = 0.97, 
CH2Cl2). ee = 95.8%. The spectral data of (3R,4R)-3-benzyloxy-4-hydroxy-1-
isopropylpiperidine 179 were judged to be identical to those for (3S,4S)-3-
benzyloxy-4-hydroxy-1-isopropylpiperidine 176 (Section 5.7.5.2.1). 
 
 
5.7.6 Synthesis of 4-(formyloxy)piperidines 
As a representative example, the synthesis of cis-4-formyloxy-1-isopropyl-3-phenoxypiperidine 173a 
is described. A solution of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a (0.31 g, 1 
mmol, 1 equiv) in DMF (15 mL) was heated at 80 °C for 3 hours. Subsequently, the reaction mixture 
was poured into water (15 mL) and extracted with Et2O (3 × 15 mL). Afterwards, the organic phase 
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was washed intensively with brine (4 × 20 mL). Drying (MgSO4), filtration of the drying agent, and 
removal of the solvent in vacuo afforded cis-4-formyloxy-1-isopropyl-3-phenoxypiperidine 173a, 
which was further purified in 53% yield by column chromatography on silica gel (hexane/EtOAc 2/1). 
 
Cis-4-formyloxy-1-isopropyl-3-phenoxypiperidine 173a 
Colourless oil. Rf = 0.07 (hexane/EtOAc 2/1). Yield 53%. 
1
H NMR (300 MHz, CDCl3): δ 1.04 (6H, d, J = 
6.1 Hz, (CH3)2CHN); 1.82-1.93 and 2.04-2.13 (2 × 1H, 2 × m, NCH2(HCH)); 2.57-2.60 
(2H, m, NCH2CH2); 2.70-2.87 (3H, m, (CH3)2CHN and NCH2CHO); 4.49 (1H, d × d × d, 
J = 8.4, 4.0, 4.0 Hz, CHOPh); 5.34-5.36 (1H, m, CHOC=O); 6.90-6.99 and 7.24-7.31 
(5H, 2 × m, CHarom); 8.14 (1H, s, HC=O). 
13
C NMR (75 MHz, CDCl3): δ 17.9 and 18.4 
((CH3)2CHN); 28.7 (NCH2CH2); 43.8 (NCH2CH2); 47.7 (NCH2CHO); 54.4 ((CH3)2CHN); 
69.2 (CHOC=O); 74.0 (CHOPh); 116.3, 121.6 and 129.6 (5 x HCarom); 157.3 and 
160.5 (OCarom,quat and C=O). IR (ATR, cm
-1
): νC=O = 1721; νmax = 2964, 1492, 1238, 
1166, 752, 692. MS (70 eV): m/z (%) 264 (M
+
+1, 100). HRMS (ESI) Calcd. for C15H22NO3 264.1600 [M + 
H]
+
, found 264.1602. 
 
Cis-3-benzyloxy-4-formyloxy-1-isopropylpiperidine 173b 
Colourless oil. Rf = 0.06 (hexane/EtOAc 1/2). Yield 68%. 
1
H NMR (300 MHz, CDCl3): δ 1.03 and 1.04 (2 
× 3H, 2 × d, J = 6.3 Hz, (CH3)2CHN); 1.71-1.82 and 1.94-2.02 (2 × 1H, 2 × m, 
NCH2(HCH)); 2.45-2.63 (3H, m, NCH2CH2 and N(HCH)CHO); 2.68-2.72 (1H, m, 
N(HCH)CHO); 2.79 (1H, septet, J = 6.3 Hz, (CH3)2CHN); 3.64 (1H, d × d × d, J = 9.1, 
4.1, 4.1 Hz, NCH2CHO); 4.54 and 4.66 (2 × 1H, 2 × d, J = 11.9 Hz, O(HCH)Ph); 5.38 
(1H, s(broad), CHOC=O); 7.24-7.39 (5H, m, CHarom); 8.15 (1H, s, HC=O). 
13
C NMR 
(75 MHz, ref = CDCl3): δ 18.0 and 18.5 ((CH3)2CHN); 28.8 (NCH2CH2); 43.6 
(NCH2CH2); 48.4 (NCH2CHO); 54.5 ((CH3)2CHN); 68.4 (CHOC=O); 71.1 (OCH2); 74.8 (NCH2CHO); 127.9, 
128.0 and 128.5 (5 x HCarom); 138.1 (Carom,quat); 160.7 (C=O). IR (ATR, cm
-1
): νC=O = 1720; νmax = 2963, 
1170, 1090, 736, 698. MS (70 eV): m/z (%) 278 (M
+
+1, 100). HRMS (ESI) Calcd. for C16H24NO3 278.1756 
[M + H]
+
, found 278.1770. 
 
Cis-3-benzyloxy-1-cyclohexyl-4-(formyloxy)piperidine 173c 
Colourless oil. Rf = 0.06 (hexane/EtOAc 4/1). Yield 70%. 
1
H NMR (300 MHz, CDCl3): δ 1.05-1.28, 1.59-
1.66 and 1.73-1.83 (6H, 1H and 4H, 3 × m, (CH2)5CHN and NCH2(HCH)); 1.92-2.01 
(1H, m, NCH2(HCH)); 2.29-2.38 (1H, m, CHN); 2.54-2.60 (2H, m, NCH2CH2); 2.63-
2.78 (2H, m, NCH2CHO); 3.62 (1H, d × d × d, J = 9.0, 3.9, 3.9 Hz, NCH2CHO); 4.54 
and 4.64 (2 × 1H, 2 × d, J = 11.6 Hz, O(HCH)Ph); 5.36 (1H, s(broad), CHOC=O); 
7.28-7.36 (5H, m, CHarom); 8.14 (1H, s, HC=O). 
13
C NMR (75 MHz, ref = CDCl3): δ 
26.09, 26.13, 26.4, 28.6 and 28.9 ((CH2)5CHN); 29.1 (NCH2CH2); 44.0 (NCH2CH2); 
48.9 (NCH2CHO); 63.8 (CHN); 68.6 (CHOC=O); 71.0 (OCH2); 74.9 (NCH2CHO); 
127.8, 127.9 and 128.5 (5 x HCarom); 138.2 (Carom,quat); 160.8 (C=O). IR (ATR, cm
-1
): 
νC=O = 1724; νmax = 2926, 1452, 1177, 1099, 734, 696. MS (70 eV): m/z (%) 318 (M
+
+1, 100). HRMS 
(ESI) Calcd. for C19H28NO3 318.2069 [M + H]
+
, found 318.2077. 
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5.8 Synthesis of 1,2,5,6-tetrahydropyridines 
As a representative example, the synthesis of 1-isopropyl-3-phenoxy-1,2,5,6-tetrahydropyridine 155a 
is described. To a solution of cis-4-bromo-1-isopropyl-3-phenoxypiperidine 154a (2.98 g, 10 mmol, 1 
equiv) in DMSO (50 mL) was added NaH (1.6 g, 40 mmol, 4 equiv, 60% dispersion in mineral oil), after 
which the resulting suspension was stirred for 15 hours at 150 °C. Subsequently, the reaction mixture 
was poured into water (40 mL) and extracted with Et2O (3 × 25 mL). Afterwards, the organic phase 
was washed intensively with brine (4 × 30 mL). Drying (MgSO4), filtration of the drying agent, and 
removal of the solvent afforded 1-isopropyl-3-phenoxy-1,2,5,6-tetrahydropyridine 155a, which was 
further purified in 56% yield by column chromatography on silica gel (hexane/EtOAc 2/1). 
 
1-Isopropyl-3-phenoxy-1,2,5,6-tetrahydropyridine 155a 
Yellow oil. Rf = 0.08 (hexane/EtOAc 2/1). Yield 56%. 
1
H NMR (300 MHz, CDCl3): δ 1.11 (6H, d, J = 6.4 
Hz, (CH3)2CHN); 2.16-2.21 (2H, m, NCH2CH2); 2.60 (2H, ~t, J = 5.8 Hz, NCH2CH2); 2.82 
(1H, septet, J = 6.4 Hz, (CH3)2CHN); 3.17 (2H, s(broad), NCH2Cquat); 4.91-4.94 (1H, m, 
C=CH); 7.03-7.10 and 7.29-7.34 (5H, 2 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
18.6 ((CH3)2CHN); 24.4 (NCH2CH2); 45.9 (NCH2CH2); 48.9 (NCH2Cquat); 54.0 
((CH3)2CHN); 102.7 (C=CH); 119.5, 123.3 and 129.6 (5 x HCarom); 152.1 and 155.9 (2 × OCquat). IR (ATR, 
cm
-1
): νC=C = 1685; νmax = 2964, 1590, 1489, 1220, 1176, 753, 693. MS (70 eV): m/z (%) 218 (M
+
+1, 
100). HRMS (ESI) Calcd. for C14H20NO 218.1545 [M + H]
+
, found 218.1548. 
 
3-Benzyloxy-1-isopropyl-1,2,5,6-tetrahydropyridine 155b 
Light-brown oil. Rf = 0.04 (hexane/EtOAc 2/1). Yield 60%. 
1
H NMR (300 MHz, CDCl3): δ 1.08 and 1.09 
(2 × 3H, 2 × d, J = 6.5 Hz, (CH3)2CHN); 2.16-2.23 (2H, m, NCH2CH2); 2.56 (2H, ~t, J = 
5.5 Hz, NCH2CH2); 2.77 (1H, septet, J = 6.5 Hz, (CH3)2CHN); 3.08 (2H, s(broad), 
NCH2Cquat); 4.74 (2H, s, OCH2); 4.77 (1H, t, J = 3.3 Hz, C=CH); 7.27-7.39 (5H, m, 
CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 18.7 ((CH3)2CHN); 24.5 (NCH2CH2); 46.4 
(NCH2CH2); 49.9 (NCH2Cquat); 54.0 ((CH3)2CHN); 69.0 (OCH2); 92.6 (C=CH); 127.7, 
127.9 and 128.5 (5 x HCarom); 137.4 (Carom,quat); 153.2 (OCquat). IR (ATR, cm
-1
): νC=C = 
1677; νmax = 2963, 1217, 1183, 1016, 797, 734, 697. MS (70 eV): m/z (%) 232 (M
+
+1, 100). HRMS (ESI) 
Calcd. for C15H22NO 232.1701 [M + H]
+
, found 232.1700. 
 
5.9 Synthesis of piperidin-4-ones 
As a representative example, the synthesis of 1-isopropyl-3-phenoxypiperidin-4-one 15a is described. 
To a solution of cis-1-isopropyl-2-(2-mesyloxyethyl)-3-phenoxyazetidine 13a (3.15 g, 10 mmol, 1 
equiv) in DMSO (40 mL) was added K2CO3 (6.90 g, 50 mmol, 5 equiv). After stirring at 100 °C for 18 
hours, the reaction mixture was poured into water (40 mL) and extracted with diethyl ether (3 × 50 
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mL). Afterwards, the organic phase was washed intensively with brine (4 × 40 mL). Drying (MgSO4), 
filtration of the drying agent, and removal of the solvent afforded 1-isopropyl-3-phenoxypiperidin-4-
one 15a, which was further purified in 43% yield by column chromatography on silica gel 
(hexane/EtOAc 1/1). 
 
1-Isopropyl-3-phenoxypiperidin-4-one 15a 
Colourless oil. Rf = 0.10 (hexane/EtOAc 1/1). Yield 43%. 
1
H NMR (300 MHz, CDCl3): δ 1.09 (6H, d, J = 
6.5 Hz, (CH3)2CHN); 2.52-2.70 and 3.06-3.13 (4H and 1H, 2 × m, NCH2CH2 and 
N(HCH)CHO); 3.00 (1H, septet, J = 6.5 Hz, (CH3)2CHN); 3.42 (1H, d × d × d, J = 10.8, 
6.3, 2.9 Hz, N(HCH)CHO); 4.83 (1H, d × d, J = 10.3, 6.3 Hz, CHO); 6.85-6.91, 6.94-7.00 
and 7.23-7.31 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 18.4 
and 18.5 ((CH3)2CHN); 41.0 and 49.0 (NCH2CH2); 53.9 (NCH2CHO); 54.0 ((CH3)2CHN); 
79.2 (CHO); 115.5, 121.6 and 129.6 (5 x HCarom); 157.7 (Carom,quat); 205.6 (C=O). IR 
(ATR, cm
-1
): νC=O = 1733; νmax = 2966, 1588, 1493, 1241, 1174, 907, 751. MS (70 eV): m/z (%) 234 
(M
+
+1, 100). HRMS (ESI) Calcd. for C14H20NO2 234.1494 [M + H]
+
, found 234.1496. 
 
3-Benzyloxy-1-isopropylpiperidin-4-one 15b 
Colourless oil. Rf = 0.06 (hexane/EtOAc 1/1). Yield 45%. 
1
H NMR (300 MHz, CDCl3): δ 1.00 (6H, d, J = 
6.6 Hz, (CH3)2CHN); 2.36-2.51 and 2.82-2.98 (4H and 2H, 2 × m, NCH2CH2, 
N(HCH)CHO and (CH3)2CHN); 3.19 (1H, d × d × d, J = 10.7, 6.3, 2.8 Hz, N(HCH)CHO); 
4.00 (1H, d × d, J = 10.2, 6.3 Hz, CHO); 4.49 and 4.84 (2 × 1H, 2 × d, J = 12.1 Hz, 
(HCH)O); 7.21-7.36 (5H, m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 18.38 and 
18.42 ((CH3)2CHN); 40.9 and 48.8 (NCH2CH2); 54.0 ((CH3)2CHN); 54.4 (NCH2CHO); 
72.4 (OCH2); 80.1 (CHO); 127.9, 128.0 and 128.5 (5 x HCarom); 137.9 (Carom,quat); 
208.0 (C=O). IR (ATR, cm
-1
): νC=O = 1727; νmax = 2965, 1455, 1121, 1104, 1018, 736, 697. MS (70 eV): 
m/z (%) 248 (M
+
+1, 100). HRMS (ESI) Calcd. for C15H22NO2 248.1651 [M + H]
+
, found 248.1653. 
 
3-Benzyloxy-1-cyclohexylpiperidin-4-one 15c 
Colourless oil. Rf = 0.04 (hexane/EtOAc 4/1). Yield 48%. 
1
H NMR (300 MHz, CDCl3): δ 1.19-1.31, 1.62-
1.66 and 1.78-1.81 (5H, 1H and 4H, 3 × m, (CH2)5CHN); 2.40-2.64 (5H, m, 
N(HCH)CHO, N(HCH)CH2 and (CH2)5CHN); 3.03-3.09 (1H, m, N(HCH)CH2); 3.29 (1H, 
d × d × d, J = 11.0, 6.5, 2.8 Hz, N(HCH)CHO); 4.03 (1H, d × d, J = 10.2, 6.5 Hz, CHO); 
4.53 and 4.87 (2 × 1H, 2 × d, J = 12.1 Hz, (HCH)O); 7.27-7.39 (5H, m, CHarom). 
13
C 
NMR (75 MHz, ref = CDCl3): δ 26.0, 26.2, 29.0 and 29.1 ((CH2)5CHN); 41.0 
(NCH2CH2); 49.2 (NCH2CH2); 54.9 (NCH2CHO); 62.9 ((CH2)5CHN); 72.2 (OCH2); 80.2 
(CHO); 127.7, 127.8 and 128.4 (5 x HCarom); 138.0 (Carom,quat); 207.6 (C=O). IR (ATR, 
cm
-1
): νC=O = 1727; νmax = 2926, 1451, 1149, 1100, 734, 697. MS (70 eV): m/z (%) 288 (M
+
+1, 100). 
HRMS (ESI) Calcd. for C18H26NO2 288.1964 [M + H]
+
, found 288.1965. 
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5.10 Synthesis of cis-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones 
As a representative example, the synthesis of cis-6-isopropyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 
18a is described. Palladium on activated carbon (20% w/w) was added to a solution of cis-3-
benzyloxy-1-isopropyl-4-(2-mesyloxyethyl)azetidin-2-one 17a (1.54 g, 4.5 mmol, 1 equiv) in methanol 
(30 mL), and the resulting mixture was placed in a Parr apparatus. The inside of the Parr apparatus 
was then degassed and filled with hydrogen gas, after which the mixture was stirred for 60 hours at 
room temperature while applying 5 bar of hydrogen gas. Filtration of the heterogeneous mixture 
through Celite® and evaporation of the solvent in vacuo afforded cis-3-hydroxy-1-isopropyl-4-(2-
mesyloxyethyl)azetidin-2-one in high purity (> 90%, 
1
H NMR), which was used as such in the next 
reaction step. To an ice-cold solution of the latter β-lactam (1.18 g, 4.5 mmol, 1 equiv) in 
tetrahydrofuran (30 mL) was added sodium hydride (0.18 g, 4.5 mmol, 1 equiv, 60% dispersion in 
mineral oil), after which the mixture was heated under reflux for 15 hours. The reaction mixture was 
poured into brine (1 × 30 mL) and extracted with ethyl acetate (3 × 30 mL), after which the organic 
fraction was dried (MgSO4), followed by removal of the drying agent and evaporation of the solvent 
in vacuo. Purification by means of column chromatography on silica gel (hexane/EtOAc 1/1) afforded 
pure cis-6-isopropyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 18a in 52% yield. 
 
Cis-6-isopropyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 18a 
Colourless oil. Rf = 0.10 (hexane/EtOAc 1/1). Yield 52%. 
1
H NMR (300 MHz, CDCl3): δ 1.26 and 1.28 (2 
× 3H, 2 × d, J = 6.6 Hz, (CH3)2CHN); 1.60-1.73 (1H, m, (HCH)CHN); 2.07 (1H, ~(d × d), J = 
13.8, 5.0 Hz, (HCH)CHN); 3.86-3.98 (2H, m, (CH3)2CHN and (HCH)O); 4.20-4.29 (2H, m, 
(HCH)O and CH2CHN); 5.03 (1H, d, J = 3.3 Hz, CHO). 
13
C NMR (75 MHz, CDCl3): δ 20.4 and 
21.9 ((CH3)2CHN); 29.7 (CH2CHN); 43.9 ((CH3)2CHN); 56.9 (CH2CHN); 67.2 (CH2O); 85.7 
(CHO); 165.6 (C=O). IR (ATR, cm
-1
): νC=O = 1732; νmax = 2974, 1390, 1230, 1099, 922, 772. 
MS (70 eV): m/z (%) 156 (M
+
+1, 100). HRMS (ESI) Calcd. for C8H14NO2 156.1025 [M + H]
+
, found 
156.1020. 
 
Cis-6-cyclohexyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 18b 
Colourless oil. Rf = 0.05 (hexane/EtOAc 3/1). Yield 62%. 
1
H NMR (300 MHz, CDCl3): δ 1.09-1.98 (11H, 
m, (CH2)5CHN and OCH2(HCH)); 2.06 (1H, ~(d × d), J = 13.5, 4.7 Hz, OCH2(HCH)); 3.48-
3.58 (1H, m, (CH2)5CHN); 3.89 (1H, d × d × d, J = 11.6, 9.3, 5.0 Hz, (HCH)O); 4.20-4.28 
(2H, m, (HCH)O and CHOCHN); 5.02 (1H, d, J = 3.3 Hz, CHO). 
13
C NMR (75 MHz, CDCl3): 
δ 25.0, 25.1, 25.3, 29.8, 30.8 and 32.2 ((CH2)5CHN and OCH2CH2); 51.7 ((CH2)5CHN); 
57.2 (CHOCHN); 67.1 (CH2O); 85.8 (CHO); 165.6 (C=O). IR (ATR, cm
-1
): νC=O = 1736; νmax 
= 2930, 1391, 1085, 924. MS (70 eV): m/z (%) 196 (M
+
+1, 100). HRMS (ESI) Calcd. for C11H18NO2 
196.1338 [M + H]
+
, found 196.1335. 
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5.11 Synthesis of methyl cis-3-aminotetrahydrofuran-2-
carboxylates 
As a representative example, the synthesis of methyl cis-3-(isopropylamino)tetrahydrofuran-2-
carboxylate 19a is described. To a solution of cis-6-isopropyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-one 
18a (0.38 g, 2.44 mmol, 1 equiv) in methanol (20 mL) was added a solution of HCl in MeOH (3 M, 4.1 
mL), followed by a reflux period of 24 hours. Afterwards, methanol was removed in vacuo, followed 
by the addition of anhydrous CH2Cl2 (20 mL) and triethylamine (0.49 g, 4.88 mmol, 2 equiv). 
Subsequently, the resulting mixture was heated under reflux for 4 hours, after which the solvent was 
removed under reduced pressure. Addition of dry diethyl ether, filtration of the precipitated 
triethylamine hydrochloride, drying of the filtrate (MgSO4), filtration of the drying agent and removal 
of the solvent in vacuo yielded methyl cis-3-(isopropylamino)tetrahydrofuran-2-carboxylate 19a, 
which was further purified in 66% yield by means of column chromatography on silica gel 
(hexane/EtOAc 4/1). 
 
Methyl cis-3-(isopropylamino)tetrahydrofuran-2-carboxylate 19a 
Light-yellow oil. Rf = 0.08 (hexane/EtOAc 4/1). Yield 66%. 
1
H NMR (300 MHz, CDCl3): δ 1.00 and 1.04 
(2 × 3H, 2 × d, J = 6.3 Hz, (CH3)2CHN); 1.83-1.95 and 2.10-2.21 (2 × 1H, 2 × m, 
(HCH)CHN); 2.83 (1H, septet, J = 6.3 Hz, (CH3)2CHN); 3.67 (1H, ~q, J = 6.6 Hz, CH2CHN); 
3.75 (3H, s, CH3O); 3.92 (1H, d × d × d, J = 8.3, 8.3, 7.5 Hz, (HCH)O); 4.18 (1H, d × d × 
d, J = 8.3, 8.3, 5.5 Hz, (HCH)O); 4.47 (1H, d, J = 6.6 Hz, CHO). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 23.1 and 23.4 ((CH3)2CHN); 32.6 (CH2CHN); 47.3 ((CH3)2CHN); 51.7 (CH3O); 58.4 (CH2CHN); 
67.7 (CH2O); 80.4 (CHO); 171.9 (C=O). IR (ATR, cm
-1
): νC=O = 1742; νmax = 2959, 1437, 1204, 1174, 1094, 
752. MS (70 eV): m/z (%) 188 (M
+
+1, 100). HRMS (ESI) Calcd. for C9H18NO3 188.1287 [M + H]
+
, found 
188.1289. 
 
Methyl cis-3-(cyclohexylamino)tetrahydrofuran-2-carboxylate 19b 
Colourless oil. Rf = 0.07 (hexane/EtOAc 6/1). Yield 70%. 
1
H NMR (300 MHz, CDCl3): δ 0.96-1.30, 1.57-
1.61 and 1.68-1.94 (5H, 1H and 5H, 3 × m, (CH2)5CHN and OCH2(HCH)); 2.09-2.19 
(1H, m, OCH2(HCH)); 2.40-2.49 (1H, m, (CH2)5CHN); 3.73 (1H, d × d × d, J = 10.3, 
5.5, 5.4 Hz, CHOCHN); 3.75 (3H, s, CH3O); 3.91 and 4.18 (2 × 1H, 2 × ~q, J = 7.5 Hz, 
(HCH)O); 4.46 (1H, d, J = 5.5 Hz, CHO). 
13
C NMR (75 MHz, CDCl3): δ 24.9, 25.0, 
26.2, 32.7, 33.6 and 34.2 ((CH2)5CHN and OCH2CH2); 51.5 ((CH2)5CHN); 55.1 (CH3O); 58.0 (CHOCHN); 
67.6 (CH2O); 80.6 (CHO); 171.8 (C=O). IR (ATR, cm
-1
): νC=O = 1742; νmax = 2925, 1448, 1202, 1179, 1096, 
730. MS (70 eV): m/z (%) 228 (M
+
+1, 100). HRMS (ESI) Calcd. for C12H22NO3 228.1600 [M + H]
+
, found 
228.1603. 
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5.12 Synthesis of 2-hydroxy-1,4-oxazin-3-ones 
As a representative example, the synthesis of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a is 
described. Saturated aqueous sodium hydrogen carbonate (2 mL) was added to a solution of (3R,4S)-
3-hydroxy-4-[(1S)-1,2-dihydroxyethyl]-1-isopropylazetidin-2-one 193a (1.89 g, 10 mmol, 1 equiv) in 
CH2Cl2 (30 mL). Solid sodium periodate (4.28 g, 20 mmol, 2 equiv) was added over a 10 min. period 
with vigorous stirring, and the reaction was allowed to proceed for 2 hours at room temperature. 
The solid was removed by filtration and the filtrate was washed with water (25 mL), after which the 
organic fraction was dried over MgSO4, followed by removal of the drying agent by filtration. 
Removal of the solvent in vacuo yielded 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a, which was 
further purified in 69% yield by means of column chromatography on silica gel (hexane/EtOAc 1/1). 
 
2-Hydroxy-4-isopropyl-1,4-oxazin-3-one 194a 
Yellow oil. Rf = 0.32 (hexane/EtOAc 1/1). Yield 69%. 
1
H NMR (300 MHz, CDCl3): δ 1.22 and 1.24 (2 × 
3H, 2 × d, J = 6.6 Hz, (CH3)2CH); 4.39 (1H, d, J = 4.7 Hz, OH); 4.74 (1H, septet, J = 6.6 Hz, 
(CH3)2CH); 5.41 (1H, d, J = 4.7 Hz, OCHO); 5.78 and 6.24 (2 × 1H, 2 × d, J = 4.1 Hz, HC=CH). 
13
C NMR (75 MHz, ref = CDCl3): δ 19.9 and 20.5 ((CH3)2CH); 44.5 ((CH3)2CH); 90.6 (OCHO); 
104.8 and 128.3 (HC=CH); 160.6 (C=O). IR (ATR, cm
-1
): νOH = 3288; νC=O,C=C = 1671, 1642; 
νmax = 1406, 1213, 1069, 1027, 955, 699. MS (70 eV): m/z (%) 158 (M
+
+1, 100). HRMS (ESI) Calcd. for 
C7H12NO3 158.0817 [M + H]
+
, found 158.0819. 
 
2-Hydroxy-4-isobutyl-1,4-oxazin-3-one 194b 
Yellow oil. Rf = 0.41 (hexane/EtOAc 1/1). Yield 73%. 
1
H NMR (300 MHz, CDCl3): δ 0.92 and 0.93 (2 × 
3H, 2 × d, J = 7.2 Hz, (CH3)2CH); 2.00 (1H, nonet, J = 7.2 Hz, (CH3)2CH); 3.31 and 3.37 (2 × 
1H, 2 × (d × d), J = 13.5, 7.2, 7.2 Hz, (HCH)N); 4.72 (1H, d, J = 4.7 Hz, OH); 5.47 (1H, d, J = 
4.7 Hz, OCHO); 5.69 and 6.18 (2 × 1H, 2 × d, J = 4.1 Hz, HC=CH). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 19.8 ((CH3)2CH); 27.6 ((CH3)2CH); 53.1 (CH2N); 90.6 (OCHO); 110.6 and 127.3 
(HC=CH); 161.5 (C=O). IR (ATR, cm
-1
): νOH = 3288; νC=O,C=C = 1672, 1649; νmax = 2961, 
1389, 1283, 1028, 959, 729. MS (70 eV): m/z (%) 172 (M
+
+1, 100). HRMS (ESI) Calcd. for C8H14NO3 
172.0974 [M + H]
+
, found 172.0971. 
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4-Butyl-2-hydroxy-1,4-oxazin-3-one 194c 
Yellow crystals. Mp 85.5 °C. Rf = 0.24 (hexane/EtOAc 1/1). Yield 75%. 
1
H NMR (300 MHz, CDCl3): δ 
0.93 (3H, t, J = 7.2 Hz, CH2CH3); 1.34 (2H, sextet, J = 7.2 Hz, CH2CH3); 1.59 (2H, pentet, J 
= 7.2 Hz, CH2CH2N); 3.44 and 3.60 (2 × 1H, 2 × (d × t), J = 13.7, 7.2 Hz, (HCH)N); 5.55 
(1H, s, OCHO); 5.70 and 6.19 (2 × 1H, 2 × d, J = 4.4 Hz, HC=CH). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 13.8 (CH2CH3); 19.8 (CH2CH3); 30.2 (CH2CH2N); 45.9 (CH2N); 90.6 (OCHO); 
110.2 and 127.7 (HC=CH); 161.2 (C=O). IR (ATR, cm
-1
): νOH = 3301; νC=O,C=C = 1672, 1650; 
νmax = 2959, 1432, 1030, 959, 728. MS (70 eV): m/z (%) 172 (M
+
+1, 100). HRMS (ESI) 
Calcd. for C8H14NO3 172.0974 [M + H]
+
, found 172.0965. 
 
4-Cyclohexyl-2-hydroxy-1,4-oxazin-3-one 194d 
Yellow oil. Rf = 0.43 (hexane/EtOAc 1/1). Yield 94%. 
1
H NMR (300 MHz, CDCl3): δ 1.05-1.22, 1.33-1.48 
and 1.68-1.88 (1H, 4H and 5H, 3 × m, (CH2)5CHN); 4.25-4.41 (2H, m, (CH2)5CHN and OH); 
5.40 (1H, s, OCHO); 5.81 and 6.21 (2 × 1H, 2 × d, J = 4.4 Hz, HC=CH). 
13
C NMR (75 MHz, ref 
= CDCl3): δ 25.3, 25.5, 30.2 and 30.9 ((CH2)5CHN); 52.2 ((CH2)5CHN); 90.6 (OCHO); 105.7 
and 127.9 (HC=CH); 160.7 (C=O). IR (ATR, cm
-1
): νOH = 3297; νC=O,C=C = 1671, 1646; νmax = 
2931, 1409, 1196, 1026, 957, 728. MS (70 eV): m/z (%) 198 (M
+
+1, 100). HRMS (ESI) Calcd. 
for C10H16NO3 198.1130 [M + H]
+
, found 198.1132. 
 
2-Hydroxy-4-isopentyl-1,4-oxazin-3-one 194e 
Colourless oil. Rf = 0.35 (hexane/EtOAc 1/1). Yield 70%. 
1
H NMR (300 MHz, CDCl3): δ 0.94 (6H, d, J = 
6.6 Hz, (CH3)2CH); 1.43-1.53 (2H, m, CH2CH2N); 1.55-1.68 (1H, m, (CH3)2CH); 3.45-3.62 
(2H, m, CH2N); 4.30 (1H, d, J = 6.1 Hz, OH); 5.43 (1H, d, J = 6.1 Hz, OCHO); 5.71 and 6.19 
(2 × 1H, 2 × d, J = 4.4 Hz, HC=CH). 
13
C NMR (75 MHz, ref = CDCl3): δ 22.5 ((CH3)2CH); 
25.7 ((CH3)2CH); 36.8 (CH2CH2N); 44.4 (CH2N); 90.6 (OCHO); 109.9 and 127.7 (HC=CH); 
161.1 (C=O). IR (ATR, cm
-1
): νOH = 3300; νC=O,C=C = 1671, 1649; νmax = 2956, 1429, 1263, 
1035, 953, 726. MS (70 eV): m/z (%) 186 (M
+
+1, 100). HRMS (ESI) Calcd. for C9H16NO3 
186.1130 [M + H]
+
, found 186.1132. 
 
5.13 Synthesis of 2-camphanoyloxy-4-isopropyl-1,4-oxazin-3-one 
To a solution of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a (1.57 g, 10 mmol, 1 equiv) and (1S)-(-)-
camphanic chloride (2.17 g, 10 mmol, 1 equiv) in dry dichloromethane (50 mL) was added 
triethylamine (3.04 g, 30 mmol, 3 equiv) dropwise at 0 °C. The mixture was stirred at the same 
temperature for 2 hours, after which the reaction mixture was quenched with a saturated solution of 
NaHCO3 (30 mL) and extracted with dichloromethane (3 × 30 mL). The combined organic layers were 
washed with a 10% aq. HCl solution (2 × 20 mL) and water (20 mL). Drying (MgSO4), removal of the 
drying agent by filtration and evaporation of the solvent in vacuo afforded crude 2-camphanoyloxy-4-
N
OHO
O
N
OHO
O
N
OHO
O
Chapter 5  Experimental Part 
128 
 
isopropyl-1,4-oxazin-3-one 198, which was further purified as a diastereoisomeric mixture by means 
of recrystallization. 
 
White crystals. Mp 141.0 °C. Recrystallization from EtOAc/hexane (30/1). Yield 33%. 
 1
H NMR (300 
MHz, CDCl3): δ 0.95, 0.97, 1.03, 1.04 and 1.11 (4 × 3H and 6H, 5 × s, 6 × CquatCH3); 
1.23, 1.25 and 1.27 (6H, 3H and 3H, 3 × d, J = 6.6 Hz, 2 × (CH3)2CH); 1.64-1.75, 
1.88-1.98, 2.01-2.10 and 2.37-2.47 (4 × 2H, 4 × m, 4 × CH2); 4,80 (2H, septet, J = 
6.6 Hz, 2 × (CH3)2CH); 5.87, 5.89, 6.20 and 6.22 (4 × 1H, 4 × d, J = 4.4 Hz, 2 × 
HC=CH); 6.59 and 6.61 (2 × 1H, 2 × s, 2 × OCHO). 
13
C NMR (75 MHz, ref = CDCl3): δ 
9.7, 16.59, 16.62 and 16.7 (6 × CquatCH3); 20.0, 20.51 and 20.54 (2 × (CH3)2CH); 
29.0, 30.5 and 30.7 (4 × CH2); 44.7 and 44.8 (2 × (CH3)2CH); 54.7, 54.8, 54.9 (4 × 
CquatCH3); 88.9 and 89.0 (2 × OCHO); 90.66 and 90.75 (2 × CquatO); 105.8, 126.9 and 127.0 (2 × HC=CH); 
156.3, 166.0, 166.1 and 178.0 (6 × C=O). IR (ATR, cm
-1
): νOC=O = 1785, 1764, 1747; νNC=O,C=C = 1682, 
1666; νmax = 2956, 2043, 1432, 1267, 1223, 1174, 1099, 1078, 1052, 986, 960, 926, 740. MS (70eV): 
m/z (%) 337 (M
+
, 64), 308 (43), 140 (48), 128 (57), 125 (100), 98 (40), 97 (56), 83 (96). 
 
5.14 Synthesis of 1H-pyrazin-2-ones 
As a representative example, the synthesis of 1-isopropyl-1H-pyrazin-2-one 211a is described. To a 
solution of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a (15.7 mg, 0.1 mmol, 1 equiv) in EtOAc (1.0 
mL) was added NH4OAc (92.4 mg, 1.2 mmol, 12 equiv) and HOAc (1.0 mL). After a reflux period of 24 
hours, the resulting reaction mixture was neutralized with solid NaHCO3, after which EtOAc (10 mL) 
was added. Subsequently, the reaction mixture was washed with a saturated solution of NaHCO3 (10 
mL) and brine (5 mL). Drying (MgSO4), removal of the drying agent by filtration and evaporation of 
the solvent in vacuo afforded crude 1-isopropyl-1H-pyrazin-2-one 211a, which was further purified in 
45% yield by means of recrystallization from EtOAc/hexane (30/1). 
 
1-Isopropyl-1H-pyrazin-2-one 211a 
White crystals. Mp 85.2 °C. Recrystallization from EtOAc/hexane (30/1). Yield 45%. 
1
H NMR (300 
MHz, CDCl3): δ 1.38 (6H, d, J = 6.8 Hz, (CH3)2CH); 5.13 (1H, septet, J = 6.8 Hz, (CH3)2CH); 7.15 
(1H, d × d, J = 4.4, 1.1 Hz, HC=NCH); 7.37 (1H, d, J = 4.4 Hz, HC=NCHCH); 8.14 (1H, d, J = 1.1 
Hz, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 21.4 ((CH3)2CH); 46.9 ((CH3)2CH); 124.0 
(HC=NCH); 124.4 (HC=NCHCH); 149.4 (HC=N); 155.9 (C=O). IR (ATR, cm
-1
): νC=O,C=N,C=C = 1660, 
1651, 1590; νmax = 2978, 1490, 1450, 1251, 1225, 1188, 1105, 799. MS (70eV): m/z (%) 139 (M
+
+1, 
100). HRMS (ESI) Calcd. for C7H11N2O 139.0871 [M + H]
+
, found 139.0870. 
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1-Isobutyl-1H-pyrazin-2-one 211b 
Orange oil. Rf = 0.20 (hexane/EtOAc 1/1). Yield 51%. 
1
H NMR (300 MHz, CDCl3): δ 0.88 (6H, d, J = 7.2 
Hz, (CH3)2CH); 2.10 (1H, nonet, J = 7.2 Hz, (CH3)2CH); 3.64 (2H, d, J = 7.2 Hz, CH2N); 7.00 
(1H, d × d, J = 4.4, 1.1 Hz, HC=NCH); 7.23 (1H, d, J = 4.4 Hz, CH2NCH); 8.07 (1H, s, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 19.8 ((CH3)2CH); 27.7 ((CH3)2CH); 56.7 (CH2N); 123.5 
(CH2NCH); 129.2 (HC=NCH); 149.8 (HC=N); 156.4 (C=O). IR (ATR, cm
-1
): νC=O,C=N,C=C = 1649, 
1590; νmax = 2961, 1496, 1454, 1142, 1102, 800. MS (70eV): m/z (%) 153 (M
+
+1, 100). 
HRMS (ESI) Calcd. for C8H13N2O 153.1028 [M + H]
+
, found 153.1027. 
 
1-Butyl-1H-pyrazin-2-one 211c 
Orange oil. Rf = 0.15 (hexane/EtOAc 1/1). Yield 30%. 
1
H NMR (300 MHz, CDCl3): δ 0.97 (3H, t, J = 7.4 
Hz, CH3); 1.33-1.45 (2H, m, CH2CH3); 1.69-1.79 (2H, m, CH2CH2CH3); 3.90 (2H, t, J = 7.4 Hz, 
CH2(CH2)2CH3); 7.12 (1H, d × d, J = 4.4, 1.1 Hz, HC=NCH); 7.32 (1H, d, J = 4.4 Hz, CH2NCH); 
8.14 (1H, s, HC=N). 
13
C NMR (75 MHz, ref = CDCl3): δ 13.7 (CH3); 19.8 (CH2CH3); 30.7 
(CH2CH2CH3); 49.3 (CH2(CH2)2CH3); 123.8 (CH2NCH); 128.7 (HC=NCH); 149.7 (HC=N); 156.3 
(C=O). IR (ATR, cm
-1
): νC=O,C=N,C=C = 1649, 1590; νmax = 2958, 1496, 1457, 1190, 1140, 1102, 
799, 623. MS (70eV): m/z (%) 153 (M
+
+1, 100). HRMS (ESI) Calcd. for C8H13N2O 153.1028 
[M + H]
+
, found 153.1027. 
 
5.15 Synthesis of 2-benzoyloxy-1,4-oxazin-3-ones 
As a representative example, the synthesis of 2-benzoyloxy-4-isopropyl-1,4-oxazin-3-one 225a is 
described. To a solution of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a (1.57 g, 10 mmol, 1 equiv) 
and benzoyl chloride (4.22 g, 30 mmol, 3 equiv) in dry dichloromethane (50 mL) was added 
triethylamine (3.04 g, 30 mmol, 3 equiv) dropwise at 0 °C. The mixture was stirred at the same 
temperature for 2 hours, after which the reaction mixture was quenched with a saturated solution of 
NaHCO3 (30 mL) and extracted with dichloromethane (3 × 30 mL). The combined organic layers were 
washed with a 10% aq. HCl solution (2 × 20 mL) and water (20 mL). Drying (MgSO4), removal of the 
drying agent by filtration and evaporation of the solvent in vacuo afforded crude 2-benzoyloxy-4-
isopropyl-1,4-oxazin-3-one 225a, which was further purified in 45% yield by means of 
recrystallization from EtOAc/hexane (30/1). 
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2-Benzoyloxy-4-isopropyl-1,4-oxazin-3-one 225a 
White crystals. Mp 99.3 °C. Recrystallization from EtOAc/hexane (30/1). Yield 45%. 
1
H NMR (300 
MHz, CDCl3): δ 1.26 and 1.32 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CH); 4.89 (1H, septet, J = 
6.8 Hz, (CH3)2CH); 5.90 and 6.23 (2 × 1H, 2 × d, J = 4.7 Hz, HC=CH); 6.72 (1H, s, 
OCHO); 7.42-7.47, 7.56-7.62 and 8.00-8.03 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR 
(75 MHz, ref = CDCl3): δ 20.2 and 20.6 ((CH3)2CH); 44.6 ((CH3)2CH); 88.9 (OCHO); 
105.5 and 127.4 (HC=CH); 128.6 (2 × HCarom); 129.0 (Carom,quat); 130.2 and 133.8 (3 × 
HCarom); 157.0 and 164.8 (2 × C=O). IR (ATR, cm
-1
): νOC=O = 1731; νNC=O,C=C = 1679, 
1664; νmax = 1429, 1261, 1215, 1052, 987, 945, 702. MS (70 eV): m/z (%) 261 (M
+
, 3), 
156 (10), 140 (3), 105 (100), 98 (3), 77 (17). Anal. Calcd. for C14H15NO4: C 64.36, H 5.79, N 5.36. Found: 
C 64.40, H 5.58, N 5.48. 
 
2-Benzoyloxy-4-isobutyl-1,4-oxazin-3-one 225b 
Colourless oil. Rf = 0.11 (hexane/EtOAc 19/1). Yield 64%. 
1
H NMR (300 MHz, CDCl3): δ 0.96 (6H, d, J = 
6.6 Hz, (CH3)2CH); 1.98-2.12 (1H, m, (CH3)2CH); 3.37 and 3.48 (2 × 1H, 2 × (d × d), J 
= 13.4, 7.7, 7.4 Hz, (HCH)N); 5.86 and 6.18 (2 × 1H, 2 × d, J = 4.4 Hz, HC=CH); 6.79 
(1H, s, OCHO); 7.37-7.42, 7.52-7.57 and 7.98-8.08 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 19.7 and 19.8 ((CH3)2CH); 27.6 ((CH3)2CH); 53.1 
(CH2N); 88.7 (OCHO); 111.2 and 126.4 (HC=CH); 128.6 and 130.0 (4 × HCarom); 
133.5 (Carom,quat); 133.8 (HCarom); 157.8 and 164.6 (2 × C=O). IR (ATR, cm
-1
): νOC=O = 
1734; νNC=O,C=C = 1687; νmax = 2960, 1451, 1427, 1256, 1246, 1207, 1079, 1052, 
1024, 987, 947, 733, 707, 686. MS (70eV): m/z (%) 275 (M
+
, 8), 246 (4), 170 (12), 
154 (4), 122 (4), 106 (7), 105 (100), 77 (15). 
 
2-Benzoyloxy-4-butyl-1,4-oxazin-3-one 225c 
Colourless oil. Rf = 0.09 (hexane/EtOAc 19/1). Yield 93%. 
1
H NMR (300 MHz, CDCl3): δ 0.96 (3H, t, J = 
7.3 Hz, CH3); 1.39 (2H, sextet, J = 7.3 Hz, CH2CH3); 1.65 (2H, pentet, J = 7.3 Hz, 
CH2CH2CH3); 3.53-3.71 (2H, m, CH2(CH2)2CH3); 5.84 and 6.19 (2 × 1H, 2 × d, J = 4.4 
Hz, HC=CH); 6.74 (1H, s, OCHO); 7.40-7.45, 7.55-7.60 and 8.00-8.03 (2H, 1H and 
2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 13.8 (CH3); 19.8 (CH2CH3); 30.2 
(CH2CH2CH3); 45.9 (CH2(CH2)2CH3); 88.7 (OCHO); 110.7 and 126.8 (HC=CH); 128.6 
(2 × HCarom); 128.9 (Carom,quat); 130.1 (2 × HCarom); 133.9 (HCarom); 157.6 and 164.8 (2 
× C=O). IR (ATR, cm
-1
): νOC=O = 1734; νNC=O,C=C = 1686; νmax = 2959, 1451, 1427, 1246, 
1079, 1051, 1023, 986, 945, 707, 686. MS (70eV): m/z (%) 275 (M
+
, 6), 246 (2), 170 
(10), 154 (3), 122 (3), 106 (7), 105 (100), 77 (13). 
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2-Benzoyloxy-4-cyclohexyl-1,4-oxazin-3-one 225d 
White crystals. Mp 94.6 °C. Recrystallization from EtOAc/hexane (30/1). Yield 34%. 
1
H NMR (300 
MHz, CDCl3): δ 1.08-1.25, 1.35-1.58 and 1.70-1.93 (1H, 4H and 5H, 3 × m, 
(CH2)5CHN); 4.42-4.53 (1H, m, (CH2)5CHN); 5.92 and 6.20 (2 × 1H, 2 × d, J = 4.4 Hz, 
HC=CH); 6.72 (1H, s, OCHO); 7.42-7.47, 7.56-7.62 and 8.00-8.03 (2H, 1H and 2H, 3 × 
m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 25.3, 25.5, 30.4 and 31.0 ((CH2)5CHN); 
52.3 ((CH2)5CHN); 88.9 (OCHO); 106.4 and 127.0 (HC=CH); 128.6 (2 × HCarom); 128.9 
(Carom,quat); 130.1 and 133.8 (3 × HCarom); 157.1 and 164.8 (2 × C=O). IR (ATR, cm
-1
): 
νOC=O = 1783; νNC=O,C=C = 1727, 1687; νmax = 1450, 1209, 1173, 1014, 986, 871, 702, 
670. MS (70 eV): m/z (%) 301 (M
+
, 10), 272 (5), 196 (15), 105 (100), 77 (15), 55 (5). 
Anal. Calcd. for C17H19NO4: C 67.76, H 6.36, N 4.65. Found: C 67.82, H 6.15, N 4.38. 
 
5.16 Synthesis of 2-benzoyloxymorpholin-3-ones 
As a representative example, the synthesis of 2-benzoyloxy-4-isopropylmorpholin-3-one 226a is 
described. Palladium on activated carbon (20% w/w) was added to a solution of 2-benzoyloxy-4-
isopropyl-1,4-oxazin-3-one 225a (2.61 g, 10 mmol, 1 equiv) in methanol (60 mL) and the resulting 
mixture was placed in a Parr apparatus. The inside of the Parr apparatus was then degassed and filled 
with hydrogen gas, after which the mixture was stirred for 18 hours at room temperature while 
applying 5 bar of hydrogen gas. Filtration of the heterogeneous mixture through Celite® and 
evaporation of the solvent in vacuo afforded crude 2-benzoyloxy-4-isopropylmorpholin-3-one 226a, 
which was purified in 69% yield by means of recrystallization from EtOAc/hexane (30/1). 
 
2-Benzoyloxy-4-isopropylmorpholin-3-one 226a 
White crystals. Mp 124.2 °C. Recrystallization from EtOAc/hexane (30/1). Yield 69%. 
1
H NMR (300 
MHz, CDCl3): δ 1.20 and 1.22 (2 × 3H, 2 × d, J = 6.7 Hz, (CH3)2CH); 3.23 (1H, d × d × d, 
J = 12.3, 3.2, 1.4 Hz, (HCH)N); 3.53 (1H, d × d × d, J = 12.3, 11.9, 4.8 Hz, (HCH)N); 3.98 
(1H, d × d × d, J = 11.8, 4.8, 1.4 Hz, (HCH)O); 4.20 (1H, d × d × d, J = 11.8, 11.9, 3.2 Hz, 
(HCH)O); 4.90 (1H, septet, J = 6.7 Hz, (CH3)2CH); 6.40 (1H, s, CHO); 7.42-7.47, 7.56-
7.61 and 8.07-8.10 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 
19.0 and 19.4 ((CH3)2CH); 39.2 (CH2N); 44.4 ((CH3)2CH); 59.7 (CH2O); 89.2 (CHO); 
128.5 (2 × HCarom); 129.5 (Carom,quat); 130.2 (2 × HCarom) and 133.6 (HCarom); 162.1 and 
165.4 (2 × C=O). IR (ATR, cm
-1
): νOC=O = 1719; νNC=O = 1654; νmax = 2927, 1475, 1263, 1210, 1178, 1138, 
1081, 1062, 1024, 995, 961, 908, 712, 684. MS (70eV): m/z (%) 264 (M
+
+1, 100). HRMS (ESI) Calcd. for 
C14H18NO4 264.1236 [M + H]
+
, found 264.1233. 
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2-Benzoyloxy-4-isobutylmorpholin-3-one 226b 
Yellow oil. Rf = 0.18 (hexane/EtOAc 3/1). Yield 79%. 
1
H NMR (300 MHz, CDCl3): δ 0.82 and 0.84 (2 × 
3H, 2 × d, J = 6.8 Hz, (CH3)2CH); 1.92 (1H, nonet, J = 6.8 Hz, (CH3)2CH); 3.12 (1H, d × 
d, J = 12.4, 2.5 Hz, (CH2(HCH)N); 3.18 (2H, d, J = 6.8 Hz, CHCH2N); 3.55 (1H, d × d × 
d, J = 12.4, 12.0, 3.9 Hz, (CH2(HCH)N); 3.80 (1H, d × d, J = 12.0, 3.9 Hz, (HCH)O); 
4.14 (1H, d × d × d, J = 12.0, 12.0, 2.5 Hz, (HCH)O); 6.33 (1H, s, CHO); 7.22-7.33, 
7.37-7.47 and 7.86-7.96 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 19.9 and 20.1 ((CH3)2CH); 26.3 ((CH3)2CH); 46.4 (CH2CH2N); 54.0 
(CHCH2N); 59.3 (CH2O); 89.0 (CHO); 128.5 (2 × HCarom); 129.3 (Carom,quat); 130.0 (2 × 
HCarom); 133.6 (HCarom); 163.1 and 165.2 (2 × C=O). IR (ATR, cm
-1
): νOC=O = 1727; 
νNC=O = 1669; νmax = 2960, 1451, 1259, 1152, 1082, 1063, 1024, 1012, 955, 907, 709, 687. MS (70eV): 
m/z (%) 278 (M
+
+1, 100). HRMS (ESI) Calcd. for C15H20NO4 278.1392 [M + H]
+
, found 278.1391. 
 
2-Benzoyloxy-4-butylmorpholin-3-one 226c 
Yellow oil. Rf = 0.30 (hexane/EtOAc 3/1). Yield 82%. 
1
H NMR (300 MHz, CDCl3): δ 0.95 (3H, t, J = 7.3 
Hz, CH3); 1.36 (2H, sextet, J = 7.3 Hz, CH2CH3); 1.50-1.67 (2H, m, CH2CH2CH3); 3.23 
(1H, d × d, J = 12.4, 2.6 Hz, OCH2(HCH)N); 3.36-3.56 (2H, m, CH2(CH2)2CH3); 3.68 
(1H, d × d × d, J = 12.4, 12.0, 4.0 Hz, (OCH2(HCH)N); 3.91 (1H, d × d, J = 11.8, 4.0 
Hz, (HCH)O); 4.24 (1H, d × d × d, J = 12.0, 11.8, 2.6 Hz, (HCH)O); 6.40 (1H, s, CHO); 
7.39-7.44, 7.53-7.58 and 8.05-8.08 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 
MHz, ref = CDCl3): δ 13.8 (CH3); 20.0 (CH2CH3); 28.9 (CH2CH2CH3); 45.8 
(OCH2CH2N); 46.7 (CH2(CH2)2CH3); 59.3 (CH2O); 89.0 (CHO); 128.5 (2 × HCarom); 
129.4 (Carom,quat); 130.1 (2 × HCarom); 133.6 (HCarom); 162.6 and 165.2 (2 × C=O). IR 
(ATR, cm
-1
): νOC=O = 1728; νNC=O = 1667; νmax = 2931, 1451, 1258, 1151, 1082, 1063, 1024, 947, 881, 
710, 687. MS (70eV): m/z (%) 278 (M
+
+1, 100). HRMS (ESI) Calcd. for C15H20NO4 278.1392 [M + H]
+
, 
found 278.1392. 
 
2-Benzoyloxy-4-cyclohexylmorpholin-3-one 226d 
Light-yellow crystals. Mp 96.1 °C. Rf = 0.63 (EtOAc). Yield 89%. 
1
H NMR (300 MHz, CDCl3): δ 1.05-1.19, 
1.34-1.54 and 1.69-1.90 (1H, 4H and 5H, 3 × m, (CH2)5CHN); 3.26 (1H, d × d × d, J = 
12.4, 3.3, 1.6 Hz, (HCH)N); 3.54 (1H, d × d × d, J = 12.4, 11.9, 4.4 Hz, (HCH)N); 3.96 
(1H, d × d × d, J = 11.9, 4.4, 1.6 Hz, (HCH)O); 4.20 (1H, d × d × d, J = 11.9, 11.9, 3.3 Hz, 
(HCH)O); 4.41-4.52 (1H, m, (CH2)5CHN); 6.39 (1H, s, OCHO); 7.42-7.47, 7.55-7.61 and 
8.07-8.11 (2H, 1H and 2H, 3 × m, CHarom). 
13
C NMR (75 MHz, ref = CDCl3): δ 25.5, 25.6, 
29.5 and 29.6 ((CH2)5CHN); 40.4 (CH2N); 52.6 ((CH2)5CHN); 59.8 (CH2O); 89.3 (OCHO); 
128.5 (2 × HCarom); 129.5 (Carom,quat); 130.1 and 133.6 (3 × HCarom); 162.2 and 165.4 (2 
× C=O). IR (ATR, cm
-1
): νOC=O = 1724; νNC=O = 1649; νmax = 2924, 1398, 1251, 1079, 888, 
688. MS (70 eV): m/z (%) 304 (M
+
+1, 100). Anal. Calcd. for C17H21NO4: C 67.31, H 
6.98, N 4.62. Found: C 67.56, H 6.89, N 4.78. 
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5.17 Synthesis of 2-fluoro-1,4-oxazin-3-ones 
As a representative example, the synthesis of 2-fluoro-4-isopropyl-1,4-oxazin-3-one 232a is 
described. To a solution of 2-hydroxy-4-isopropyl-1,4-oxazin-3-one 194a (1.57 g, 10 mmol, 1 equiv) in 
dry dichloromethane (50 mL) at -78 °C under nitrogen atmosphere was added Morph-DAST (3.50 g, 
20 mmol, 2 equiv) dropwise. The resulting mixture was allowed to warm to room temperature and 
was further stirred for 5 hours. A saturated solution of NaHCO3 (50 mL) was carefully dropped to the 
mixture and the mixture was stirred for 15 min. The organic layer was separated and washed with 
water (25 mL) and brine (25 mL), after which the organic fraction was dried over MgSO4, followed by 
removal of the drying agent by filtration. After evaporation of the solvent in vacuo, the crude 
reaction mixture was purified by means of column chromatography on silica gel (hexane/EtOAc 9/1), 
affording pure 2-fluoro-4-isopropyl-1,4-oxazin-3-one 228a in 87% yield. 
 
2-Fluoro-4-isopropyl-1,4-oxazin-3-one 232a 
Colourless oil. Rf = 0.10 (hexane/EtOAc 9/1). Yield 87%. 
1
H NMR (300 MHz, CDCl3): δ 1.23 and 1.27 (2 
× 3H, 2 × d, J = 6.8 Hz, (CH3)2CH); 4.80 (1H, septet, J = 6.8 Hz, (CH3)2CH); 5.90 (1H, d, J = 52.7 
Hz, CHF); 5.92 and 6.27 (2 × 1H, 2 × d, J = 4.4 Hz, HC=CH). 
19
F NMR (282 MHz, CDCl3): δ -
127.92 (d, J = 52.7 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 19.9 and 20.6 ((CH3)2CH); 44.7 
((CH3)2CH); 102.0 (d, J = 234.2 Hz, CHF); 105.8 and 126.5 (HC=CH); 156.0 (d, J = 32.3 Hz, 
C=O). IR (ATR, cm
-1
): νC=O,C=C = 1685, 1664; νmax = 2980, 1424, 1223, 1073, 985, 951, 769, 
699. MS (70eV): m/z (%) 159 (M
+
, 83), 117 (100), 88 (37), 69 (43), 43 (17), 41 (25), 40 (11). 
 
2-Fluoro-4-isobutyl-1,4-oxazin-3-one 232b 
Colourless oil. Rf = 0.24 (hexane/EtOAc 9/1). Yield 78%. 
1
H NMR (300 MHz, CDCl3): δ 0.94 (6H, d, J = 
7.0 Hz, (CH3)2CH); 2.02 (1H, nonet, J = 7.0 Hz, (CH3)2CH); 3.38 (2H, d × d, J = 7.0, 1.1 Hz, 
CH2N); 5.83 (1H, d, J = 4.4 Hz, HC=CH); 5.91 (1H, d, J = 52.7 Hz, CHF); 6.22 (1H, d, J = 4.4 
Hz, HC=CH). 
19
F NMR (282 MHz, CDCl3): δ -127.69 (d, J = 52.7 Hz, CHF). 
13
C NMR (75 MHz, 
ref = CDCl3): δ 19.80 and 19,84 ((CH3)2CH); 27.7 ((CH3)2CH); 53.3 (CH2N); 102.0 (d, J = 
234.2 Hz, CHF); 111.4 and 125.6 (HC=CH); 156.8 (d, J = 32.3 Hz, C=O). IR (ATR, cm
-1
): 
νC=O,C=C = 1686; νmax = 2963, 1426, 1285, 1211, 1072, 989, 954, 727. MS (70eV): m/z (%) 173 (M
+
, 61), 
130 (13), 117 (100), 102 (52), 69 (16), 57 (13), 41 (20). 
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4-Butyl-2-fluoro-1,4-oxazin-3-one 232c 
Light-yellow oil. Rf = 0.20 (hexane/EtOAc 9/1). Yield 94%. 
1
H NMR (300 MHz, CDCl3): δ 0.95 (3H, t, J = 
7.5 Hz, CH3); 1.35 (2H, sextet, J = 7.5 Hz, CH2CH3); 1.56-1.66 (2H, m, CH2CH2CH3); 3.48-
3.66 (2H, m, CH2(CH2)2CH3); 5.85 (1H, d, J = 4.4 Hz, HC=CH); 5.90 (1H, d, J = 52.8 Hz, CHF); 
6.23 (1H, d, J = 4.4 Hz, HC=CH). 
19
F NMR (282 MHz, CDCl3): δ -127.57 (d, J = 52.8 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 13.7 (CH3); 19.7 (CH2CH3); 30.1 (CH2CH2CH3); 45.9 
(CH2(CH2)2CH3); 102.0 (d, J = 234.2 Hz, CHF); 110.9 and 125.8 (HC=CH); 156.5 (d, J = 32.3 
Hz, C=O). IR (ATR, cm
-1
): νC=O,C=C = 1686; νmax = 2960, 1427, 1071, 987, 955, 728. MS 
(70eV): m/z (%) 173 (M
+
, 99), 144 (52), 131 (17), 130 (27), 124 (24), 117 (100), 102 (57), 88 (17), 69 
(33), 57 (19), 41 (35). 
 
4-Cyclohexyl-2-fluoro-1,4-oxazin-3-one 232d 
Yellow crystals. Mp 91.2 °C. Rf = 0.51 (hexane/EtOAc 1/1). Yield 90%. 
1
H NMR (300 MHz, CDCl3): δ 
1.05-1.20, 1.34-1.51 and 1.68-1.89 (1H, 4H and 5H, 3 × m, (CH2)5CHN); 4.34-4.45 (1H, m, 
(CH2)5CHN); 5.90 (1H, d, J = 53.7 Hz, CHF); 5.93 and 6.24 (2 × 1H, 2 × d, J = 4.4 Hz, HC=CH). 
19
F NMR (282 MHz, CDCl3): δ -127.83 (d, J = 53.7 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 
25.2, 25.4, 25.5, 30.2 and 30.9 ((CH2)5CHN); 52.3 ((CH2)5CHN); 102.0 (d, J = 233.1 Hz, CHF); 
106.6 and 126.1 (HC=CH); 156.0 (d, J = 32.3 Hz, C=O). IR (ATR, cm
-1
): νC=O,C=C = 1684, 1662; 
νmax = 2932, 1421, 1205, 1075, 987, 956, 728. MS (70 eV): m/z (%) 200 (M
+
+1, 100). Anal. 
Calcd. for C10H14FNO2: C 60.29, H 7.08, N 7.03. Found: C 60.50, H 6.99, N 7.08. 
 
5.18 Synthesis of 2-benzoyloxy-6-bromo-5-fluoromorpholin-3-ones 
As a representative example, the synthesis of 2-benzoyloxy-6-bromo-5-fluoro-4-isopropylmorpholin-
3-one 234a and 235a is described. To a solution of 2-benzoyloxy-4-isopropyl-1,4-oxazin-3-one 225a 
(2.61 g, 10 mmol, 1 equiv) in dry dichloromethane (50 mL) was added Et3N·3HF (4.03 g, 25 mmol, 2.5 
equiv) at 0 °C. Subsequently, N-bromosuccinimide (3.67 g, 15 mmol, 1.5 equiv) was added at 0 °C and 
the resulting mixture was stirred at room temperature for 24 hours. Afterwards, the mixture was 
poured in aq. 0.5 M NaOH (50 mL) and extraction was performed with dichloromethane (3 × 50 mL). 
The combined organic layers were washed with aq. 1 M NaOH (2 × 50 mL) and brine (50 mL). After 
drying with MgSO4 and filtration of the drying agent, the solvent was evaporated in vacuo, affording 
a diastereoisomeric mixture of 2-benzoyloxy-6-bromo-5-fluoro-4-isopropylmorpholin-3-one 234a 
and 235a, which were separated by means of recrystallization from EtOAc/hexane (30/1). 
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2-Benzoyloxy-6-bromo-5-fluoro-4-isopropylmorpholin-3-one 234a (major diastereoisomer) 
White crystals. Mp 122.8 °C. Recrystallization from EtOAc/hexane (30/1). Yield 63%. 
1
H NMR (300 
MHz, CDCl3): δ 1.31 (3H, d × d, J = 6.7, 1.4 Hz, CH3CHCH3); 1.33 (3H, d, J = 6.7 Hz, 
CH3CHCH3); 4.84 (1H, septet × d, J = 6.7, 1.2 Hz, CH3CHCH3); 5.72 (1H, d × d, J = 
56.8, 1.5 Hz, CHF); 6.38 (1H, d × d, J = 5.1, 1.5 Hz, CHBr); 6.69 (1H, s, OCHO); 7.43-
7.48, 7.57-7.63 and 8.10-8.13 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, 
CDCl3): δ -118.95 (d × d, J = 56.8, 5.1 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 
19.5 and 20.6 ((CH3)2CH); 45.9 (d, J = 2.3 Hz, (CH3)2CH); 75.0 (d, J = 33.4 Hz, CHBr); 
85.8 (OCHO); 91.5 (d, J = 210.0 Hz, CHF); 128.6, 130.4 and 134.0 (HCarom, 
Carom,quat); 161.2 (d, J = 3.5 Hz, NC=O); 164.7 (OC=O). IR (ATR, cm
-1
): νOC=O = 1735; νNC=O = 1690; νmax = 
2978, 2600, 2494, 1474, 1450, 1396, 1384, 1266, 1226, 1172, 1143, 1105, 1079, 1062, 1036, 973, 
945, 807, 708. MS (70eV): m/z (%) 360/2 (M
+
+1, 100). Anal. Calcd. for C14H15BrFNO4: C 46.69, H 4.20, 
N 3.89. Found: C 46.89, H 4.66, N 4.45. 
 
2-Benzoyloxy-6-bromo-5-fluoro-4-isopropylmorpholin-3-one 235a (minor diastereoisomer) 
Colourless oil. Filtrate after recrystallization from EtOAc/hexane (30/1). Yield 16%. 
1
H NMR (300 MHz, 
CDCl3): δ 1.28-1.35 (6H, m, (CH3)2CH); 4.82 (1H, septet × d, J = 6.6, 1.5 Hz, 
(CH3)2CH); 5.68 (1H, d × d, J = 57.4, 1.3 Hz, CHF); 6.44 (1H, d, J = 1.1 Hz, OCHO); 
6.46 (1H, d × d, J = 4.5, 1.3 Hz, CHBr); 7.38-7.48, 7.57-7.63 and 8.08-8.13 (2H, 1H 
and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, CDCl3): δ -116.94 (d × d, J = 57.4, 4.5 
Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 19.3 and 20.5 ((CH3)2CH); 46.0 (d, J = 
2.3 Hz, (CH3)2CH); 78.0 (d, J = 35.7 Hz, CHBr); 87.4 (OCHO); 91.2 (d, J = 211.1 Hz, 
CHF); 128.2 (Carom,quat); 128.6, 130.4 and 134.2 (HCarom); 161.8 (d, J = 3.5 Hz, 
NC=O); 164.3 (OC=O). IR (ATR, cm
-1
): νOC=O = 1736; νNC=O = 1691; νmax = 2980, 1451, 1263, 1225, 1144, 
1105, 1078, 1058, 1024, 970, 944, 706. MS (70eV): m/z (%) 360/2 (M
+
+1, 100). 
 
2-Benzoyloxy-6-bromo-5-fluoro-4-isobutylmorpholin-3-one 234b (major diastereoisomer) 
Colourless oil. Rf = 0.14 (hexane/EtOAc 19/1). Yield 33%. 
1
H NMR (300 MHz, CDCl3): δ 1.04 (6H, d, J = 
7.2 Hz, (CH3)2CH); 2.03-2.17 (1H, m, (CH3)2CH); 3.29 and 3.64 (2 × 1H, 2 × (d × d × 
d), J = 13.9, 7.2, 1.2 Hz, (HCH)N); 5.68 (1H, d × d, J = 57.7, 1.4 Hz, CHF); 6.34 (1H, 
d × d, J = 5.3, 1.4 Hz, CHBr); 6.70 (1H, s, OCHO); 7.44-7.49, 7.58-7.64 and 8.10-
8.13 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, CDCl3): δ -122.75 (d × d, J 
= 57.7, 5.3 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 20.1 and 20.2 ((CH3)2CH); 
27.5 ((CH3)2CH); 53.3 (CH2N); 74.2 (d, J = 33.5 Hz, CHBr); 85.9 (OCHO); 95.7 (d, J = 
212.3 Hz, CHF); 128.6, 130.5 and 134.0 (HCarom, Carom,quat); 161.9 (d, J = 3.5 Hz, 
NC=O); 164.6 (OC=O). IR (ATR, cm
-1
): νOC=O = 1736; νNC=O = 1704; νmax = 2964, 
1467, 1374, 1257, 1222, 1152, 1091, 1060, 1017, 965, 908, 728, 708. MS (70eV): m/z (%) 374/6 
(M
+
+1, 100). 
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2-Benzoyloxy-6-bromo-5-fluoro-4-isobutylmorpholin-3-one 235b (minor diastereoisomer) 
Colourless oil. Rf = 0.14 (hexane/EtOAc 19/1). Yield 12%. 
1
H NMR (300 MHz, CDCl3): δ 1.01 and 1.04 (2 
× 3H, 2 × d, J = 7.2 Hz, (CH3)2CH); 2.08 (1H, nonet, J = 7.2 Hz, (CH3)2CH); 3.29 and 
3.65 (2 × 1H, 2 × (d × d × d), J = 13.9, 7.2, 1.5 Hz, (HCH)N); 5.62 (1H, d × d, J = 
58.0, 1.2 Hz, CHF); 6.43 (1H, d × d, J = 5.4, 1.2 Hz, CHBr); 6.47 (1H, d, J = 1.2 Hz, 
OCHO); 7.44-7.49, 7.59-7.64 and 8.08-8.13 (2H, 1H and 2H, 3 × m, CHarom). 
19
F 
NMR (282 MHz, CDCl3): δ -121.17 (d × d, J = 58.0, 5.4 Hz, CHF). 
13
C NMR (75 MHz, 
ref = CDCl3): δ 20.07 and 20.13 ((CH3)2CH); 27.3 ((CH3)2CH); 53.1 (CH2N); 77.3 (d, J 
= 32.3 Hz, CHBr); 87.4 (OCHO); 95.5 (d, J = 212.3 Hz, CHF); 128.2 (Carom,quat); 128.7, 
130.5 and 134.2 (HCarom); 162.8 (d, J = 3.5 Hz, NC=O); 164.3 (OC=O). IR (ATR, cm
-
1
): νOC=O = 1744; νNC=O = 1705; νmax = 2963, 1468, 1377, 1257, 1225, 1155, 1110, 1078, 1060, 1024, 972, 
707. MS (70eV): m/z (%) 374/6 (M
+
+1, 100).  
 
2-Benzoyloxy-6-bromo-4-butyl-5-fluoromorpholin-3-one 234c (major diastereoisomer) 
Colourless oil. Rf = 0.12 (hexane/EtOAc 19/1). Yield 42%. 
1
H NMR (300 MHz, CDCl3): δ 0.98 (3H, t, J = 
7.5 Hz, CH3); 1.44 (2H, sextet, J = 7.5 Hz, CH2CH3); 1.61-1.81 (2H, m, CH2CH2CH3); 
3.44-3.54 and 3.71-3.81 (2 × 1H, 2 × m, (CH2(CH2)2CH3); 5.67 (1H, d × d, J = 57.9, 
1.1 Hz, CHF); 6.33 (1H, d × d, J = 5.4, 1.1 Hz, CHBr); 6.68 (1H, s, OCHO); 7.44-7.49, 
7.58-7.64 and 8.10-8.14 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, 
CDCl3): δ -122.55 (d × d, J = 57.9, 5.4 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 
13.8 (CH3); 20.0 (CH2CH3); 29.6 (CH2CH2CH3); 46.3 (CH2(CH2)2CH3); 74.3 (d, J = 32.3 
Hz, CHBr); 85.8 (OCHO); 95.5 (d, J = 212.3 Hz, CHF); 128.6, 130.5 and 134.0 
(HCarom, Carom,quat); 161.5 (d, J = 3.4 Hz, NC=O); 164.6 (OC=O). IR (ATR, cm
-1
): νOC=O 
= 1736; νNC=O = 1702; νmax = 2959, 1452, 1380, 1247, 1148, 1093, 1059, 1017, 964, 706, 686. MS 
(70eV): m/z (%) 374/6 (M
+
+1, 100). 
 
2-Benzoyloxy-6-bromo-4-butyl-5-fluoromorpholin-3-one 235c (minor diastereoisomer) 
Colourless oil. Rf = 0.12 (hexane/EtOAc 19/1). Yield 13%. 
1
H NMR (300 MHz, CDCl3): δ 0.97 (3H, t, J = 
7.4 Hz, CH3); 1.42 (2H, sextet, J = 7.4 Hz, CH2CH3); 1.64-1.76 (2H, m, CH2CH2CH3); 
3.39-3.53 and 3.72-3.82 (2 × 1H, 2 × m, (CH2(CH2)2CH3); 5.61 (1H, d × d, J = 58.2, 
1.1 Hz, CHF); 6.42 (1H, d × d, J = 5.7, 1.1 Hz, CHBr); 6.44 (1H, d, J = 1.1 Hz, OCHO); 
7.43-7.48, 7.58-7.64 and 8.08-8.13 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 
MHz, CDCl3): δ -120.66 (d × d, J = 58.2, 5.7 Hz, CHF). 
13
C NMR (75 MHz, ref = 
CDCl3): δ 13.8 (CH3); 19.9 (CH2CH3); 29.5 (CH2CH2CH3); 46.1 (CH2(CH2)2CH3); 77.4 
(d, J = 34.6 Hz, CHBr); 87.3 (OCHO); 95.4 (d, J = 213.5 Hz, CHF); 128.2 (Carom,quat); 
128.7, 130.5 and 134.2 (HCarom); 162.4 (d, J = 3.4 Hz, NC=O); 164.3 (OC=O). IR 
(ATR, cm
-1
): νOC=O = 1743; νNC=O = 1702; νmax = 2960, 1453, 1378, 1248, 1225, 1110, 1059, 1024, 953, 
908, 730, 705. MS (70eV): m/z (%) 374/6 (M
+
+1, 100). 
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2-Benzoyloxy-6-bromo-4-cyclohexyl-5-fluoromorpholin-3-one 234d (major diastereoisomer) 
White crystals. Mp 101.5 °C. Recrystallization from EtOAc/hexane (30/1). Yield 67%. 
1
H NMR (300 
MHz, CDCl3): δ 1.08-1.25, 1.34-1.54, 1.69-1.75 and 1.86-1.99 (1H, 4H, 1H and 4H, 
4 × m, (CH2)5CHN); 4.41-4.50 (1H, m, (CH2)5CHN); 5.73 (1H, d × d, J = 57.3, 1.3 Hz, 
CHF); 6.36 (1H, d × d, J = 4.7, 1.3 Hz, CHBr); 6.69 (1H, s, OCHO); 7.43-7.48, 7.58-
7.63 and 8.10-8.13 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, CDCl3): δ -
117.86 (d × d, J = 57.3, 4.7 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 25.4, 25.5, 
25.8, 30.0 and 31.0 ((CH2)5CHN); 53.4 ((CH2)5CHN); 75.0 (d, J = 33.4 Hz, CHBr); 
85.9 (OCHO); 91.8 (d, J = 211.2 Hz, CHF); 128.6, 130.4, 134.0 (HCarom, Carom,quat); 
161.2 (d, J = 3.4 Hz, NC=O); 164.7 (OC=O). IR (ATR, cm
-1
): νOC=O = 1736; νNC=O = 
1681; νmax = 2936, 1452, 1247, 1090, 987, 708. MS (70 eV): m/z (%) 400/2 (M
+
+1, 100). Anal. Calcd. 
for C17H19BrFNO4: C 51.01, H 4.78, N 3.50. Found: C 51.13, H 4.78, N 3.45. 
 
2-Benzoyloxy-6-bromo-4-cyclohexyl-5-fluoromorpholin-3-one 235d (minor diastereoisomer) 
Spectral data based on 
1
H NMR and 
13
C NMR of the crude reaction mixture. 
 
1
H NMR (300 MHz, CDCl3): δ 1.08-1.23, 1.34-1.54, 1.70-1.74 and 1.86-1.99 (1H, 4H, 1H and 4H, 4 × m, 
(CH2)5CHN); 4.37-4.51 (1H, m, (CH2)5CHN); 5.69 (1H, d × d, J = 56.7, 1.1 Hz, CHF); 
6.43 (1H, d, J = 1.1 Hz, OCHO); 6.45 (1H, d × d, J = 4.9, 1.1 Hz, CHBr); 7.43-7.49, 
7.58-7.64 and 8.08-8.14 (2H, 1H and 2H, 3 × m, CHarom). 
19
F NMR (282 MHz, 
CDCl3): δ -115.96 (d × d, J = 56.7, 4.9 Hz, CHF). 
13
C NMR (75 MHz, ref = CDCl3): δ 
25.4, 25.5, 25.8, 29.8 and 31.1 ((CH2)5CHN); 53.5 ((CH2)5CHN); 77.9 (d, J = 35.8 Hz, 
CHBr); 87.4 (OCHO); 91.5 (d, J = 212.3 Hz, CHF); 128.3 (Carom,quat); 128.6, 130.4, 
134.2 (HCarom); 161.8 (d, J = 3.5 Hz, NC=O); 164.4 (OC=O). IR (ATR, cm
-1
): νOC=O = 
1736; νNC=O = 1681; νmax = 2936, 1452, 1247, 1090, 987, 708. MS (70 eV): m/z (%) 
400/2 (M
+
+1, 100). 
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6 Summary 
β-Lactams comprise a very interesting class of compounds both from a biological and a chemical 
point of view. Besides their well-known significance as antibacterial agents in the treatment of 
bacterial infections and microbial diseases, a renewed interest has been focused on the synthesis and 
selective functionalization of β-lactams possessing diverse pharmacological properties such as 
cholesterol absorption inhibitory activity, antidiabetic, anti-HIV, antiviral, antiparkinsonian, and anti-
inflammatory activity. In addition to their indisputable importance as bioactive agents, β-lactams 
have also been widely recognized as excellent and versatile building blocks in organic chemistry for 
further elaboration toward a variety of nitrogen-containing acyclic and heterocyclic target 
compounds by exploiting the strain energy associated with the four-membered ring system. Indeed, 
selective bond cleavage of the β-lactam nucleus followed by further intruiging synthetic 
transformations renders these compounds powerful synthetic building blocks (this had led to the 
introduction of the term “β-lactam synthon method”). In that respect, the synthesis and synthetic 
applicability of four classes of β-lactams, i.e., 3-chloro-1-(2-chloroethyl)azetidin-2-ones i, 4-(2-bromo-
1,1-dimethylethyl)azetidin-2-ones ii, 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-ones iii and 3-
hydroxy-4-(1,2-dihydroxyethyl)azetidin-2-ones iv, were accomplished in this PhD thesis, resulting in 
the selective synthesis of a variety of valuable new structures with diverse potential applications. 
N
O Cl
R
Cl
N
R1
BrR2O
O
N
R1
R2O OTBDMS
O
N
O R
H H
HO
OH
R
SS
OH
Functionalized 
nitrogen-containing compounds
i ii iii iv
 
In a first approach, trans-4-aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones i, prepared via Staudinger 
reaction between N-(arylmethylidene)-(2-chloroethyl)amines and chloroacetyl chloride, were 
selectively transformed into novel 3-aryl-2-(ethylamino)propan-1-ols xi in 61-70% yield upon 
treatment with three molar equiv of LiAlH4 in THF under reflux for 48 hours. β-Aminoalcohols are 
applied extensively in organic chemistry as building blocks in designing natural and biologically active 
substances, and their chiral versions are also used in asymmetric synthesis. In order to elucidate the 
mechanistic background of this intriguing transformation, different experiments were conducted 
involving variation of the reaction time, reaction temperature, solvent and number of molar equiv of 
LiAlH4, thus revealing the intermediacy of γ-aminoalcohols v, 1-(1-aryl-2-chloro-3-
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hydroxypropyl)aziridines vi and trans-2-aryl-1-ethyl-3-(hydroxymethyl)aziridines x. From a 
mechanistic point of view, these results were rationalized considering an initial hydride-induced 1,2-
fission of the amide bond in the starting β-lactams i, followed by intramolecular displacement of the 
chloride at the primary carbon atom by the nucleophilic nitrogen, furnishing 1-(2-chloro-3-
hydroxypropyl)aziridines vi, which subsequently underwent a hydride-mediated rearrangement 
toward 1-ethyl-3-(hydroxymethyl)aziridines x. The latter peculiar transformation was explained 
considering the intramolacular activation of the aziridine moiety in chair-like intermediates vii by the 
Lewis acid character of aluminium, resulting in aziridine ring opening and consecutive nucleophilic 
attack at the chlorinated carbon atom. Alternatively, initial intramolecular displacement of chloride 
by the nucleophilic nitrogen lone pair in aziridines viii toward reactive N-spiro bis-aziridinium 
intermediates ix, followed by hydride-induced ring opening could not be excluded. Finally, 
regioselective transfer of hydride to the C-2 carbon atom of aziridines x resulted in the formation of 
3-aryl-2-(ethylamino)propan-1-ols xi. 
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xia (R = 4-Me, 61%)
xib (R = H, 70%)
xic (R = 4-Cl, 65%)
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In addition, reductive ring contraction of 3-chloro-1-(2-chloroethyl)azetidin-2-ones ia,b toward 1-(2-
chloro-3-hydroxypropyl)aziridines via,b was achieved utilizing one molar equiv of LiAlH4 at room 
temperature. 
N
O
Cl
Cl
N
HO
Cl
ia,b
1 equiv LiAlH4
THF, rt, 91 h
via (R = 4-Me, 40%)
vib (R = H, 50%)
R
R
 
The piperidine ring comprises an important structural unit in natural products and biologically active 
agents, and a broad variety of drugs accommodating this skeleton in their structure are on the 
market. Furthermore, azetidines are frequently deployed as versatile synthetic intermediates for the 
preparation of a variety of (a)cyclic amines via regio- and stereoselective transformations. In that 
respect, as an extension of the previously reported ring expansion toward 4-bromo-, 4-cyano-, 4-
azido-, and 4-fluoro-5,5-dimethylpiperidines, 2-(2-bromo-1,1-dimethylethyl)azetidines xii, prepared 
via monochloroalane reduction of the corresponding β-lactams, were used as building blocks for the 
stereoselective synthesis of novel 4-acetoxy-5,5-dimethylpiperidines xiv via transient 1-
azoniabicyclo[2.2.0]hexanes xiii. Eventually, 4-acetoxypiperidines xiv were hydrolyzed toward the 
corresponding 4-hydroxypiperidines xv, which are valuable target compounds as a vast array of 
molecules containing the 4-hydroxypiperidine skeleton has been used in the treatment of inter alia 
arrhythmia, hypotension, tuberculosis, diarrhea, rheumatoid arthritis, multiple sclerosis and Crohn’s 
disease.  
xiva (R1 = allyl, R2 = Bn, 64%)
xivb (R1 = tBu, R2 = Bn, 71%)
xivc (R1 = iPr, R2 = Ph, 62%)
xivd (R1 = cHex, R2 = Ph, 72%)
N
R1
R2O Br
N
R1
R2O
O
10 equiv NaOAc
DMSO, 100 °C, 18 h
O
xiia-d
N
R1
R2O
AcO
xiiia-d
N
R1
R2O
OH
3 equiv LiOH.H2O
MeOH, ∆, 15 h
H
xva (R1 = allyl, R2 = Bn, 62%)
xvb (R1 = tBu, R2 = Bn, 66%)
xvc (R1 = iPr, R2 = Ph, 86%)
xvd (R1 = cHex, R2 = Ph, 71%)
 
Chapter 6  Summary 
142 
 
In a third part of this work, the synthesis of the dinor-dimethyl analogues of the aforementioned 5,5-
dimethylpiperidines was investigated, as, given the broad medicinal relevance of piperidines in 
general, the absence of a 5,5-gem-dimethyl group might modify the related bioactivity due to 
changes in conformational and stereochemical properties. In order to achieve this goal, special 
attention was devoted to the diastereoselective Staudinger synthesis of 4-[2-(tert-
butyldimethylsilyloxy)ethyl]azetidin-2-ones iii from (E)-N-[3-(tert-
butyldimethylsilyloxy)propylidene]amines xvi, inevitable leading to the formation of mixtures of β-
lactams iii and N-acyl enamines xvii (22/78 – 83/17). Because of the combination of a strained four-
membered ring system, a nucleophilic nitrogen lone pair (after elaboration) and an electrophilic 
center in the side chain, β-lactams iii, which were isolated in pure form by column chromatography 
on silica gel, proved to be eligible substrates for further elaboration toward a variety of 
azaheterocyclic compounds as they were converted in 2-(2-mesyloxyethyl)azetidines xix upon 
consecutive monochloroalane reduction, TBAF-mediated deprotection, and mesylation. In this way, 
mesylated azetidines xix were prepared in high yields and purity as the dinor-dimethyl variants of 
brominated azetidines xii. 
N
H
R1
OTBDMS N
R2O
O R1
OTBDMS
+
1.3 equiv
3 equiv Et3N
CH2Cl2, rt, 15 h
R2O Cl
O
(22/78 - 83/17)
N
R1R2O
O
OTBDMS
iiia (R1 = iPr, R2 = Ph, 47%)
iiib (R1 = iPr, R2 = Bn, 35%)
iiic (R1 = cHex, R2 = Bn, 55%)
iiid (R1 = iBu, R2 = Bn, 5%) xviid (R1 = iBu, R2 = Bn, 66%)
1 equiv AlH2Cl
Et2O, rt, 1 h; 0 °C, 2 h
1.1 equiv TBAF
THF, 0 °C     rt, 5 h
N
R2O
R1
OH
N
R2O
R1
OMs
1.05 equiv MsCl
1.1 equiv Et3N
0.1 equiv DMAP
1)
2)
CH2Cl2, 0 °C, 3 h
xviiia (R1 = iPr, R2 = Ph, 48%)
xviiib (R1 = iPr, R2 = Bn, 49%)
xviiic (R1 = cHex, R2 = Bn, 50%)
xixa (R1 = iPr, R2 = Ph, 90%)
xixb (R1 = iPr, R2 = Bn, 88%)
xixc (R1 = cHex, R2 = Bn, 85%)
xvia (R1 = iPr)
xvib (R1 = cHex)
xvic (R1 = iBu)
xvid (R1 = allyl)
xvie (R1 = nPr)
xvif (R1 = nBu)
xvig (R1 = Bn)
xvih (R1 = Ph)
 
In the next phase, the reactivity of 2-(2-mesyloxyethyl)azetidines xix toward different nucleophiles 
was evaluated for the first time, resulting in the stereoselective ring enlargement toward a variety of 
4-acetoxy- xxiii, 4-hydroxy- xxiv, 4-bromo- xx and 4-(formyloxy)piperidines xxv through 
regioselective SN2 ring opening of intermediate 1-azoniabicyclo[2.2.0]hexanes xxvi. It has to be 
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mentioned that in all cases small amounts of 2-vinylazetidines (2-9%) were observed in the crude 
reaction mixtures as well. This approach constitutes a convenient alternative for the above-
mentioned preparation of 3,4-disubstituted 5,5-dimethylpiperidines, providing an easy access to the 
5,5-dinor-dimethyl analogues as valuable templates in medicinal chemistry. Furthermore, a new 
entry into the piperidin-3-one scaffold is provided through dehydrobromination of 4-bromo-3-
(phenoxy- or benzyloxy)piperidines xx followed by acid hydrolysis. In addition to the experimental 
results, the intermediacy of transient 1-azoniabicyclo[2.2.0]hexanes xxvi in these four- to six-
membered ring expansion reactions was further verified by means of high-level computational 
analysis (performed at the Centre for Molecular Modeling, UGent). 
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MeOH, ∆, 1 h
xxiiia (R1 = iPr, R2 = Ph, 63%)
xxiiib (R1 = iPr, R2 = Bn, 55%)
xxiiic (R1 = cHex, R2 = Bn, 66%)
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xxivc (R1 = cHex, R2 = Bn, 60%)
OH
N
R1
R2O
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xxva (R1 = iPr, R2 = Ph, 53%)
xxvb (R1 = iPr, R2 = Bn, 68%)
xxvc (R1 = cHex, R2 = Bn, 70%)
O
H
DMF
80 °C, 3 h
 
Attempts toward the selective synthesis of 4-fluoro-5,5-dinor-dimethylpiperidines failed under the 
applied reaction conditions and clearly needs further elaboration.  
In a fourth part of this work, the intrinsic reactivity of 2-(2-mesyloxyethyl)azetidines xix upon heating 
in DMSO in the presence of K2CO3 was envisaged, resulting in the selective formation of piperidin-4-
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ones xxviii via DMSO-mediated regioselective ring opening of bicyclic azetidinium intermediates xxvi. 
From a biological point of view, piperidin-4-ones represent an important class of azaheterocycles 
exhibiting antiviral, antitumor, analgesic, local anaesthetic, antimicrobial, bactericidal, fungicidal, 
herbicidal, insecticidal, antihistaminic, anti-inflammatory, anticancer, CNS stimulant and depressant 
activities. In addition, the synthetic applicability of the latter 5,5-dinor-dimethylpiperidin-4-ones 
xxviii was demonstrated by means of both a chemical and an enzymatic reduction. Whereas the 
NaBH4-induced reduction is characterized by a cis-diastereoselectivity, the alcohol dehydrogenase-
mediated reductions proceeded with S- or R-enantioselectivity at the carbonyl functionality. 
N
R1
R2O OMes
xixa-c
N
R1
R2O
N
R1
R2O
O
S Me
MeB
H
S
O
Me Me
-Me2S
xxvia-c xxviia-c
H
5 equiv K2CO3
N
R1
R2O
O
xxviiia (R1 = iPr, R2 = Ph, 43%)
xxviiib (R1 = iPr, R2 = Bn, 45%)
xxviiic (R1 = cHex, R2 = Bn, 48%)
DMSO, 100 °C, 18 h N
O
OH
*
*
alcohol 
dehydrogenase
R1 = iPr
R2 = Bn
xxix (43-49%)
2 equiv NaBH4
MeOH, ∆, 2 h N
R1
R2O
OH
xxiva (R1 = iPr, R2 = Ph, 88%)
xxivb (R1 = iPr, R2 = Bn, 79%)
xxivc (R1 = cHex, R2 = Bn, 73%)
 
Next, the synthesis of novel unconventional 3,4-fused (C-fused) bicyclic β-lactams as potential 
antimicrobial agents and/or β-lactamase inhibitors was studied. 3-Benzyloxy-4-(2-mesyloxyethyl)-β-
lactams iii were transformed into novel cis-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones xxxii in 52-62% 
overall yield through hydrogenolysis and subsequent intramolecular nucleophilic substitution by 
means of sodium hydride addition. Conversion of the latter bicyclic β-lactams xxxii into cis-3-
aminotetrahydrofuran-2-carboxylates xxxiii was accomplished in 66-70% yield by means of acidic 
methanolysis. β-Amino acids comprise a valuable class of compounds because of their broad 
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biological and synthetic applicability. In particular, cyclic β-amino acids are present in a variety of 
natural products, and β-peptides form much more stable secondary structures than their α-peptidic 
natural counterparts. This approach comprises a valuable alternative for the known preparation of 
4,4-dimethyl-2-oxa-6-azabicyclo[3.2.0]heptan-7-ones and 3-amino-4,4-dimethyletrahydrofuran-2-
carboxylates, thus furnishing their dinor-dimethyl analogues.  
N
BnO
O R1
OTBDMS
1.1 equiv TBAF
THF, 0 °C     rt, 5 h N
BnO
R1
OH
N
BnO
R1
OMs
1.05 equiv MsCl
1.1 equiv Et3N
0.1 equiv DMAP
CH2Cl2, 0 °C, 3 h
iiib,c xxxa (R1 = iPr, 49%)
xxxb (R1 = cHex, 60%)
O O
xxxia (R1 = iPr, 89%)
xxxib (R1 = cHex, 86%)
20% Pd/C, H2
5 bar, MeOH, rt, 60 h
1 equiv NaH
THF, ∆, 15 h
N
O
R1O
H H
xxxiia (R1 = iPr, 52%)
xxxiib (R1 = cHex, 62%)
1)
2)O
HN R1
OMe
O
xxxiiia (R1 = iPr, 66%)
xxxiiib (R1 = cHex, 70%)
5 equiv 
HCl/MeOH (3 M)
MeOH, ∆, 24 h
 
In a final part of this PhD thesis, the reactivity of 3-hydroxy-4-(1,2-dihydroxyethyl)-β-lactams iv, 
prepared through consecutive acidic hydrolysis of the acetal functionality and hydrogenolysis of the 
benzylether substituent in β-lactams xxxvi, with regard to the oxidant sodium periodate was 
evaluated for the first time, unexpectedly resulting in the exclusive formation of novel 2-hydroxy-1,4-
oxazin-3-ones xxxvii, most probably via a C3-C4 bond cleavage of the intermediate 4-formyl-3-
hydroxy-β-lactams followed by ring enlargement. This transformation is indeed peculiar, as 3-alkoxy- 
and 3-phenoxy-4-(1,2-dihydroxyethyl)-β-lactams are known to be oxidized to the corresponding 4-
formyl-β-lactam derivatives under the same reaction conditions without subsequent rearrangement 
into six-membered heterocycles. In addition to the experimental results, the rationale of this novel 
ring-expansion reaction was further validated by means of theoretical calculations performed at the 
Centre for Molecular Modeling (UGent). 
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O
H O
O 1 equiv RNH22 equiv MgSO4
 
CH2Cl2, rt, 2 h
1 equiv pTsOH.H2O
THF/H2O (1/1), ∆, 4 h
R
xxxiv
N
O R
H H
BnO O
O
R
SS
1)
2)NO R
H H
HO
OH
R
SS
1.3 equiv BnOCH2COCl
3 equiv Et3N 
CH2Cl2, 0 °C - rt, 15 h
20% Pd/C, H2
5 bar, MeOH, rt, 18 h
OH
N
H O
O
S
R
H H H
de 82-90%
2 equiv NaIO4
N
O
R
HO
O
xxxviia (R = iPr, 69%)
xxxviib (R = iBu, 73%)
xxxviic (R = nBu, 75%)
xxxviid (R = cHex, 94%)
xxxviie (R = iPent, 70%)
xxxva (R = iPr, 93%)
xxxvb (R = iBu, 94%)
xxxvc (R = nBu, 95%)
xxxvd (R = cHex, 90%)
xxxve (R = nPr, 92%)
xxxvf (R = iPent, 85%)
xxxvia (R = iPr, 81%)
xxxvib (R = iBu, 50%)
xxxvic (R = nBu, 43%)
xxxvid (R = cHex, 65%)
xxxvie (R = nPr, 70%)
xxxvif (R = iPent, 50%)
iva (R = iPr, 83%)
ivb (R = iBu, 74%)
ivc (R = nBu, 63%)
ivd (R = cHex, 88%)
ive (R = nPr, 68%)
ivf (R = iPent, 93%)
NaHCO3/CH2Cl2 (1/15), rt, 2 h
 
In order to show the capacity of this new ring-expanion reaction to prepare a broad array of six-
membered heterocycles bearing chemical diversity, 2-hydroxy-1,4-oxazin-3-ones xxxvii were used as 
building blocks for the selective synthesis of novel heterocyclic compounds. 2-Hydroxy-1,4-oxazin-3-
ones xxxvii were converted into novel 2-benzoyloxy-1,4-oxazin-3-ones xxxix via protection of the 
hydroxyl moiety upon treatment with benzoylchloride. The latter heterocycles xxxix were then used 
as eligible substrates for the synthesis of 2-benzoyloxymorpholin-3-ones xxxx in 69-89% yield. 
Morpholin-3-ones comprise a very interesting class of compounds as they are for example used as 
cornea permeable calpain inhibitors exhibiting anticataract properties, potassium channel openers 
useful in the treatment of urinary incontinence, and non-peptide ligands with high affinity and 
selectivity for tachykinin receptors. Furthermore, with the intention to incorporate fluorine in a site-
selective manner, 2-hydroxy-1,4-oxazin-3-ones xxxvii were employed as substrates for the 
construction of 2-fluoro-1,4-oxazin-3-ones xxxxi and 2-benzoyloxy-6-bromo-5-fluoromorpholin-3-
ones xxxxii and xxxxiii upon treatment with Morph-DAST and triethylamine trihydrofluoride, 
respectively. Finally, 2-hydroxy-1,4-oxazin-3-ones xxxvii smoothly rearranged into 1H-pyrazin-2-ones 
xxxviii in 30-51% yield using NH4OAc and HOAc in ethyl acetate.  
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N
O
R
HO
O
xxxviia-d
N
N
O
12 equiv NH4OAc
10 equiv HOAc
EtOAc, ∆, 24 h
R
xxxviiia (R = iPr, 45%)
xxxviiib (R = iBu, 51%)
xxxviiic (R = nBu, 30%)
3 equiv PhCOCl
3 equiv Et3N
CH2Cl2, 0 °C, 2 h
N
O
R
O
O
O
MeOH, rt, 18 h N
O
R
O
O
O
20% Pd/C
H2, 5 bar
xxxixa (R = iPr, 45%)
xxxixb (R = iBu, 64%)
xxxixc (R = nBu, 93%)
xxxixd (R = cHex, 34%)
xxxxa (R = iPr, 69%)
xxxxb (R = iBu, 79%)
xxxxc (R = nBu, 82%)
xxxxd (R = cHex, 89%)
N
O
R
F
O
2 equiv Morph-DAST
xxxxia (R = iPr, 87%)
xxxxib (R = iBu, 78%)
xxxxic (R = nBu, 94%)
xxxxid (R = cHex, 90%)
N
O
R
O
O
O
N
O
R
O
O
O
2.5 equiv Et3N.3HF
1.5 equiv NBS
CH2Cl2, rt, 24 h
F
Br Br
F
xxxxiiia-d
+
xxxxii/xxxxiii
67-80/20-33
(79-94%)
xxxxiia (R = iPr, 63%, dr >99/1)
xxxxiib (R = iBu, 33%, dr >99/1)
xxxxiic (R = nBu, 42%, dr >99/1)
xxxxiid (R = cHex, 67%, dr >99/1)
CH2Cl2, -78 °C to rt, 5 h
 
In this PhD thesis, the high synthetic potential of diversely functionalized azetidin-2-ones as synthons 
in organic chemistry has been illustrated by means of their elaboration toward a vast number of 
novel acyclic and cyclic nitrogen-containing compounds, including β-aminoalcohols, aziridines, 
azetidines, piperidines, piperidin-4-ones, oxazin-3-ones, morpholin-3-ones, pyrazinones, cyclic β-
amino acids and bicyclic β-lactams. It is clear that, although the β-lactam nucleus has been 
extensively studied in the past, the impressive variety of transformations which can be derived from 
this system renders β-lactam chemistry a very intriguing and promising area of research for the 
synthesis of different types of novel (azaheterocyclic) compounds.  
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7 Samenvatting 
β-Lactamen vormen een zeer interessante klasse van verbindingen, zowel vanuit een biologisch als 
vanuit een chemisch standpunt. Zo vormen β-lactamen gegeerde targets in de geneeskunde wegens 
hun uitgesproken antibiotische eigenschappen en het klassieke probleem van resistentievorming. 
Bovendien vertonen verschillende β-lactamen andere belangrijke biologische eigenschappen; ze 
worden bijvoorbeeld gebruikt als cholesterolabsorptie-inhibitoren en ontstekingsremmers en bij de 
behandeling van onder meer diabetes, HIV, en parkinson. Naast hun waarde als biologisch actieve 
verbindingen worden β-lactamen algemeen beschouwd als uitstekende bouwstenen in de organische 
chemie voor verdere omzetting tot een brede waaier aan stikstofhoudende acyclische en 
heterocyclische verbindingen door gebruik te maken van de spanningsenergie geassocieerd met de 
vierringstructuur. Selectieve splitsing van één der bindingen van de β-lactamkern gevolgd door 
verdere interessante synthetische omzettingen maakt deze verbindingen krachtige synthetische 
bouwstenen (dit heeft geleid tot de introductie van de term “β-lactam synthon method”). Vanuit dit 
standpunt werden in dit doctoraatsonderzoek de synthese en transformatie van vier klassen van β-
lactamen, namelijk 3-chloor-1-(2-chloorethyl)azetidin-2-onen i, 4-(2-broom-1,1-
dimethylethyl)azetidin-2-onen ii, 4-[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-onen iii en 3-
hydroxy-4-(1,2-dihydroxyethyl)azetidin-2-onen iv, voltooid, resulterend in de selectieve synthese van 
verscheidene waardevolle nieuwe verbindingen met diverse potentiële toepassingen. 
N
O Cl
R
Cl
N
R1
BrR2O
O
N
R1
R2O OTBDMS
O
N
O R
H H
HO
OH
R
SS
OH
Gefunctionaliseerde 
stikstofbevattende verbindingen
i ii iii iv
 
In een eerste luik werden trans-4-aryl-3-chloor-1-(2-chloorethyl)-β-lactamen i, bereid via 
Staudingerreactie tussen N-(arylmethylideen)-(2-chloorethyl)aminen en chlooracetylchloride, 
selectief omgezet tot nieuwe 3-aryl-2-(ethylamino)propan-1-olen xi in 61-70% rendement door 
behandeling met drie molaire equiv LiAlH4 in THF onder reflux voor 48 uur. β-Aminoalcoholen 
worden veelvuldig ingezet in de organische chemie als synthons in de bereiding van natuurproducten 
en biologisch actieve stoffen, en chirale β-aminoalcoholen worden ook gebruikt in katalytische 
asymmetrische synthese. Om de mechanistische achtergrond van deze intrigerende transformatie op 
te helderen werden verschillende experimenten uitgevoerd door variatie van de reactietijd, 
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reactietemperatuur, solvent en aantal molaire equiv LiAlH4, aldus wijzend op de tussenkomst van 
intermediaire γ-aminoalcoholen v, 1-(1-aryl-2-chloor-3-hydroxypropyl)aziridinen vi en trans-2-aryl-1-
ethyl-3-(hydroxymethyl)aziridinen x in het reactiemechanisme. Vanuit mechanistisch oogpunt werd 
een initiële hydride-geïnduceerde splitsing van de amidebinding in β-lactamen i gevolgd door 
intramoleculaire substitutie van chloride door aanval van het nucleofiele stikstofatoom op het 
primair gechloreerd koolstofatoom, hetgeen aanleiding gaf tot de selectieve vorming van 1-(2-
chloor-3-hydroxypropyl)aziridinen vi, dewelke vervolgens via een hydride-geïnduceerde omlegging 
werden omgezet in 1-ethyl-3-(hydroxymethyl)aziridinen x. Deze opmerkelijke transformatie werd 
verklaard aan de hand van intramoleculaire activatie van de aziridinering door het Lewiszuur karakter 
van aluminium ter vorming van stoelvormintermediairen vii, uiteindelijk resulterend in aziridine 
ringopening en daaropvolgende nucleofiele aanval op het secundair gechloreerd koolstofatoom. Als 
alternatieve route kan een initiële intramoleculaire substitutie van chloride door het vrij 
elektronenpaar van stikstof in aziridinen viii aanleiding geven tot de vorming van reactieve N-spiro-
bis-aziridiniumintermediaten ix, dewelke vervolgens een hydride-geïnduceerde ringopening 
ondergaan. Uiteindelijk werden 3-aryl-2-(ethylamino)propan-1-olen xi bekomen via regioselectieve 
hydride-transfer. 
N
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Cl
Cl
N
O
Cl
N
O
HO
HNR
H
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N
Cl
Cl
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H
H
H
H
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δ
R R
R
3 equiv LiAlH4
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H
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Al
H
H
H
Al
HH
H
Route A
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xia (R = 4-Me, 61%)
xib (R = H, 70%)
xic (R = 4-Cl, 65%)
xid (R = 3-OMe, 68%)
R R
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Daarnaast werden 1-(2-chloor-3-hydroxypropyl)aziridines via,b selectief gevormd in 40-50% 
rendement na behandeling van 3-chloor-1-(2-chloorethyl)azetidin-2-ones ia,b met één equiv LiAlH4 
bij kamertemperatuur. 
N
O
Cl
Cl
N
HO
Cl
ia,b
1 equiv LiAlH4
THF, kt, 91 h
via (R = 4-Me, 40%)
vib (R = H, 50%)
R
R
 
De piperidinering vormt een belangrijke structurele eenheid in natuurproducten en biologisch 
actieve agentia, en een grote variëteit aan geneesmiddelen bevatten deze bouwsteen in hun 
structuur. Daarnaast worden azetidinen vaak aangewend als veelvuldige precursoren in de synthese 
van (a)cyclische aminen, via regio- en stereoselectieve transformaties. In dat opzicht werden, als 
uitbreiding op de eerder bestudeerde ringexpansie tot 4-broom-, 4-cyaan-, 4-azide- en 4-fluor-5,5-
dimethylpiperidinen, 2-(2-broom-1,1-dimethylethyl)azetidinen xii, bereid uit de overeenkomstige β-
lactamen via monochlooralaanreductie, ingezet als synthetische bouwstenen voor de 
stereoselectieve synthese van nieuwe biologisch relevante 4-acetoxy-5,5-dimethylpiperidinen xiv via 
transiente 1-azoniabicyclo[2.2.0]hexanen xiii. Uiteindelijk werden 4-acetoxypiperidinen xiv 
gehydrolyseerd tot de overeenkomstige 4-hydroxypiperidinen xv, dewelke als waardevolle 
structurele eenheden worden gebruikt in de behandeling van onder meer hartritmestoornissen, 
hypotensie, tuberculose, diarree, reumatoïde artritis, multiple sclerose, en de ziekte van Crohn. 
xiva (R1 = allyl, R2 = Bn, 64%)
xivb (R1 = tBu, R2 = Bn, 71%)
xivc (R1 = iPr, R2 = Ph, 62%)
xivd (R1 = cHex, R2 = Ph, 72%)
N
R1
R2O Br
N
R1
R2O
O
10 equiv NaOAc
DMSO, 100 °C, 18 h
O
xiia-d
N
R1
R2O
AcO
xiiia-d
N
R1
R2O
OH
3 equiv LiOH.H2O
MeOH, ∆, 15 h
H
xva (R1 = allyl, R2 = Bn, 62%)
xvb (R1 = tBu, R2 = Bn, 66%)
xvc (R1 = iPr, R2 = Ph, 86%)
xvd (R1 = cHex, R2 = Ph, 71%)
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In een derde luik van dit werk werd bijzondere aandacht besteed aan de stereoselectieve bereiding 
van de overeenkomstige dinor-dimethylanaloga van bovenvermelde 5,5-dimethylpiperidinen, daar, 
gezien de belangrijke biologische eigenschappen van de piperidinering, de afwezigheid van een 5,5-
dimethylgroep een grote invloed kan uitoefenen op de bioactiviteit ten gevolge van wijzigingen in 
conformationele en stereochemische eigenschappen. Teneinde deze doelstelling te realiseren 
werden nieuwe methodologieën ontwikkeld voor de diastereoselectieve Staudingersynthese van 4-
[2-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-onen iii uitgaande van (E)-N-[3-(tert-
butyldimethylsilyloxy)propylidene]aminen xvi, hetgeen onvermijdelijk resulteerde in de vorming van 
mengsels van β-lactamen iii en N-acylenaminen xvii (22/78 – 83/17). Omwille van de aanwezigheid 
van een gespannen vierringstructuur, een nucleofiel stikstofatoom (na omzetting) en een elektrofiel 
centrum in de zijketen, bleken β-lactamen iii, dewelke werden geïsoleerd via kolomchromatografie 
op silicagel, uitstekende substraten te zijn voor verdere omzetting tot andere azaheterocyclische 
verbindingen waaronder 2-(2-mesyloxyethyl)azetidinen xix via opeenvolgende reductie met 
monochlooralaan, ontscherming met TBAF en mesylering. Op deze manier werden gemesyleerde 
azetidinen xix aangemaakt in hoge rendementen en zuiverheid als de dinor-dimethylvarianten van 
gebromineerde azetidinen xii. 
N
H
R1
OTBDMS N
R2O
O R1
OTBDMS
+
1.3 equiv
3 equiv Et3N
CH2Cl2, kt, 15 h
R2O Cl
O
(22/78 - 83/17)
N
R1R2O
O
OTBDMS
iiia (R1 = iPr, R2 = Ph, 47%)
iiib (R1 = iPr, R2 = Bn, 35%)
iiic (R1 = cHex, R2 = Bn, 55%)
iiid (R1 = iBu, R2 = Bn, 5%) xviid (R1 = iBu, R2 = Bn, 66%)
1 equiv AlH2Cl
Et2O, kt, 1 h; 0 °C, 2 h
1.1 equiv TBAF
THF, 0 °C     kt, 5 h
N
R2O
R1
OH
N
R2O
R1
OMs
1.05 equiv MsCl
1.1 equiv Et3N
0.1 equiv DMAP
1)
2)
CH2Cl2, 0 °C, 3 h
xviiia (R1 = iPr, R2 = Ph, 48%)
xviiib (R1 = iPr, R2 = Bn, 49%)
xviiic (R1 = cHex, R2 = Bn, 50%)
xixa (R1 = iPr, R2 = Ph, 90%)
xixb (R1 = iPr, R2 = Bn, 88%)
xixc (R1 = cHex, R2 = Bn, 85%)
xvia (R1 = iPr)
xvib (R1 = cHex)
xvic (R1 = iBu)
xvid (R1 = allyl)
xvie (R1 = nPr)
xvif (R1 = nBu)
xvig (R1 = Bn)
xvih (R1 = Ph)
 
Vervolgens werd het reactiviteitsprofiel van 2-(2-mesyloxyethyl)azetidinen xix ten opzichte van 
verschillende nucleofielen in detail bestudeerd teneinde inzicht te verwerven in hun synthetisch 
potentieel, hetgeen resulteerde in de stereoselectieve ringexpansie tot biologisch interessante 4-
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acetoxy- xxiii, 4-hydroxy- xxiv, 4-broom- xx en 4-(formyloxy)piperidinen xxv via regioselectieve SN2 
ringopening van intermediaire bicyclische azetidiniumionen xxvi. Hierbij dient opgemerkt te worden 
dat in alle gevallen kleine hoeveelheden van de overeenkomstige 2-vinylazetidinen (2-9%) aanwezig 
waren in de reactiemengsels. Deze benadering vormt een waardig alternatief voor de aanwezigheid 
van de gem-dimethylgroep in de hierboven onderzochte 3,4-digesubstitueerde 5,5-
dimethylpiperidinen, en vormt aldus een efficiënte toegang tot de 5,5-dinor-dimethylanaloga als 
waardevolle templates in de medicinale chemie. Bovendien werd een nieuwe toetreding tot de 
interessante klasse der piperidin-3-onen uitgewerkt via dehydrobrominering van 4-bromo-3-
(phenoxy- or benzyloxy)piperidinen xx gevolgd door zure hydrolyse. Deze experimentele resultaten 
werden onderbouwd met theoretische berekeningen (uitgevoerd aan het centrum voor Moleculaire 
Modellering, UGent), hetgeen de aanwezigheid van bicyclische azetidiniumionen xxvi in de 
ringexpansie van azetidinen xix tot piperidinen xx, xxiii en xxv ondersteunde. 
N
R2O
R1
OMs
xixa-c
N
R2O
R1
H
Nu
xxvia-c
N
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R2O
Br
2 equiv LiBr
CH3CN, ∆, 15 h
4 equiv NaH
N
R2O
DMSO, 150 °C, 15 h
2 M HCl, H2O
N
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O
xxa (R1 = iPr, R2 = Ph, 47%)
xxb (R1 = iPr, R2 = Bn, 62%)
xxc (R1 = cHex, R2 = Bn, 65%)
xxia (R2 = Ph, 56%)
xxib (R2 = Bn, 60%) (78-85%)
40 °C, 40 h
R1 = iPr
N
R1
R2O
O
2 equiv NaOAc
CH3CN, ∆, 15 h
2 equiv K2CO3
N
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R2O
MeOH, ∆, 1 h
xxiiia (R1 = iPr, R2 = Ph, 63%)
xxiiib (R1 = iPr, R2 = Bn, 55%)
xxiiic (R1 = cHex, R2 = Bn, 66%)
O
xxiva (R1 = iPr, R2 = Ph, 56%)
xxivb (R1 = iPr, R2 = Bn, 70%)
xxivc (R1 = cHex, R2 = Bn, 60%)
OH
N
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R2O
O
xxva (R1 = iPr, R2 = Ph, 53%)
xxvb (R1 = iPr, R2 = Bn, 68%)
xxvc (R1 = cHex, R2 = Bn, 70%)
O
H
DMF
80 °C, 3 h
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Pogingen tot de selectieve synthese van 4-fluor-5,5-dinor-dimethylpiperidinen faalden echter onder 
de gebruikte reactieomstandigheden en vergen duidelijk verder onderzoek. 
In een vierde deel van dit werk werd, als uitbreiding op de eerder bestudeerde ringexpansie-oxidatie 
van 2-(broomethyl)azetidinen xii, de intrinsieke reactiviteit van 2-(2-mesyloxyethyl)azetidinen xix ten 
aanzien van verwarmen in DMSO in aanwezigheid van K2CO3 onderzocht, hetgeen aanleiding gaf tot 
de selectieve vorming van piperidin-4-onen xxviii via DMSO-geïnduceerde regioselectieve 
ringopening van bicyclische azetidiniumintermediairen xxvi. Vanuit biologisch oogpunt vormen 
piperidin-4-onen een belangrijke klasse van azaheterocyclische verbindingen met onder meer 
antivirale, antitumor, pijnstillende, antimicrobiële, fungicidale, herbicidale, en ontstekingsremmende 
activiteiten. Bovendien werd het synthetisch nut van deze 5,5-dinor-dimethylpiperidin-4-onen xxviii 
aangetoond door middel van zowel een chemische als een enzymatische reductie van 3-benzyloxy-1-
isopropylpiperidin-4-on xxviiib. Daar waar de NaBH4-geïnduceerde reductie werd gekenmerkt door 
een cis-diastereoselectiviteit, verliep de alcohol dehydrogenase-geïnduceerde reductie met een S- of 
R-enantioselectiviteit ter hoogte van de carbonylfunctionaliteit. 
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DMSO, 100 °C, 18 h N
O
OH
*
*
alcohol 
dehydrogenase
R1 = iPr
R2 = Bn
xxix (43-49%)
2 equiv NaBH4
MeOH, ∆, 2 h N
R1
R2O
OH
xxiva (R1 = iPr, R2 = Ph, 88%)
xxivb (R1 = iPr, R2 = Bn, 79%)
xxivc (R1 = cHex, R2 = Bn, 73%)
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In een volgende fase werd de aanmaak van nieuwe niet-conventionele bicyclische β-lactamen als 
potentieel antimicrobiële verbindingen en/of β-lactamase-inhibitoren beoogd. 3-Benzyloxy-4-(2-
mesyloxyethyl)-β-lactamen iii werden omgezet tot nieuwe cis-2-oxa-6-azabicyclo[3.2.0]heptan-7-
onen xxxii in 52-62% totaalrendement via hydrogenolyse gevolgd door intramoleculaire nucleofiele 
substitutie door additie van NaH. Via zure methanolyse werden de gesynthetiseerde bicyclische 
verbindingen xxxii vervolgens omgezet tot de overeenkomstige cis-3-aminotetrahydrofuran-2-
carboxylaten xxxiii in 66-70% rendement. β-Aminozuren vormen een zeer waardevolle klasse van 
verbindingen, die zowel van synthetisch als biologisch nut zijn. Meer specifiek zijn cyclische β-
aminozuren als basisskelet aanwezig in een brede waaier aan natuurproducten, en β-peptiden 
vormen stabielere secundaire structuren in vergelijking met hun α-peptide natuurlijke tegenhangers. 
Deze benadering vormt een waardig alternatief voor de gekende synthese van 4,4-dimethyl-2-oxa-6-
azabicyclo[3.2.0]heptan-7-onen en 3-amino-4,4-dimethyletrahydrofuran-2-carboxylaten, resulterend 
in de efficiënte bereiding van de overeenkomstige dinor-dimethylanaloga. 
N
BnO
O R1
OTBDMS
1.1 equiv TBAF
THF, 0 °C     kt, 5 h N
BnO
R1
OH
N
BnO
R1
OMs
1.05 equiv MsCl
1.1 equiv Et3N
0.1 equiv DMAP
CH2Cl2, 0 °C, 3 h
iiib,c xxxa (R1 = iPr, 49%)
xxxb (R1 = cHex, 60%)
O O
xxxia (R1 = iPr, 89%)
xxxib (R1 = cHex, 86%)
20% Pd/C, H2
5 bar, MeOH, kt, 60 h
1 equiv NaH
THF, ∆, 15 h
N
O
R1O
H H
xxxiia (R1 = iPr, 52%)
xxxiib (R1 = cHex, 62%)
1)
2)O
HN R1
OMe
O
xxxiiia (R1 = iPr, 66%)
xxxiiib (R1 = cHex, 70%)
5 equiv 
HCl/MeOH (3 M)
MeOH, ∆, 24 h
 
In een laatste deel van deze thesis werd de reactiviteit van 3-hydroxy-4-(1,2-dihydroxyethyl)-β-
lactamen iv, bereid via zure hydrolyse van de acetaaleenheid gevolgd door hydrogenolyse van de 
benzylethersubstituent in β-lactamen xxxvi, ten opzichte van het oxidant natriumperiodaat voor het 
eerst uitgebreid geëvalueerd, hetgeen onverwacht aanleiding gaf tot de exclusieve vorming van 
nieuwe 2-hydroxy-1,4-oxazin-3-onen xxxvii, meest waarschijnlijk via splitsing van de C3-C4-binding in 
intermediaire 4-formyl-3-hydroxy-β-lactamen gevolgd door ringexpansie. Deze transformatie is 
inderdaad merkwaardig gezien 3-alkoxy- en 3-fenoxy-4-(1,2-dihydroxyethyl)-β-lactamen onder 
identieke omstandigheden worden omgezet tot de overeenkomstige 4-formyl-β-lactamderivaten 
zonder verdere omleggingen. Deze resultaten werden onderbouwd met theoretische berekeningen 
(uitgevoerd aan het centrum voor Moleculaire Modellering, UGent).  
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O
H O
O 1 equiv RNH22 equiv MgSO4
 
CH2Cl2, kt, 2 h
1 equiv pTsOH.H2O
THF/H2O (1/1), ∆, 4 h
R
xxxiv
N
O R
H H
BnO O
O
R
SS
1)
2)
N
O R
H H
HO
OH
R
SS
1,3 equiv BnOCH2COCl
3 equiv Et3N 
CH2Cl2, 0 °C - kt, 15 h
20% Pd/C, H2
5 bar, MeOH, kt, 18 h
OH
N
H O
O
S
R
H H H
de 82-90%
2 equiv NaIO4
N
O
R
HO
O
xxxviia (R = iPr, 69%)
xxxviib (R = iBu, 73%)
xxxviic (R = nBu, 75%)
xxxviid (R = cHex, 94%)
xxxviie (R = iPent, 70%)
xxxva (R = iPr, 93%)
xxxvb (R = iBu, 94%)
xxxvc (R = nBu, 95%)
xxxvd (R = cHex, 90%)
xxxve (R = nPr, 92%)
xxxvf (R = iPent, 85%)
xxxvia (R = iPr, 81%)
xxxvib (R = iBu, 50%)
xxxvic (R = nBu, 43%)
xxxvid (R = cHex, 65%)
xxxvie (R = nPr, 70%)
xxxvif (R = iPent, 50%)
iva (R = iPr, 83%)
ivb (R = iBu, 74%)
ivc (R = nBu, 63%)
ivd (R = cHex, 88%)
ive (R = nPr, 68%)
ivf (R = iPent, 93%)
NaHCO3/CH2Cl2 (1/15), kt, 2 h
 
Vervolgens werden de gesynthetiseerde 2-hydroxy-1,4-oxazin-3-onen xxxvii aan een uitgebreide 
reactiviteitsstudie onderworpen met het oog op de selectieve aanmaak van heterocyclische targets, 
waarbij verschillende strategieën op hun haalbaarheid werden getest. Vooreerst werden 2-hydroxy-
1,4-oxazin-3-onen xxxvii gebruikt als geschikte substraten voor de bereiding van nieuwe 2-
benzoyloxy-1,4-oxazin-3-onen xxxix via bescherming van de hydroxylgroep door behandeling met 
benzoylchloride. Deze gesynthetiseerde heterocyclische verbindingen xxxix werden dan ingezet in de 
synthese van 2-benzoyloxymorfolin-3-onen xxxx in 69-89% rendement. Morfolin-3-onen vertonen 
interessante biologische eigenschappen; zo staan ze onder meer in de belangstelling als hoornvlies 
doorlatende calpaïne-remmers met anticatarct eigenschappen, kaliumkanaal openers bruikbaar in de 
behandeling van urine-incontinentie, en niet-peptide liganden met hoge affiniteit en selectiviteit 
voor tachykinine receptoren. Met het oog op het inbouwen van fluor op een plaatsspecifieke wijze 
werden 2-hydroxy-1,4-oxazin-3-onen xxxvii behandeld met Morf-DAST en triethylamine 
trihydrofluoride voor de selectieve constructie van respectievelijk 2-fluor-1,4-oxazin-3-onen xxxxi en 
2-benzoyloxy-6-broom-5-fluormorpholin-3-onen xxxxii en xxxxiii. Ten slotte werden 2-hydroxy-1,4-
oxazin-3-onen xxxvii ingezet in de eenstapssynthese van 1H-pyrazin-2-onen xxxviii in 30-51% 
rendement via behandeling met NH4OAc en HOAc in ethylacetaat. 
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N
O
R
HO
O
xxxviia-d
N
N
O
12 equiv NH4OAc
10 equiv HOAc
EtOAc, ∆, 24 h
R
xxxviiia (R = iPr, 45%)
xxxviiib (R = iBu, 51%)
xxxviiic (R = nBu, 30%)
3 equiv PhCOCl
3 equiv Et3N
CH2Cl2, 0 °C, 2 h
N
O
R
O
O
O
MeOH, kt, 18 h N
O
R
O
O
O
20% Pd/C
H2, 5 bar
xxxixa (R = iPr, 45%)
xxxixb (R = iBu, 64%)
xxxixc (R = nBu, 93%)
xxxixd (R = cHex, 34%)
xxxxa (R = iPr, 69%)
xxxxb (R = iBu, 79%)
xxxxc (R = nBu, 82%)
xxxxd (R = cHex, 89%)
N
O
R
F
O
2 equiv Morph-DAST
xxxxia (R = iPr, 87%)
xxxxib (R = iBu, 78%)
xxxxic (R = nBu, 94%)
xxxxid (R = cHex, 90%)
N
O
R
O
O
O
N
O
R
O
O
O
2,5 equiv Et3N.3HF
1,5 equiv NBS
CH2Cl2, kt, 24 h
F
Br Br
F
xxxxiiia-d
+
xxxxii/xxxxiii
67-80/20-33
(79-94%)
xxxxiia (R = iPr, 63%, dr >99/1)
xxxxiib (R = iBu, 33%, dr >99/1)
xxxxiic (R = nBu, 42%, dr >99/1)
xxxxiid (R = cHex, 67%, dr >99/1)
CH2Cl2, -78 °C to kt, 5 h
 
In deze doctoraatsthesis werd het synthetisch potentieel van divers gefunctionaliseerde azetidinonen 
als nieuwe synthons in de organische chemie geïllustreerd aan de hand van hun omzettingen tot een 
groot aantal nieuwe acyclische en cyclische stikstofbevattende verbindingen, inclusief β-
aminoalcoholen, aziridinen, azetidinen, piperidinen, piperidin-4-onen, oxazin-3-onen, morfolin-3-
onen, pyrazinonen, cyclische β-aminozuren en bicyclische β-lactamen. Het is duidelijk dat, ondanks 
het feit dat de β-lactamkern reeds uitgebreid werd bestudeerd in het verleden, de β-lactamchemie 
nog steeds een zeer intrigerend en veelbelovend onderzoeksdomein vormt voor de aanmaak van 
nieuwe (a)cyclische targets omwille van de indrukwekkende verscheidenheid aan mogelijke 
transformaties.  
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